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ACE- Angiotensin-Converting Enzyme 
ACTR- hRARβ-stimulatory protein 
AF1- Activation Function 1  
AF2- Activation Function 2 
AIPs- Aldosterone-Induced Proteins  
AKT- Protein Kinase B 
AME- Apparent Mineralocorticoid Excess  
AngII- Angiotensin II  
ANOVA- analysis of variance  
AR- Androgen Receptor 
AT1- G-protein-coupled receptor, type 1 
AT2- G-protein-coupled receptor, type 2 
ATCC- American Type Culture Collection 
BSA- Bovine Serum Albumin  
CaM- Ca2+-calmodulin 
CaMK- Calcium/calmodulin-Dependent Protein Kinase 
CAV1- caveolin 1 
CAV2- caveolin 2 
CAV3- caveolin 3 
CBP- cAMP Response Element Binding Protein 
cDNA- complementary Deoxyribonucleic acid 
CHIF- Channel-Inducing Factor 
Co-IP- co-immunoprecipitation 
COX2- Cyclo-Oxygenase 2  
CRE- cyclic AMP Response Element  
CREB- cyclic AMP response element binding protein  
CSD- caveolin scaffolding domain 
Ct – Cycle Threshold 
D- Flexible hinge region 
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DBD- DNA Binding Domain 
DMEM- Dulbecco’s Modified Eagle’s Medium 
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eNOS- endothelial nitric oxide synthase  
ER- Estrogen Receptor 
EGFR- Epidermal Growth Factor Receptor 
ENaC- Epithelial Na+ Channel 
ER- Estrogen Receptor 
ERK 1/2- Extracellular signal-regulated kinase 1/2 
FBS- Foetal Bovine Serum 
G6PDH- Glucose-6-phosphate dehydrogenase 
GPCR- G-protein coupled receptor 
GR- Glucocorticoid Receptor 
GRIP1- Glucocorticoid Receptor-Interacting Protein 1 
H1- Histone 1 
H12- Helix 12 
12- HETE- 12-lipoxygenase to generate 12-hydroxyeicosatetraenoic acid 
HAT- Histone acetyltransferase 
HSD3B2- Type 2 3-Hydroxysteroid Dehydrogenase 
HSP90- Heat Shock Protein 90 
HRE- Hormone Response Element  
11HSD- 11β-hydroxysteroid dehydrogenase  
11HSD2- 11β-hydroxysteroid dehydrogenase type II isoform  
IgG- Immunoglobulin G 
IGF-1R- Insulin-like growth factor 1 receptor 
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IL-6- Interleukin 6  
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kDa- kilo Dalton 
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MAPK- Mitogen Activated Protein Kinase 
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M-MuLV - Moloney Murine Leukaemia Virus 
mTOR- Rapamycin 
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NLS- Nuclear Localization Signal  
NO- Nitric Oxide 
NOS- Nitric Oxide Synthase  
NR- Nuclear Receptors 
NTD- N-terminal domain 
OD- Optical Density 
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PAI-1- Plasminogen Activator Inhibitor-1 
PBS- Phosphate Buffered Saline 
p/CIP- mouse homolog CBP-interacting protein 
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peNOS- phosho endothelial nitric oxide synthase 
PKA- Protein Kinase A 
PKC- Protein Kinase C  
PMSF- phenylmethanesulfonylfluoride  
PPIase- Peptidylprolyl Isomerase  
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PLC- Phopholipase C 
PR- Progestrone Receptor 
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PTGS- post-transcriptional gene silencing 
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qPCR- quantitative real time polymerase chain reaction 
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-SMA- alpha smooth muscle actin 
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Abstract 
 
The cellular responses to steroids are mediated by two general mechanisms: 
genomic and rapid/nongenomic effects. Identification of the mechanisms underlying 
aldosterone’s rapid versus their genomic actions have been difficult to study and are 
not clearly understood. I explored the hypothesis that striatin is a critical intermediary 
of the rapid/nongenomic effects of aldosterone and that striatin serves as a novel link 
between the actions of the mineralocorticoid and estrogen receptors. In human and 
mouse endothelial cells, aldosterone promoted an increase in pERK that peaked at 
15 minutes. Striatin is a critical mediator in this process as reducing striatin levels 
with siRNA technology prevented the rise in pERK levels. In contrast, reducing 
striatin did not significantly affect two well-characterized genomic responses to 
aldosterone. Down regulation of striatin with siRNA produced similar effects on 
estrogen’s actions – reducing nongenomic, but not the genomic actions investigated. 
Aldosterone, but not estrogen, increased striatin levels. When endothelial cells were 
pre-treated with aldosterone, the rapid/nongenomic response to estrogen on 
peNOS/eNOS ratio was enhanced and accelerated significantly. Importantly, pre-
treatment with estrogen did not enhance aldosterone’s nongenomic response on 
pERK. In conclusion, these results indicate that striatin is a novel mediator for both 
aldosterone’s and estrogen’s rapid and nongenomic mechanisms of action on pERK 
and peNOS, respectively, thereby providing evidence for a synergistic effect between 
the mineralocorticoid receptor and the estrogen receptor. Furthermore, these results 
suggest a unique level of interactions between steroids on the cardiovascular system 
that may have broad application for the treatment of cardiovascular diseases. 
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Introduction 
 
The Merriam-Webster dictionary states that the definition for steroid hormone 
is: “any of numerous hormones (as estrogen, testosterone, cortisone, and 
aldosterone) having the characteristic ring structure of steroids and formed in the 
body from cholesterol”. The etymology of the term itself comes from a mixture of 
Greek and Latin words like: stereos, solid; oleum, oil; eidos, form and hormaein, to 
set in motion. 
Steroids are a class of organic 
compounds with a chemical structure that 
contains a gonane core i.e., a specific 
arrangement of four cycloalkane rings that 
are joined to each other (Figure 1) or a 
derived skeleton. Usually, methyl groups 
are present at the carbons C-10 and C-
13. It is also possible for an alkyl side 
chain to be present at carbon C-17.  
In physiology steroid hormones are involved in various aspects of growth, 
development, differentiation, reproduction and homeostasis. They exert their effects 
by means of specific receptors, the steroid hormone receptors, such as estrogen 
(ER), progesterone (PR), androgen (AR), glucocorticoid (GR) and the 
mineralocorticoid receptor (MR). Steroid hormone receptors (SHR) belong to the 
steroid/thyroid hormone receptor superfamily, which includes thyroid hormone (TR), 
retinoic acid (RAR), and vitamin D3 receptors, as well as “orphan” receptors, for 
which no ligands have yet been found. 
All members of the steroid and thyroid hormone receptor superfamily (more 
commonly called nuclear receptors (NR)) share a similar structure consisting of 
modular domains A though F (from NH2 to COOH terminus) (4): a variable N-terminal 
domain (NTD, A/B); a highly conserved DNA Binding Domain (DBD, C); a flexible 
hinge region (D); and a C-terminal Ligand Binding Domain (LBD, E). The estrogen 
receptor α is unique in that it contains an additional C-terminal (F) domain with 
unknown function (5).  
Figure 1- IUPAC recommended ring 
lettering (left) and atom numbering (right) 
of cholestane, a prototypical steroid 
skeleton (2). The four rings A-D form the 
gonane nucleus of the steroid. 
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A/B REGION (N-TERMINAL DOMAIN) 
 
 The A/B region in the different SHR is highly variable, revealing a weak 
evolutionary conservation, in fact, this is the least conserved region both in size and 
sequence (6). All the receptors have a unique N- terminal region (100-500 amino 
acids) whose 3D structure has not been clarified. This poorly defined region contains 
a transcriptional activation function, referred to as activation function 1 (AF-1) that 
can operate autonomously (independent of the presence of ligand). The A/B region is 
potentially involved in multiple protein-protein interactions and the length of this 
domain has a positive correlation with the activity of AF-1 for different members of 
the SHR superfamily (7). 
C REGION (DNA BINDING DOMAIN)  
The DNA binding domain lies toward the centre of the molecule and is a highly 
conserved residue core. The amino acid sequence of this domain is similar among 
different steroid receptors (56–79% identity). The 3D structure of the DBD has been 
resolved for a number of nuclear receptors.  
D REGION (HINGE REGION)  
The D region, which is a poorly conserved domain, serves as a hinge between 
the DBD and the LBD, allowing rotation of the DBD. The hinge region allows the DBD 
and LBD to adopt different conformations without creating a steric hindrance. This 
domain also harbours a nuclear localization signal (NLS) or at least some elements 
of a functional nuclear localization signal.  
E REGION (LIGAND BINDING DOMAIN)  
The largest domain and the hallmark of a nuclear receptor is its moderately 
conserved ligand-binding domain (LBD). This domain is highly structured, and 
encodes a wealth of distinct functions most of which operate in a ligand-dependent 
manner. The highly conserved region of the nuclear receptor proteins lies near the 
carboxyl terminus.  
The LBD is a region where chaperone proteins, such as Hsp90, bind NR when 
they are present in the cytoplasm. Upon ligand binding, exposure of a nuclear 
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localization signal in the LBD induces the nuclear translocation of the NR (6). After 
dissociation of the chaperones, the liganded NR–complexes can bind to particular 
DNA sites within gene promoters termed hormone response elements (HRE). The 
HRE-recruited hormone-receptor-complexes are then able to initiate chromatin 
remodelling and to relay activating or repressing signals to the target genes 
transcription machinery.  
Nuclear receptor pharmacology has made us understand that ligands may 
exert very diverse effects, this is dependent on individual chemical structure and the 
allosteric changes induced in the receptor/accessory protein complex (8). Binding of 
agonistic or antagonistic ligands leads to different allosteric changes of NR making 
them able to exert positive or negative effects on the expression of target genes by 
different mechanisms.  
 
Figure 2- Steroid hormone receptors consist of six domains (A-F) based on regions of 
conserved sequence and function (5). The domains starting from the N-terminus (left) to C-
terminus (right) are: NTD- N-terminal domain; DBD- DNA binding domain; LBD- ligand-
binding domain; AF- activation function. The numbers to the right represent the lengths in 
amino acid residues (6). 
 
Although a lot is known in the field of steroid hormone action, this is a 
relatively new area and no more than five decades old. Pivotal experiments in the 
late 1950’s and 1960’s showed that hormone-binding components exist within the 
nuclei of target tissues and that steroid hormones act by regulating gene expression, 
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Figure 3- On the right
Professor Gerald C. 
Mueller, M.D., Ph.D. 1920-
2010 and on the left 
Professor Elwood V. 
Jensen, Ph.D. 
rather than directly influencing enzymatic processes. The understanding that steroid 
hormone receptors interact with the general transcription machinery and alter 
chromatin structure came in the 1970’s and 1980’s, and details of these mechanisms 
continue to be elucidated in contemporary bio-medical research. 
In addition, the discovery of rapid cellular responses to steroid hormones has 
led to the identification of membrane-bound receptors that act without affecting gene 
transcription which is the main focus of this thesis. 
 
The birth of the field of steroid hormone action 
 
 Pivotal experiments performed in the late 1950’s and early 1960’s primarily in 
the laboratories of Gerald Mueller and Elwood Jensen, 
set the stage for the development of the field of steroid 
hormone action. Jensen’s laboratory showed that 
tritiated (H3) estradiol was specifically taken up and 
retained in the immature rat uterus, indicating the 
presence of an “estrogen-binding component” or 
“estrophilin” later termed “estrogen receptor” by Jensen 
(9, 10). This was the first time that target tissue 
specificity was observed for a hormone. During the same period Dr. Mueller’s 
laboratory reported that estrogen treatment induced RNA and protein synthesis. 
Later the same laboratory showed that uterine responses to estrogen were blocked 
when both RNA or protein synthesis was inhibited, showing that gene transcription 
and protein translation were required for its effects (9). 
 Still in the 1960’s Jensen in collaboration with Jack Gorski and others 
demonstrated that after treatment estrogen, or estradiol, travelled from the cell 
cytosol to the nucleus (9, 10). This led to the belief that the ER bound estrogen in the 
cytoplasm and then translocated to the nucleus. However, it is currently known that 
the ER is in fact a nuclear factor that initiates its interaction with estrogen in the 
nucleus (11). Scientists at this time also concluded that steroid hormones, through 
their receptors, regulate gene expression rather than influencing enzymatic 
metabolism directly. It was in 1966 that a collaboration between Gorski and Angelo 
Notides showed that estrogen treatment resulted in the production of a specific 
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uterine protein (12). Subsequently, Bert O’Malley’s laboratory demonstrated steroid-
mediated mRNA induction of ovalbumin in response to estrogen and of avidin in 
response to progesterone (10). The 60’s culminated with the first Gordon Conference 
on Hormone Action, establishing steroid hormone action as a legitimate and growing 
field of research.  
 The early 1970’s came with an explosion of research on steroid hormone 
receptors. In 1972 the first steroid hormone receptor was purified, O’Malley’s 
laboratory purified PR from chicken (13). Soon after the purification of PR, ER and 
AR were purified, (14, 15) and finally many years later in 1990 MR was purified (16). 
 
The molecular biology revolution 
 
 With the advent of recombinant DNA and DNA sequencing technologies in the 
mid 1970’s came the ability to characterize the steroid hormone receptors and their 
target genes in more detail. Again, O’Malley’s laboratory was the first to clone (1977) 
and sequence (1978) a target gene for steroid hormones, ovalbumin from chicken. 
Cloning of the first steroid hormone receptor (GR) occurred in 1985 through 
collaboration between Ronald Evans’, Michael Rosenfeld’s, and Brad Thompson’s 
laboratories. Shortly after this breakthrough, the receptors for estrogen (1986), 
progesterone (1987), aldosterone (1987) and androgen (1988) were cloned (17). 
 Through the work of a number of laboratories in the 1980’s and early 1990’s, a 
model for steroid receptor action at gene level began to emerge. In 1983, Keith 
Yamamoto’s and Jan-Åke Gustaffson’s laboratories demonstrated for the first time 
that a steroid hormone receptor (GR) binds DNA in a sequence-specific manner. The 
receptor binding site, now termed the steroid response element (SRE), is located 
within the steroid hormone-regulated promoters. In general, SREs are 15-base pair 
consensus sequences consisting of two half sites, arranged as 6-base pair inverted 
repeats separated by a few random base pairs. The SREs for various receptors 
exhibit significant sequence similarity, with SREs for GR, PR and AR oftentimes 
being identical (18).   
 In 1988, O’Malley’s laboratory was again instrumental in showing that 
receptors bind the SREs cooperatively as dimmers, with one receptor molecule at 
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each half site (18). In vitro experiments performed in the mid 1990s demonstrated 
that receptor binding to DNA is not hormone dependent (19). 
 Still in the 1980 decade, the laboratories of Etienne-Emile Baulieu, David Toft, 
and William Pratt discovered that inactive steroid hormone receptors interact with a 
non-hormone protein, later identified as heat shock protein 90 (hsp90) (20, 21). Heat 
shock proteins likely stabilize unliganded steroid hormone receptors by preventing 
folding, aggregation and DNA binding (22). Steroid hormone receptors are the only 
members of the steroid/thyroid superfamily know to bind to these proteins (23). 
Experiments performed by the Pratt and Toft laboratories in the late 1980s 
demonstrated that the dissociation of heat shock proteins from receptors is hormone-
dependent (24). During this decade it was also shown that hormone receptors are 
phosphorylated in a hormone-dependent manner. Edwin Milgrom’s laboratory 
showed that PR is phosphorylated, and with hormone administration, becomes 
hyperphosphorylated (25) leading investigators to believe that steroid hormone 
receptor action is dependent on phosphorylation state.  
 After the discovery that receptors bind the SREs as dimmers, O’Malley’s 
laboratory showed that steroid hormone receptors interact with transcription factor IIB 
(TFIIB), leading to the hypothesis that steroid hormone receptors facilitate 
transactivation via protein-protein interactions with general transcription factors. This 
hypothesis was soon validated when they successfully reconstructed the entire 
pathway of steroid hormone action in a ligand dependent, receptor-mediated, cell-
free transcription system (10). It was shown that ligand-bound receptor binds the 
SRE and stabilizes the association of general transcription factors. This interaction 
between receptor and general transcription factors allows for the successful 
recruitment of polymerases to the promoter and subsequent transcription of the 
target gene. 
 
 These discoveries represented the culmination of three decades of research 
and led to a well supported model for steroid hormone receptor action: ligand binding 
induces a conformational change in the receptor, releasing heat shock proteins. The 
receptor undergoes hormone- and DNA-dependent hyperphosphorylation, dimerizes, 
and binds its target DNA. The binding of the receptors to the SRE allows for 
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recruitment of general transcription factors and, subsequently, RNA polymerase to 
begin efficient transcription (22, 25). 
 
 
Figure 4- General model of steroid hormone receptor action. 
 
 
Refining the model 
 
 Coactivators. In 1989, experiments performed in the laboratories of both 
O’Malley and Hinrich Gronemeyer showed that overexpression of one SHR results in 
the inhibition of itself or other SHRs. These results suggested that there might be 
other limiting factors, termed “coactivators” that modulate transactivation by steroid 
hormones. These coactivators are thought to function as bridging factors that, directly 
or indirectly, facilitate the crucial protein-protein interactions between the steroid 
hormone receptor and the general transcription machinery to ensure efficient 
transcription of target genes. 
Coactivators can be receptor-specific or general. Two general coactivators, 
steroid receptor coactivators-1 (SRC-1) and cAMP response element binding protein 
(CBP), enhance the transcriptional activities of several steroid/thyroid hormone 
receptors (4). SRC-1 was identified in 1995 by O’Malley’s laboratory and has shown 
to enhance the transcriptional activity of all the steroid receptors tested, without 
altering basal promoter activity. In 1996, Williams Chin’s laboratory showed that 
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SRC-1 interacts with a variety of steroid and thyroid hormone receptors in a ligand-
dependent manner, as well as with TATA-binding protein and TFIIB. Receptor-
specific coactivators include the androgen receptor-associated protein 70, first 
described by Chawnshang Chang’s laboratory in 1996. 
 
Corepressors. Besides activating transcription, steroid/thyroid hormone 
receptors can also silence basal promoter activity of target genes in the absence of 
hormone or in the presence of an antagonist. This phenomenon was first observed 
with TR and RAR, which have shown to bind cognate DNA response elements in the 
absence of hormone and repress basal transcription (4). Competition experiments 
suggested that this silencing activity requires binding of a “corepressor”. The 
corepressors silencing mediator for RAR and TR (SMRT) and nuclear receptor 
corepressor (N-CoR) were cloned in 1995 (4). These proteins are thought to act by 
recruiting additional proteins with histone deacetylase activity, thus inhibiting 
transcription complex formation through a chromatin dependent mechanism (26). 
Agonists, but not antagonists, are able to dislodge corepressors bound to unliganded 
receptors, thus relieving the silencing function. In the case of a mixed agonist and 
antagonist, such as tamoxifen (for ER), relief of the silencing functions may depend 
on the relative ratio of coactivators to corepressors (27). 
Evidence for corepressor interaction with the classic steroid hormones is also 
emerging. Recently, ER has been shown to interact with N-CoR (26). In addition, the 
surprising observation that human PR-A acts as a transdominant transcriptional 
inhibitor appears to be due to its interaction with the corepressor SMRT and its 
inability to interact with coactivators (27). As receptor specific coactivators and 
repressors continue to be discovered, researchers can better understand how steroid 
hormone receptors alternate between gene silencing and transactivation functions. 
The interesting fact about the biology of steroid hormone receptor action on 
gene expression is that it’s dependent on a number of factors, including the nature of 
the ligand (agonist or antagonist), the isoform or subtype of the receptor, the nature 
of the steroid response element, and the character and balance of coactivators and 
corepressors. These factors confer tissue and gene specificity and begin to explain 
the complexity and diverse cellular roles of steroid hormone receptors. 
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It has been more than 50 years since two key discoveries were made in the 
United Kingdom, the isolation of both the steroid hormone aldosterone (28) and the 
structure of DNA (29) both happened in 1953. Although these discoveries were not 
connected, the last one allowed for the technologies of molecular biology to elucidate 
the mechanism by which aldosterone regulates epithelial sodium transport. 
 
The mineralocorticoid receptor 
 
Aldosterone, like other steroid hormones, has an intracellular receptor, which 
acts through a genomic mechanism to enhance the transcription of specific genes 
that encode putative aldosterone-induced proteins (AIPs). AIPs mediate the main 
physiological response to aldosterone, epithelial Na+ transport. Various studies, now 
over three decades old (30), clearly demonstrated the presence of an intracellular 
receptor that specifically bound tritiated aldosterone in mice, these studies were later 
confirmed in the human kidney (31). In 1987, Arriza et al. cloned the human MR by 
low stringency hybridization with the glucocorticoid receptor cDNA from a human 
placental library (17). The cloned MR was found to be highly  homologous to the GR 
and curiously, although the affinity of aldosterone for the human MR was similar to 
what had been reported (31), the receptor had a much higher affinity for cortisol (17).  
The human MR is a 107 kDa protein with 984 amino acids and, as with other 
steroid receptors, contains three main domains, the central DNA-binding domain of 
68 amino acids (DBD), the C-terminal ligand-binding domain (LDB), which shares 
57% homology with the GR, and the N-terminal domain, which differs both in length 
and sequence between the two receptors (17). The DBD of the MR corresponds to a 
highly conserved region among members of the nuclear receptor superfamily 
showing 94% homology with the GR and 90% homology with other nuclear 
receptors. Two groups of four cysteines form -helixes called “zinc fingers”, one of 
which lies in the major groove of the DBD facilitating specific contacts during 
transcription (see Figure 5) (17). The zinc fingers contain a P box, the interacting 
surface with the half site of the inverse repeat of the hormone (glucocorticoid) 
response element, and a D box responsible for weak dimerization with the DNA (32, 
33). A specific MR response element has not been identified. An additional nuclear 
export signal is located between the two zinc fingers near the LBD. 
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Figure 5- Consensus structure of the MR (1). 
 
 
 The hinge region is located between residues 671 and 732 and contains a 
proline stretch, which permits a twist of the DBD relative to the LBD, positioning the 
receptor in contact with the general transcritption machinery (34). This region also 
possesses weak ligand-independent nuclear localization signal (NLS1) responsible 
for receptor subcellular translocation. 
 The MR has an activating function, AF-2, within the LBD that becomes 
activated in a ligand-dependent manner after agonist binding in the hydrophobic 
pocket of the LBD. The AF-2 sequence is highly conserved and is located in helix 12 
(H12) of MR.  
 The N-terminal domain of the MR, with 602 amino acids, is the longest and 
most highly variable among the steroid receptors. While it has only 15% homology 
with the GR, it has been conserved in evolution and is highly homologous among 
species. This domain contains multiple functional sites responsible for ligand-
independent transactivation or transrepression. 
 
Although the MR LDB binds both to aldosterone and cortisol with high affinity 
in vitro, the GR does not bind to aldosterone and the MR itself binds to cortisol with a 
lower affinity (17). However, similar binding specificities for aldosterone and cortisol 
were seen when the MR was isolated from the rat hippocampus (35). This work 
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suggested that some factor was precluding cortisol access to the MR in the kidney, 
but not the hippocampus. Subsequently, the groups of John Funder in Melbourne 
and Chris Edwards in Edinburgh showed that the carbenoxolone-sensitive enzyme, 
11β-hydroxysteroid dehydrogenase (11βHSD), was responsible for this phenomenon 
(36). In epithelial target tissues for aldosterone and in some other tissues, 
aldosterone specificity is maintained by the type II isoform of 11βHSD (11βHSD2), 
which converts cortisol to cortisone, thereby rendering it inactive as cortisone does 
not bind to the MR. Inactivation of 11βHSD by ingestion of large quantities of 
liquorice or the administration of carbenoxolene (36) results in mineralocorticoid 
excess in the presence of low aldosterone levels. These features are also seen in the 
condition of apparent mineralocorticoid excess (AME), an autossomal recessive 
condition characterized by an early onset of severe low rennin hypertension with 
hypokalemia, yet low aldosterone levels. AME results from mutations in 11βHSD2 
(36).  
 
Ligand-binding specificity 
  
To determine the structural basis of the specificity of the MR for aldosterone 
binding, Rogerson et. al. exploited (37) the differences and the similarities between 
the LBDs of the MR and GR. The MR binds and is transcriptionally active in response 
to both aldosterone and cortisol, whereas the GR responds primarily to cortisol (17, 
37). To understand the basis of this difference, a series of chimeras was created 
between the LBD of the GR and the MR (37). The 14 chimeras retained their basic 
structural integrity in that they all bound tritiated dexamethasone, albeit with variable 
affinities (38). In those chimeras in which aldosterone binding was seen, trans-
activation also occurred. MR sequences in the second region (amino acids 804-874 
of the MR sequence) were essential for activation by aldosterone. A second round of 
chimeras focusing on this region  between amino acids 804 and 874 of the MR LBD 
identified the 820-844 region as the crucial region for aldosterone binding (38). 
 The crystal structures of the LBD of many of the nuclear hormone receptors 
have been published, PR (39), AR (40), GR (41, 42). Besides containing all of the 
determinants for binding the hormone, the LBD also contains the C-terminal 
activation function-2 helix (AF-2). Crystal structures of several NR LDBs have shown 
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that correct positioning of the AF-2 is required for recruitment of co-activators of 
transcription (41-43). Understanding the ligand requirements that lead to the proper 
positioning of the AF-2 and activation of MR is fundamental to designing drugs that 
can modulate receptor activation. Overall , the MR LDB shows the three-layered α-
helical fold observed in other nuclear receptor LDBs, with aldosterone bound in a 
fully enclosed pocket containing residues in helixes 3, 4, 5, 6, 7 and 11, and the β-
turn (Figure 4A). As seen in other steroid receptor LDBs, the C-terminal extension of 
MR interacts with helix 10 via hydrogen bonds between Asp929 and the amide 
nitrogens of Phe981 and His982. The most unusual feature of the structure is that the 
residues N-terminal to helix 1 (727-737) form a short helix that associates near the 
coactivator groove of a chrystallographically related molecule. This N-terminal feature 
is present in all MR complexes. 
 
In general, MR makes interactions with aldosterone in a manner consistent 
with how other steroid receptors bind their natural ligands (Figure 6, B and C). There 
is an extensive hydrogen bond network involving the A-ring ketone of aldosterone, 
Gln776 and Arg817 of MR, and several water molecules that firmly lock the A-ring of 
the steroid in place. Specific to the MR there is a water-mediated hydrogen bond 
between Gln776 and Ser810. AR, GR, and PR have a methionine at this position so 
this interaction is not possible. Adjacent to the D-ring, the C-18 hydroxyl makes a 
hydrogen bond to the side chain carbonyl of Asn770 on helix 3. Asn770 is in position to 
coordinate a triplet of hydrogen bonds: one between the side chain carbonyl and the 
C-18 OH of the ligand, and two from the side chain nitrogen to the C-21 OH of the 
ligand and the backbone carbonyl of Glu955, a residue that lies on a loop preceding 
the AF-2 helix. The ligand is stabilized further by a pair of hydrogen bonds between 
the aldosterone C-21 hydroxyl, C-20 ketone, and Thr945 located on helix 10. This 
threonine is conserved in GR and PR but is replaced by leucine in AR. 
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Figure 6- Crystal structure of MR LDB bound to aldosterone. A- the overall fold of the 
MR is very similar to the other steroid receptors. B, helix 3 (magenta) residues Asn770 and 
Ser767 form hydrogen bonds (yellow dashed lines) with the loop (green) residue Glu955 
preceding the AF-2 (red). Thr945 present on helix 10 (orange) plays a key role in receptor 
activation by hydrogen bonding to the C-20 carbonyl and C-21 hydroxyl of aldosterone 
(yellow). C, close-up view of MR-aldosterone hydrogen bond network. The 18-OH is 
positioned for hydrogen bonding with the Asn770 carbonyl, whereas the Asn770 amide remains 
in position for hydrogen bonding to the C-21 OH of aldosterone and Glu955, which lies in the 
loop preceding the AF-2. Thr945, present on helix 10, forms a pair of hydrogen bonds with the 
C-20 and C-21 substituents of aldosterone. Cysteine 942 is in position to interact with the 18-
OH group to give aldosterone three potential hydrogen bonds to helix 10 (41). 
  
 It is clear from the crystal structure that the orientation of Thr945 is ideal for 
hydrogen bonding with steroids containing C-20 carbonyls and C-21 hydroxyl groups 
(Figure 6, B and C) (41). 
In addition to Asn770, Ser767 is in position to make a hydrogen bond to the 
backbone amide of Glu955 in the loop preceding the AF-2. This observation suggests 
that both of the helix 3 residues (Asn770 and Ser767) play a role in stabilization and 
activation of MR. Notably, interference with the interaction between helix 3 and the 
loop preceding the AF-2 reduces MR activation (44). Amino acid alignments of the 
A B
C
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receptors show that an asparagine is conserved in a similar position in all of the 
oxosteroid receptors, suggesting that the interaction between helix 3 and the loop 
preceding the AF-2 may be a conserved mechanism of steroid receptor action. Two 
properties of steroid ligands dictate that an asparagine is required at position 770 in 
MR to stabilize the helix 3/loop interaction. First is the length of the steroid itself, and 
second are substituents at the C-11 position of the steroid. 
 
In summary, maximum MR activation occurs only when there is simultaneous 
stabilization of the loop preceding the AF-2 helix and a strong interaction of the ligand 
with helix 10. Stabilization of the loop preceding the AF-2 requires hydrogen bonds 
between Asn770 and Ser767 on helix 3 and Glu955 present on this loop. Ligands that 
promote this hydrogen bond network and interact with helix 10 via hydrogen bonds or 
hydrophobic interaction with Thr945 induce a stabilization of helix 3 and a movement 
of the AF-2, enabling coactivator recruitment and ultimately gene transcritption. This 
series of ligand-mediated activation steps ensures that ligands such as progesterone 
and cortisone fail to activate MR even though these ligands will be in excess over 
aldosterone in many tissues. Likewise, spironolactone also fails to activate MR 
because of an inability to create the hydrogen bonding network and thus behave as a 
passive MR antagonist. 
 
Genomic Structure and Organization 
  
The human MR gene (NR3C2)  is located in chromosome 4 in the q31.1 
region (43), spans 450 kb and is composed of ten exons (45). The two first exons 
are referred as exon 1 and 1 and correspond to the 5’ untranslated region in the 
human. They are followed by eight exons that code for the protein with exon 2 
encoding the N-terminal domain (NTD or A/B region). Exons 3 and 4 code for the 2 
zinc fingers of the DNA binding domain (C region) and the last five exons code for 
the LDB (45). Alternative transcription for these 5’-untranslated exons generate 
different mRNA isoforms that are differentially expressed in aldosterone target 
tissues (46, 47). Mineralocorticoid receptor translation starts 2 bp downstream from 
the beginning of exon 2 and the translated protein is the same for the two 5’-
untranslated isoforms.  
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 There are functional splice variants of the MR. A 12 bp insertion between the 
two zinc fingers results from the use of a cryptic splice site at the exon3/intron C 
splice junction creating a splice variant that is expressed in most tissues (44), but its 
transactivation activities are not significantly different from the wild-type (48-50). A 10 
bp deletion in the rat and human MR leads to a truncation in the LBD and 
unresponsiveness to aldosterone. It is expressed at low levels in the rat and human 
tissues and does not interfere with the wild-type mRNA activity (51). An additional 
alternative splice variant skips exons 5 and/or 6, leading to the co-repression of the 
5 or the 5,6 human mineralocorticoid receptor mRNA isoforms (52). This isoform 
retains de DNA-binding domain and can act in a ligand-independent manner (52). 
 
Post-Translational Modifications of the MR 
  
The MR is a phosphoprotein (53-55) with multiple consensus sites for 
phosphorylation (Figure 5). Rapid phosphorylation of serine and threonine residues 
occurs within minutes of exposure to aldosterone. These are mediated in part by 
protein kinase C alpha (PKC) activation and might be involved in the rapid, 
nongenomic effects of aldosterone (56). There is some evidence that 
phosphorylation by PKC enhances MR function, but this could be due to 
phosphorylation of an associated co-regulator rather than a direct effect (57). 
Inhibition of serine/threonine phosphatases inhibits MR transformation and inhibits 
DNA binding (55). Except for the nongenomic effects, the role of phosphorylation 
remains unclear (56, 58). 
Sumoylation, modification by SUMO (small ubiquitin-related modifier), is a 
post-translational modification common to most steroid receptors (59-61). The MR 
has four sumoylation consensus motifs in the N-terminal end at positions K89, K399, 
K428 and one in the LBD at K593 of the human sequence (Figure 7). The consensus 
motifs for sumoylation are named synergy control motifs and are defined by the 
sequence consensus KXE, where X is any residue and the  is an aliphatic 
residue. These sites are highly conserved through evolution. Studies have shown 
that the transcriptional activity of the MR can be modulated by its sumoylation 
potential, as well as the sumoylation of MR-interacting proteins, and requires the 
continuous function of the proteosome (62). Acetylation of the receptor is also 
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theoretically possible as it has a consensus sequence for acetylation, but it remains 
to be demonstrated (63). 
 
 
Figure 7- The human mineralocorticoid receptor gene, mRNA, protein functional domains 
and post-translational modifications. The intron, exon structure of the gene and the two 
different promoters are shown in the upper part of the figure. The middle part represents the 
mRNA and in the lower part the MR protein and its different domains are shown (1). 
 
MR Trafficking 
 
 In their mature form, steroid receptors are associated to 90-kDa and 70-kDa 
heat shock proteins, the small acidic protein p23 and proteins that posses 
tetratricopeptide repeats (TPR), i.e. sequences of 34 amino acids repeated in tandem 
that are critical for protein-protein interactions. In the steroid receptor heterocomplex, 
the TPR-acceptor site of hsp90 is normally occupied by either high molecular weight 
immunophilin (IMM) FKBP52, FKBP51, CyP40 or PP5 (64). IMMs are a family of 
intracellular receptors for immunosuppressant drugs also characterized for having 
peptidylprolyl isomerase (PPIase) enzymatic activity, which directs cis-trans 
isomerization of peptidylprolyl bonds (65). The oligomeric structure of untransformed 
SRs is also found in primarily nuclear receptors such as progesterone and estrogen 
receptors. 
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Upon aldosterone binding, the MR moves rapidly, within minutes, towards the 
nucleus, whereas it cycles back to the cytoplasm upon ligand withdrawal much more 
slowly, more than 18 hours. A classical model accepted for more than two decades 
posits that the ligand binding-dependent dissociation of the hsp90-based 
heterocomplex (a process frequently referred to as “transformation”) is a must for the 
nuclear translocation of SRs (66, 67). This model was based on the assumption that 
the chaperone complex anchors the SR to the cytoplasm, impairing its nuclear 
translocation. The transformation model, although unproven, prevailed until recent 
years. 
A key discovery was that a cytoplasmic dynein co-immunoprecipitates with 
FKBP52 (68). Dyneins are molecular motors that generate force towards the minus 
end of microtubules and are related to the retrograde movement of vesicles. Cargo 
attachment occurs via the dynein intermediate chain, whereas the ATP-hydrolitic 
domain responsible for the motor function is located in the heavy chains. The actual 
microtubule-binding site is a small globular unit that protrudes from heavy chains. It 
then became clear that the dynein-IMM interaction involves the PPIase domain of the 
IMMs (68, 69), a property that appears to be a common feature for most high 
molecular weight IMMs associated with SRs (70). Importantly, at least two of the 
most abundant IMMs found in SRhsp90 complexes, FKBP52 and PP5, co-localize 
with microtubules.  These observations implied that an active transport system 
requiring hsp90, IMMs, dynein motor proteins and cytoskeletal tracts moves SRs 
within the cell towards the nucleus.  
If correct, this would mean that the hsp90IMM complex associated with the 
untransformed receptor should not dissociate upon ligand biding because it would be 
required for the retrograde movement of the ligand-receptor complex. Results from 
an experiment using tritiated aldosterone and a continuous sucrose movement 
clearly contradict the unproven classical model: transformation is not an early event 
(69). Also in agreement with the new model, the cytoplasmic-nuclear movement of 
hsp90IMM-chaperoned factors is impaired or blocked by hsp90 inhibitors 
(geldanamycin or radical), overexpression of the PPIase domain of FKBP52 
(preventing dynein binding), saturation of the hsp90IMM binding site with TPR and 
by overexpression of the dynein complex subunit, p50/dynamitin, which disrupts the 
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Figure 8- The molecular machinery for 
movement of the MR and the agent for 
selectively uncoupling the system. 
Arrows show the sites of uncoupling by 
hsp90-disrupting agents such as 
geldanamycin (GA), the TPR domain 
fragment of PP5, the PPIase domain 
fragment of FKBP52 and the 
p50/dynamitin (Dyt). Immunophilin TPR 
domain (black crescent). Dynein heavy 
chains (HC), intermediate chains (IC) (1). 
dynein-dynactin complex and dissociates cargo from dynein (Figure 6). Thus, there is 
ample evidence that validates a model in which the retrograde movement of certain 
soluble factors occurs in an active manner via cytoskeletal tracts with the hsp90IMM 
complex forming the bridge between the cargo and the motor protein responsible for 
the retrograde movement of SR and that this system can be uncoupled by some 
inhibitory agents. 
 
 
 
 
Aldosterone-induced proteins 
  
Although it has been recognized many years ago that aldosterone acted to 
increase (or decrease) the expression of specific genes (30), the identification of 
these target genes has only occurred in the past decade or so (71). Six genes are 
known to be acutely regulated by a rapid and transcriptional response to aldosterone, 
namely genes encoding the three epithelial Na+ channel subunits α, β and γ 
(SCNNIA,-Band -G), channel-inducing factor (FXYD4), serum and glucocorticoid-
induced kinase (SGK) and K-ras2 (KRAS2) (Figure 9). In addition, there is evidence 
to support the regulation of three other genes, those encoding glucocorticoid-induced 
leucine zipper protein (49), N-myc downstream-regulated gene (50), and the kidney 
specific WNK1 isoform (72). 
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Figure 9- Schematic representation of an aldosterone-responsive epithelial cell. The 
putative interactions of the AIPs in relation to the epithelial Na+ channel (ENaC) and the 
basolateral Na+ pump (Na.K-ATPase) are shown (65). A possible role for phophatidylinositol 
3-kinase (PI3-k) in integrating different signalling pathways (66) is indicated. Abbreviations: 
CHIF, channel-inducing factor; sgk, serum- and glucocorticoid-induced kinase. 
 
 The amiloride-sensitive epithelial Na+ channel (ENaC) is the key rate-limiting 
step at the apical membrane for the Na+ flux across transporting epithelial cells (51, 
71). The other key mediator of epithelial Na+ transport is the energy-dependent 
pump, Na.K-ATPase, which is located in the basolateral membrane, where it 
mediates the efflux of Na+ (71). The activity of Na.K-ATPase increases in response to 
aldosterone. The genes encoding the Na.K-ATPase α- and β-subunits are not acutely 
regulated by aldosterone, although increased levels are part of the response to 
chronic aldosterone administration.  
 ENaC is a key component of the response to aldosterone and therefore an 
obvious candidate for regulation (51). The genes encoding the ENaC β- and γ-
subunits in the distal colon are regulated by aldosterone (53, 71). The gene encoding 
the α-subunit, but not the β- and γ-subunits of ENaC, is similarly upregulated in the 
kidney (54). However, the time course of this response and the magnitude of the 
change are inadequate to explain the increased amiloride-sensitive Na+ flux that 
occurs in response to aldosterone (71). 
 Probably the best characterized AIP is sgk (73, 74). This protein is rapidly 
upregulated by aldosterone in the colon and distal nephron (1, 32). Two studies (33, 
75) have demonstrated the ability of sgk to interact with the ubiquitin ligase Nedd 4-2 
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and, through that interaction, to inhibit the action of Nedd 4-2, thereby prolonging the 
half-life of the ENaC channels in the apical membrane. The molecular 
characterization of the monogenetic hypertension syndrome or Liddle’s syndrome 
(72) has shown the importance of the degradation of the ENaC channels as part of 
their regulation (75). Nedd 4-2 plays an important role in this process. When the 
interaction between Nedd 4-2 and the C-terminus of the ENaC β- and γ-subunits is 
compromised, the channels exhibit a prolonged half-life, resulting in increased Na+ 
flux (75). 
 Work on amphibian systems has shown that KRAS2, particularly the 2A 
isoform, is acutely upregulated by aldosterone (75, 76). It is possible that the 
interaction might involve the phosphatidylinositol 3-kinase pathway, which is 
responsible for the phosphorylation of sgk (66). 
 The other well characterized aldosterone-induced gene, FXYD4 (77), is 
regulated in the distal colon but not the kidney (78, 79). It is an acute primary 
transcriptional event (74). Although the initial studies of channel inducing factor 
(CHIF) (77) suggested that it might interact with a K+ channel, recent information 
from the same group has demonstrated an interaction with Na.K-ATPase (80). CHIF 
belongs to the FXYD family of small transmembrane proteins, which includes the γ-
subunit of Na.K-ATPase; this subunit is not upregulated by aldosterone in the distal 
colon (71). CHIF has the reverse effect of the γ-subunit in that it increases the affinity 
of the pump for Na+ and therefore increases flux through the pump (80). This is a 
probable mechanism through which aldosterone increases the activity of the 
basolateral pump.  
 
Regulation of Aldosterone Production 
 
 Aldosterone represents the primary mineralocorticoid produced by the adrenal 
gland and specifically within the outer adrenocortical cells of the glomerulosa layer. 
Aldosterone is synthesized in the glomerulosa from cholesterol through the 
successive actions of four enzymes (Figure 10). Cholesterol side-chain cleavage 
(CYP11A1), 21-hydroxilase (CYP21) and aldosterone synthase (CYP11B2) are 
members of the cytochrome P450 family of enzymes. CYP11A1 are localized to the 
inner mitochondrial membrane, while CYP21 is found in the endoplasmic reticulum. 
These enzymes are P450 heme-containing proteins that accept electrons from 
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NADPH via accessory proteins and utilize molecular oxygen hydroxylations (CYP21 
and CYP11B2) or other oxidative conversions (CYP11A1). The fourth enzyme, type 2 
3-hydroxysteroid dehydrogenase (HSD3B2), is a member of the short-chain 
dehydrogenase family and is localized to the endoplasmatic reticulum. 
 Historically, the regulation of aldosterone biosynthesis has been divided into 
two main phases. Acutely (minutes after a stimulus), aldosterone production is 
controlled by rapid signalling pathways that increase the movement of cholesterol 
into the mitochondria (Figure 12). This has been called the “early regulatory step” 
and, is mediated by increased expression and phosphorylation of StAR protein (81). 
Chronically (hours to days), aldosterone production is regulated at the level of 
expression of the enzymes involved in the synthesis of aldosterone (82). This has 
been called the “late regulatory step” and is particularly dependent on increased 
transcription and expression of CYP11B2 (Figure 13). 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 10- Adrenal steroid pathways leading to mineralocorticoid, glucocorticoids and 
adrenal androgens. Enzymes involved include side-chain cleavage (CYP11A1), 3-
hydroxysteroid dehydrogenase type 2 (HSD3B2),17-hydroxylase, 17,20 lyase (CYP17), 21-
hydroxylase (CYP21), 11-hydroxylase (CYP11B1), and aldosterone synthase (CYP11B2). 
Steroidogenic acute regulatory (StAR) protein is needed for the rate-limiting movement of 
cholesterol to CYP11A1 in the inner mitochondrial membrane (1).  
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Factors Regulating Aldosterone Production 
 
The Renin-Angiotensin-Aldosterone System (RAAS) 
  
Because the major function of aldosterone is to control body fluid volume by 
increasing sodium reabsorption by the kidneys, it is appropriate that the major 
regulator for aldosterone synthesis and secretion arises in the kidneys. Thus, the 
kidneys play the controlling role in the rennin-angiotensin-aldosterone feedback 
system (Figure 11). Renin is a protease produced and stored in the juxtaglomerular 
cells that surround the glomerular afferent arterioles. Renin release is controlled by at 
least three mechanisms. First, release is activated by a decrease in the perfusion 
pressure of blood traversing the renal afferent arterioles, which is sensed by the 
juxtaglomerular apparatus functioning as a baroreceptor. This reduction in perfusion 
pressure occurs as a result of a decrease in either systemic blood volume or blood 
pressure. Second, renin secretion can be stimulated by secretions from the macula 
densa as a result of a drop in sodium concentration in the distal tubule. Third, a drop 
in blood pressure will cause sympathetic stimulation of juxtaglomerular cells to 
stimulate both renin release and afferent arteriole constriction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11- Aldosterone production is primarily regulated through a feedback loop that 
focuses on kidney production of renin. Once released, renin cleaves angiotensinogen to 
angiotensin I through the action of angiotensin-converting enzyme (ACE) to produce 
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angiotensin II. Angiotensin II is the primary hormonal regulator of adrenal aldosterone 
production. Aldosterone indirectly exerts negative feedback to decrease renin release 
through renal sodium retention and elevation in the blood pressure (1). 
 
 
 Acting in the blood, renin mediates the rate-limiting step in the production of 
angiotensin II (AngII), cleaving the circulating precursor angiotensinogen to release 
the 10-amino acid peptide, angiotensin I. Thereafter, inactive angiotensin I is rapidly 
converted to the potent octapeptide hormone AngII by the action of angiotensin-
converting enzyme (ACE), which is found in the plasma membrane of vascular 
endothelial cells throughout the body. Circulating AngII is the arguably the most 
important regulator of adrenal glomerulosa aldosterone production.  
 
Angiotensin II-Regulated Intracellular Glomerulosa Cell Signalling Pathways 
  
In humans AngII has two G-protein-coupled receptors, type 1, (AT1) and type 
2 (AT2), through which this hormone can elicit intracellular responses. AngII works 
primarily through AT1 receptors to regulate aldosterone production (Figure 10). The 
expression of AT1 receptors is highest in the glomerulosa, which localizes the action 
of this hormone to aldosterone-producing cells. AT1 receptors activate a variety of 
signalling pathways including phosphoinositide-specific phopholipase C (PLC), which 
hydrolyzes phosphatylinositol 4,5-biphosphate (PIP2) to generate the two second 
messengers, inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (83). IP3 is 
thought to initiate aldosterone secretion by eliciting a transient increase in the 
cytosolic calcium concentration and activating calcium/calmodulin-dependent protein 
kinases (CaM kinase), whereas DAG increases protein kinase C (PKC) activity. PKC 
activity has been suggested to underlie sustained aldosterone secretion from 
glomerulosa cells (83). 
 34
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12- The acute regulation of aldosterone production is primarily regulated by AngII. 
AngII binds to AT1 receptor (AT1-R) activating PLC to release DAG and IP3. PLC activation 
also increases cellular levels of 12-HETE. DAG activates PKC, PKD and PLD. In turn, IP3 
causes release of intracellular calcium stores. CaM kinases, 12-HETE and PKD increase 
StAR protein levels and phosphorylation leading to increased cholesterol movement into the 
mitochondria. Within the mitochondria cholesterol is converted to pregnenolone by CYP11A1 
which is then metabolized to aldosterone (1).  
 
 AngII also increases calcium influx in glomerulosa cells. Influx of extracellular 
calcium acts to increase PKC activity, enhance PKC-stimulated steroidogenesis and 
maintain aldosterone production (84). In addition to activating PKC, the DAG 
produced by AngII-stimulated phospholipid hydrolysis also serves as a precursor for 
other signals regulating aldosterone secretion. Thus, arachidonic acid can be 
released by DAG lipase and is then metabolized by 12-lipoxygenase to generate 12-
hydroxyeicosatetraenoic acid (12-HETE) (85). 12-HETE appears to play an important 
role in mediating AngII-induced aldosterone secretion since blocking its production or 
metabolism reduces AngII-induced steroidogenesis (85).  
 The second and rate-limiting step of steroidogenesis involves transfer of the 
mobilized cholesterol from the outer mitochondrial membrane to the inner membrane, 
where CYP11A1 is localized and initiates steroid production. StAR seems to be 
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responsible for that role but the mechanism by which StAR induces cholesterol 
movement is not clear. Several hypothesis have been proposed, none of which seem 
entirely satisfactory. The molten globule model suggests that near the mitochondrial 
membrane, a high concentration of protons converts a structured tertiary 
conformation of the StAR carboxy terminus into a semi-ordered molten globule, 
which as secondary but not tertiary structure (86). However, whether the pH is 
sufficiently low to trigger this transition or whether such a relatively unstructured 
domain could efficiently transport cholesterol is unclear. Other models have similar 
shortcomings, such that the mechanism of StAR’s  action remains unclear. 
Nevertheless, StAR is clearly required for the translocation of cholesterol from the 
outer to the inner mitochondrial membrane and this rate-limiting step is controlled by 
signalling pathways that are activated by aldosterone secretagogues. 
 
Chronic Effects of Angiotensin II 
 
Chronically, AngII increases adrenal aldosterone production through two major 
actions. First, AngII increase expression of the enzymes needed to produce 
aldosterone, particularly CYP11B2. Second, AngII causes hypertrophy and 
hyperplasia of the adrenal glomerulosa, thus increasing the number of aldosterone-
producing cells. In vivo studies have provided strong evidence that sodium restriction 
increases renin/AngII levels causing an induction of glomerulosa CYP11B2 
expression (87, 88). 
The increase in CYP11B2 expression appears to result from increased 
transcription of the gene (89). Activation of the transcription appears to rely on the 
activation of transcription factors that bind to a cyclic AMP response element (CRE) 
found in the proximal region of the CYP11B2 promoter (90). In addition, both AngII 
and potassium rapidly induce the expression of the nuclear hormone receptor 
NR4A3, which also binds the promoter and activates CYP11B2 transcritption (82).  
AngII regulation of long-term aldosterone relies on other signalling pathways. 
AngII treatment activates adrenal cell protein kinase D (PKD) and this activation is 
associated with increased CYP11B2 expression, suggesting that this pathway may 
be involved in CYP11B2 regulation. Further, AngII-induced PKD activation is 
dependent upon PKC (91). However, PKD is known to phosphorylate and stimulate 
transcriptional activity of the cAMP response element binding (CREB) protein 
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transcription factor (92, 93). The promoter region is highly dependent on CREB 
response elements (89), suggesting that this PKD-mediated CREB activation may be 
important in regulating chronic aldosterone synthetic capacity.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13- The chronic regulation of aldosterone production is mainly due to angiotensin II 
and potassium. Angiotensin II binds to AT1 receptors (AT1-R) to activate PLC activity, which 
releases DAG and IP3. DAG activates PKC and PKD, and IP3 causes intracellular calcium 
release. PKC activation inhibits the transcription of CYP17, while calcium and PKD increase 
transcription of CYP11B2. This occurs through increased expression and phosphorylation of 
specific transcription factors. The increase in CYP11B2 increases the capacity to produce 
aldosterone (1).  
 
The role of potassium in the regulation of aldosterone production is often 
underestimated. Infusion of potassium will cause an acute increase in aldosterone 
production and a high potassium diet will increase aldosterone levels as well as the 
capacity of the adrenal to produce aldosterone. The mechanism by which potassium 
regulates aldosterone production relies on the extreme sensitivity of the glomerulosa 
cell membrane to small increases in potassium concentrations. Indeed, small 
increases in potassium stimulate calcium influx, via depolarization of the plasma 
membrane and activation of voltage-dependent calcium channels. As with AngII 
stimulation, this influx is also thought to activate CaM kinase (94) and is required for 
elevated potassium-induced aldosterone secretion, since inhibition of calcium influx 
abolishes the elevated potassium-stimulated secretory response (83). 
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ALDOSTERONE EFFECTS 
 
 
Kidney 
  
The kidney plays the primary role in salt and water homeostasis, maintaining 
osmolarity and volume in the extracellular space within a very narrow range despite 
wide variations in fluid and salt intake. Aldosterone plays a significant role in the 
maintenance of mammalian sodium, potassium, water and acid-base balance, 
primarily through effects on renal electrolyte excretion. Aldosterone promotes 
stimulation of Na+ absorption, potassium and hydrogen secretion by tight epithelia 
that display high transepithelial electrical resistance and amiloride-sensitive sodium 
transport. This epithelium is found in distal segments of the nephron, bladder, distal 
parts of the colon and rectum and in the ducts of exocrine glands (salivary, sweat 
glands) (95). 
 Sodium transport across the epithelia is driven by an electrochemical potential 
difference across the apical membrane allowing for passive movement of ions and 
water and by an active transport of ions across the basolateral membrane. The 
apical-membrane step is mediated by the opening of the amiloride-sensitive sodium 
channels that are sodium-selective. The basolateral extrusion of sodium is mediated 
by activation of a ouabain-sensitive sodium potassium ATPase (96). 
 Vectorial sodium transfer induced by aldosterone occurs mainly in the distal 
nephron and distal colon. Sodium entry in the cell at the apical membrane is 
regulated by the amiloride-sensitive epithelial sodium channel (ENaC). Efflux of 
sodium from the epithelial cell at the basolateral membrane is energy-dependent and 
is mediated by the sodium-potassium ATPase (Na+-K+ ATPase). Aldosterone 
stimulates Na+ transport by activating pre-existing sodium channels (96). 
 ENaC is composed of three subunits , , , which are regulated by 
corticosteroids in a tissue specific manner, however, this is not the principal 
mechanism by which aldosterone regulates ENaC activity (76). More importantly 
aldosterone can alter ENaC subunit turnover (degradation) and increase the number 
of channels located in the plasma membrane. Turnover of ENaC is mediated by 
ubiquitin protein ligase, Nedd4-2 (75). 
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 Under Na+ replete conditions, when aldosterone levels are low, ENaC is 
mainly in an intracellular location (77). Na+ absorption in response to aldosterone 
increases before any changes in mRNA for the subunits are observed (78) 
suggesting that aldosterone first induces the transcritption of proteins that modulate 
ENaC trafficking or function. One aldosterone-induced protein is SGK, a member of 
the serine-threonine kinase family. Sgk1 overexpression results n a large increase in 
Na+ current, but has no effect on K+ channel activity, due to an increase in the 
number of ENaC channels at the cell surface (74). Sgk1 phosphorylates Nedd4-2, 
decreasing its binding to ENaC and resulting in ENaC surface expression. 
Aldosterone stimulation results in a rapid increase in Sgk1 which peaks 1-2 hours 
after exposure (79).  
 The late phase of aldosterone regulation of ENaC involves the increase in the 
expression of ENaC mRNA and protein in the kidney with no changes in the  or  
subunits (80, 97). 
 
Nongenomic effects of aldosterone 
 
 Nongenomic effects of aldosterone which occur too rapidly to be mediated by 
gene transcription, insensitive to inhibitors of transcription (actinomycin D) or 
translation (cyclohexamide) have been postulated to be mediated by a membrane 
receptor different from the soluble MR (98-100). Some membrane MR effects may be 
inhibited by classical MR antagonist, but not others. 
 Nongenomic effects of aldosterone on ion transport proteins have been 
studied. Aldosterone has been show to regulate the Na+/K+ exchange isoforms 
(NHE) NHE1 and NHE3. The Maldin-Darby canine kidney cells (MDCK cells) have 
properties corresponding to collecting duct intercalated cells and demonstrate 
nongenomic responses to aldosterone. At physiologic concentrations, aldosterone 
had rapid (1-2 minutes) nongenomic stimulatory effects N+/H+ exchange in these 
cells as determined by increases in pH and Na+ concentration (101, 102). The rapid 
effects were not prevented by actinomycin D, cyclohexamide or spironolactone and 
resulted from an increase in affinity of the exchanger for intracellular H+. The rapid 
stimulation of N+/H+ exchange by aldosterone depends on an increase in intracellular 
Ca+, as well as rapid phosphorylation of the extracellular signal-regulated kinase 
(ERK1/2) (101).  
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Cardiovascular System 
 
In recent years, our understanding of aldosterone has changed from 
considering it to be a hormone mainly responsible for fluid and electrolyte balance to 
a hormone with widespread cardiovascular and metabolic effects. A large body of 
literature demonstrates that activation of the mineralocorticoid receptor by 
aldosterone increases oxidative stress, inflammation, insulin resistance and vascular 
dysfunction, leading to renovascular and cardiovascular injury and stroke. Further, 
clinical studies using the selective MR antagonist, eplerenone, or the non-selective 
antagonist, spironolactone, have demonstrated beneficial cardiovascular and 
renovascular effects in patients with heart failure, diabetes and hypertension. The 
adverse cardiovascular actions of MR involve both genomic and nongenomic 
mechanisms. 
 
 Heart  
Approximately 50 years after the discovery of aldosterone, several large-scale 
clinical studies revealed potent beneficial effects of MR antagonist on the heart. The 
Randomized Aldalactone Evaluation Study (RALES) was designed to test the effect 
of an MR antagonist in addition to standard therapy, including angiotensin-converting 
enzyme (ACE) inhibitors, on mortality in patients with severe heart failure secondary 
to systolic left ventricular dysfunction with ejection fraction  35% (103). 
Spironolactone treatment had clear benefits with a 30% reduction in relative risk of 
death. Hospitalization rate for worsening heart failure was 35% lower in the 
spironolactone group than in the placebo group. In addition, spironolactone caused a 
significant improvement in the symptoms of heart failure. Further, the beneficial effect 
of spironolactone was observed without significant effects on blood pressure.  
 The benefit of MR blockade in heart disease was confirmed in the Eplerenone 
Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study 
(EPHESUS). This study was designed to test the effect of eplerenone, a selective 
MR antagonist, on mortality and hospitalization rates in patients with left ventricular 
dysfunction and heart failure after acute myocardial infarction (104). During a mean 
follow-up of 16 months, there was a 15% relative risk reduction in overall mortality 
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and 17% relative risk reduction in cardiovascular mortality. Hospitalization rates were 
also significantly lower in the eplerenone group. 
 Two small clinical studies suggest a beneficial effect of MR blockade on 
diastolic dysfunction. Treatment for 6 months with MR antagonist canrenone 
improved diastolic function, as compared to placebo treatment, in patients with 
hypertension and left ventricular diastolic dysfunction on ACE inhibitor and calcium 
channel blockade therapy (105). The improvements in diastolic function with 
canrenone were not mediated by changes in blood pressure or left ventricular mass, 
suggesting that MR blockade has a direct beneficial effect on diastolic function. In 
another study in patients with dilated cardiomyopathy, 12 months of treatment with 
spironolactone led to decreased myocardial collagen content, decreased myocardial 
stiffness and ameliorated diastolic dysfunction (106). 
 Thus, available clinical data demonstrate benefits of MR blockade in the 
treatment of heart failure, left ventricular hypertrophy and diastolic dysfunction. The 
potential mechanisms for these beneficial effects have been investigated using cell 
culture systems and animal models of cardiovascular injuries. 
 Animal models of cardiac injury have clearly demonstrated an adverse effect 
of mineralocorticoids on the heart and vasculature. Activation of the MR for 8 weeks 
through administration of aldosterone or deoxycorticosterone led to hypertension and 
cardiac fibrosis in uninephrectomized rats on a moderately high sodium diet (1% 
NaCl in drinking water) and MR blockade prevented this damage (107, 108). In a 
short-term (14 day) rodent model of hypertension and cardiovascular injury, rats 
receiving a nitric oxide synthase (NOS) inhibitor, AngII and a moderately high sodium 
diet developed coronary artery injury, myocardial necrosis and inflammation in both 
right and left ventricles (109, 110). Vascular injury was characterized by increased 
expression of plasminogen activator inhibitor (PAI-1), inflammation, intimal thickening 
and vascular wall necrosis with surrounding granulation tissue. Treatment with 
eplerenone or spironolactone to block the actions of aldosterone or adrenalectomy to 
reduce circulating aldosterone levels prevented the injury, while injury recurred when 
adrenalectomized animals were infused with aldosterone. In this model, there was 
minimal cardiac fibrosis suggesting that vascular injury is an early event in 
aldosterone-mediated cardiovascular injury leading secondarily to myocardial 
ischemia and necrosis followed by repair and fibrosis.  
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 Several investigators demonstrated that activation of MR by administration of 
aldosterone, deoxycorticosterone acetate or an inhibitor of 11βHSD2, increased 
coronary vascular expression of pro-inflammatory molecules, cyclo-oxygenase 2 
(COX-2), monocyte chemoattractant protein-1 (MCP1) and osteopontin in 
uninephrectomized rats on a moderately high sodium diet (111, 112). These vascular 
changes preceded the development of cardiac fibrosis. In these pre-clinical studies of 
cardiovascular injury, the beneficial effects of blocking the MR or reducing 
aldosterone via adrenalectomy appeared to be independent of effects on volume 
homeostasis and blood pressure as vascular injury was ameliorated without 
reductions in blood pressure (110, 111). 
 Thus, vascular injury and dysfunction appeared to play a key role in the 
pathophysiology of aldosterone-induced cardiac injury. However, aldosterone’s 
adverse vascular effects are not limited to the heart but, extend to brain, kidney and 
peripheral vasculature. 
 
 Renal disease 
Aldosterone blockade has been shown to reduce albuminuria in hypertensive 
patients independent of an effect on blood pressure itself (113, 114). Eplerenone 
caused a reduction in 35% of urinary albumin excretion. Similarly, in older patients 
with isolated systolic hypertension, eplerenone reduced microalbuminuria to a much 
greater extent than amlodipine (a drug used to treat for this condition). One 
mechanism for the apparent increase in mineralocorticoid-mediated renal injury may 
involve increased renal expression of MR. Renal biopsies of patients with renal 
disease demonstrated a marked increase in renal expression of the MR in individuals 
with high albuminuria, compared to those with lesser amounts of albuminuria (115). 
MR blockade also reduces renal injury in non-diabetic animal models. In 
rodents on a moderately high sodium diet, administration of a NOS inhibitor and 
AngII caused proteinuria and renal arteriopathy that was prevented by administration 
of eplerenone or adrenalectomy (110). The injury was again present when 
adrenalectomized rats were infused with aldosterone, demonstrating that aldosterone 
is required for the induction of AngII renal injury in this model. Similarly, blockade of 
the MR or adrenalectomy reduced proteinuria and renal arteriopathy in other 
hypertensive rodent models of AngII-mediated renal injury (116). 
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Potential mechanisms mediating the cardiovascular effects of aldosterone  
 
 
 
 
 
 
 
 
 
 
 
 Effect of Aldosterone on Intracellular Signalling Pathways 
 In addition to aldosterone’s well characterized effects on gene transcription, 
aldosterone has rapid nongenomic effects that appear to involve cross-talk between 
the MR and other signalling cascades, many of which are associated with 
cardiovascular injury. A research group led by Grossman demonstrated that 
aldosterone increased phosphorylation of ERK through a process dependent on 
aldosterone-mediated increases in c-Src phosphorylation and transactivation of 
epidermal growth factor receptor (EGFR) (117, 118). Further, they identified the c-
terminal EF domain of the MR, which includes the ligand binding region, as the 
region that mediates these nongenomic actions of aldosterone on ERK activation 
(119). Other investigators reported that aldosterone interacts synergistically with 
angiotensin II to increase ERK activation (120). Aldosterone-mediated 
phosphorylation of c-Src also leads to increased activation of MAP kinases and 
NADPH oxidase in rat vascular smooth muscle cells (121). In endothelial cells, 
aldosterone increased superoxide generation via activation of Src, NADPH oxidase 
and the small GTP-binding protein Rac-1 (122).  
Thus, aldosterone has effects on multiple intracellular processes including 
activity of EGFR and angiotensin II receptor, oxidative stress and activity of ERK, c-
Src and MAP kinase signalling pathways. Activation of these pathways may mediate 
some of the adverse effects of aldosterone. For example, aldosterone stimulation of 
MAPK1 led to increased vascular smooth muscle proliferation (122). 
Figure 14- potential 
mechanisms of 
aldosterone-induced 
adverse cardiovascular 
effects (1). 
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 Vascular Function 
 Aldosterone affects vasoconstriction and vasodilation. In mesenteric 
resistance vessels, aldosterone potentiated phenylephrine-mediated constriction 
through a nongenomic process involving PI3K and PKC, but not ERK activation 
(123). In rabbit preglomerular arterioles, aldosterone promoted vasoconstriction 
through these same pathways, but also stimulated vasodilation through increases in 
endothelial-derived nitric oxide (NO) (124). In intact aortic rings, the vasodilatory 
effects of aldosterone appeared to dominate. However, when the endothelium was 
removed from the aortic ring, aldosterone reversed the effect, indicating dominance 
of aldosterone’s vasoconstrictive properties under these conditions (125). 
 Additional studies suggest that aldosterone may reduce endothelial NO. In 
human umbilical vein endothelial cells (HUVEC), MR activation increased generation 
of oxygen reactive species, which can inactivate NO, and decreased NOS 
expression (126). Also, aldosterone was shown do decrease endothelial glucose-6-
phosphate dehydrogenase (G6PDH) expression and activity leading to increased 
oxidative stress, decreased NO and impaired vascular reactivity (127). In conclusion, 
while aldosterone has both vasodilatory and vasoconstrictive actions, most preclinical 
studies supported an adverse effect on vascular function. In disease states, such as 
heart failure, the adverse vascular effects of aldosterone also appear dominant.  
 
 Inflammation 
 Studies in animal models of cardiac and renal injury, have clearly 
demonstrated the pro-inflammatory effects of aldosterone. In vitro studies, suggest 
that these inflammatory effects are due in part to direct pro-inflammatory actions of 
aldosterone. In human coronary artery smooth muscle cells, aldosterone increased 
gene expression of pro-inflammatory molecules as well as those involved in fibrosis 
and calcification (128). Aldosterone increased N-B transcriptional activity and   
MCP-1 expression in cultured mesangial and proximal tubule cells (129, 130) and 
increased TNF-, IL-6 and MCP-1 in adipocytes cultures (131, 132). These pro-
inflammatory effects of aldosterone are also observed in humans (133). 
 Insulin sensitivity 
 Obesity is often associated with hypertension and one of the mechanisms of 
obesity-induced hypertension involves increased mineralocorticoid activity (134). 
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Increased aldosterone levels were associated with an increase in insulin resistance 
(135). The underlying mechanism for aldosterone overproduction in obesity is not 
clear. Some studies linked increased production of aldosterone to mineralocorticoid 
releasing factors from the adipocytes (136). Another hypothesis suggests the role of 
hepatic intermediaries in the stimulation of adrenal aldosterone by fatty acids 
produced by visceral adipocytes (137). 
 The mechanism of aldosterone-induced insulin resistance may involve effects 
of aldosterone on the adipose tissue. MR has been shown to mediate corticosteroid-
induced adipocyte differentiation (138). Furthermore, aldosterone increased 
expression of pro-inflammatory factors, decreased expression of adiponectin and 
PPAR- and reduced insulin-stimulated glucose uptake in culture adipocytes (131, 
132). In vivo studies in the db/db mouse model of obesity and diabetes demonstrated 
that the blockade of the MR reduced adipose tissue inflammation, decreased adipose 
tissue expression of pro-inflammatory factors, increased adipose tissue expression of 
adiponectin and PPAR- and improve measures of insulin sensitivity (131). 
 
 Dietary Sodium 
 In animal models, dietary sodium intake has been shown to have a profound 
effect on aldosterone-mediated cardiovascular injury. A low dietary sodium intake 
prevented the development of cardiac and renal injury uninephrectomized rats 
infused with deoxycorticosterone acetate for 8 weeks, whereas the animals 
developed profound cardiac and perivascular fibrosis when consuming a high sodium 
diet (139). Also, rats receiving a NOS inhibitor and AngII developed vascular and 
cardiac injury when on a moderately high sodium diet. However, a low sodium diet 
prevented this injury despite markedly elevated blood levels of aldosterone (107). 
These studies suggest that increases in circulating aldosterone that are appropriate 
for the level of sodium consumption, i.e. elevated aldosterone levels in individuals 
consuming a low sodium diet, may not result in cardiovascular injury. Rather, 
cardiovascular injury occurs when aldosterone is elevated relative to dietary sodium 
intake (140). In contrast to dietary sodium, modulation of dietary potassium does not 
have a major effect on aldosterone-mediated cardiovascular injury (141). 
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The estrogen receptor 
 
17β-Estradiol (E2) is the main ligand to the estrogen receptor (ERα/β)     
(Figure 15). E2 is secreted into the bloodstream by the adrenal cortex and gonads 
and plays a prominent role in mediating sexual development and behaviour, 
reproductive functions, proliferation and differentiation of various tissues via ER. For 
example, E2/ERα interaction is responsible for E2-induced proliferation of breast and 
uterine tissue.  
ERα was first isolated in 1962, the 
corresponding gene cloned in the same year (142) 
and subsequently located to the long arm of 
chromosome 6 (6q24-q27; today 6q25.1) (143). 
Three decades later, in 1993, the first ERα 
knockout mouse was created and led to the 
discovery that development was possible without 
ERα (144). At that time, ERα was thought to be the 
only receptor mediating responses to E2, but in 
1996 ERβ was cloned (145). 
E2 binds with a high affinity to ER, whereas metabolic products of E2, like 
estrone or estriol, bind with a much lower affinity. Estrogenic action can be influenced 
pharmacologically by anti-estrogens and selective estrogen receptor modulators 
called SERMs. The first SERM clinically tested was tamoxifen in the 1970s and still 
today tamoxifen is used, with very good results, for the reduction of breast cancer 
incidence in high-risk premenopausal and postmenopausal women (146). 
 
 
 
 
 
 
 
Figure 15- Molecular structure of 
ERα bound to E2. Ligand Domain 
of ERα complexed to E2. Image 
based on X-ray structures (3). 
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Estrogen receptor protein structure 
  
Steroid hormone receptors share a high level of homology, conservation of 
three dimensional structure and protein domains (Figure 16). 
 
 
A/B-domain (amino acids 1-180) 
 
The A/B domain is also called activation function 1 (AF1). Concerning ERs, 
different splice variants of AF1 may modulate transcriptional activity by repressing 
AF1-mediated transactivation upon heterodimerization with full-length ER. 
Interestingly, in contrast to ERα, ERβ AF1 contains a repressor domain that 
decreases overall receptor transcriptional activity by masking transactivation of the 
amino terminal domain and it only functions in the context of a full length receptor 
(147). 
 
 
 
 
Figure 16- Estrogen receptor domains. The ER is composed of a variable N-terminal domain 
(A/B), an AF1 protein domain which is weakly conserved (<15%) among NR members and a 
highly conserved DNA-binding domain (DBD) or C-domain (96%), which in the case of ERα/β 
binds EREs. The palindromic character of this sequence supports ER binding as a dimer. 
The receptors also have a flexible hinge region (D) and a C-terminal E-domain, containing 
the ligand-dependent AF2 region. ERα and ERβ contain an additional F-domain at their 
carboxy-terminal ends. Numbers on the right represent the length of each receptor protein in 
amino acids (148). 
 
 
 
C-domain (amino acids 181-263) 
 
The C-domain of ER consists of a DNA-binding domain (DBD), which is highly 
homologous. It features two zinc-finger motifs, which are not only responsible for 
DNA-binding, but also for the dimerization of the receptors, allowing the formation of 
homo- and heterodimers. In addition to the zinc fingers, there are also two alpha-
helical motifs within the DBD, where the first helix directly interacts with the DNA 
major groove, while the second helix stabilizes the complex. ERα and ERβ dimmers 
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bind DNA with comparable affinities as either homo- or heterodimers to the same 
estrogen response elements (EREs) and regulate similar sets of genes. 
 
D-domain (amino acids 264-302) 
 
The D-domain is also referred to as the Hinge-region and contains a serine 
residue (S305) that can be phosphorylated in ERs. 
 
E and F-domains (amino acids 303-552 and 553-595) 
 
The carboxy terminal E-domain (also called AF2) represents a ligand binding 
domain (LBD) and an interaction site co-activators and co-repressors. The carboxy 
terminal F-domain represents the last 45 amino acids in ERα and approximately the 
last 30 amino acids in ERβ where it possibly functions to internally restrain 
dimerization of ER, thus protecting against improper ligand activation (149).  
 
ER isoforms 
  
With eight total ERα coding exons, up to five different ERα transcript 
isoforms/variants have been detected in humans due to alternative usage of eight 5’ 
untranslated exons, exonic duplications, alternative splicing and intronic exons (150). 
The length of human ERα correlates mainly with 595 amino acids, where in different 
cell lines protein variants derived from mRNA splice products have been confirmed, 
e.g. human ERα-36 (ERα-36 kDa), ERα-46 kDa and ERα-66 kDa (151, 152). 
Interestingly, the ERα-36 lacks both transcriptional activation domains (AF1+2) and 
contains an exon coding for myristoylation sites, thus predicting an interaction with 
the plasma membrane (152). 
 Like ERα, ERβ also displays several transcriptional isoforms/variants, 
including seven untranslated 5’ exons, alternative exonic splicing and intronic exons 
(150). 
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Co-activators and Co-repressors 
  
SRC-1 was the first co-activator identified and has been shown to interact with 
different nuclear receptors (153). SRC-2, also termed glucocorticoid receptor-
interacting protein 1 (GRIP1), transcriptional intermediary factor 2 (TIF2) or nuclear 
receptor co-activator 2 (NCoA2), binds to AF2 of specific nuclear receptors. Although 
not considered a real co-activator, the MUC1 oncoprotein not only binds directly to 
ERα, but also increases the recruitment of SRC-1 and SRC-2, thus enhancing ER 
mediated transcription following E2 stimulation of breast cancer cells (154). 
 The third member of the SRC family, SRC-3, was identified and described as 
retinoic acid receptor interacting protein (RAC3), mouse homolog CBP-interacting 
protein (p/CIP), hRARβ-stimulatory protein (ACTR) and TR-interacting protein 
(TRAM1). p/CIP and the human isoforms are involved in cellular proliferation, 
differentiation, migration and up-regulated in breast cancer (155). The demonstration 
of an interaction of SRC family members (also called the p160 family) with the CREB 
binding protein (CBP) and its homolog p300 has provided further insight into the 
molecular mechanisms. Importantly, co-activators exert their functions in at least two 
ways: on the one hand interacting with components of the transcription machinery 
(153), and on the other hand recruiting p300/CBP, which possesses both intrinsic 
and associated histone acetyltransferase (HAT) activities (156), thus promoting 
transcription by opening the chromatin structure. 
 In 2001, a novel co-activator PELP1 (proline, glutamic acid and leucine-rich 
protein), not related to the SRC family was identified (157). PELP1 also interacts with 
CBP and p300 to enhance transcription, and additionally affects cell cycle 
progression. PELP1 was also described to be involved in histone modification, 
especially in the displacement of H1 (158).  
 Evidence supports that antagonist-mediated inhibition of ERα not only blocks 
co-activator recruitment but also facilitates the recruitment of a variety of co-
repressors to ERα (159). The nuclear receptor co-repressor (NCoR1) and silencing 
mediator for retinoic and thyroid receptor (SMRT or NCoR2) are found in complexes 
with histone-deacetylases supporting their role in chromatin modification into a 
transcriptionally less active state (160). Interestingly, ER does not interact with co-
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repressors in the absence of a ligand, but only interacts when antagonists or 
modulators of estrogenic action (e.g. tamoxifen) are bound (161). 
 
Estrogen receptor signalling 
 
 The most well-characterized steroid hormone receptor signalling occurs via a 
cellular genomic response where lipophilic ligands diffuse through the cellular 
membrane, bind to ER, induce a conformational change and release heat shock 
proteins (hsp) (Figure 17). Upon unveiling a nuclear localization signal (NLS), ligand 
bound receptor dimmers translocate to the nucleus and along with a variety of 
cofactors bind to specific response elements know as estrogen response elements 
(EREs) located in the promoters of target genes resulting in a transcriptional 
regulation of such target genes. In addition to freely diffusing steroids, Hames et al. 
demonstrated that megalin, an endocytic receptor in reproductive tissues, may 
provide an active transport mechanism for cellular uptake of biologically active 
androgens and estrogens (162). Also mediated by ligand binding and even 
independent of ligands, activation of membrane associated steroid hormone 
receptors can signal via a rapid cellular but nongenomic response occurring in 
seconds or minutes where activation of signal transduction pathways or second 
messenger signalling results in target gene activation. 
 
 
Figure 17- Model of ER-signalling: the main ER-signalling in cells occurs via a genomic 
response after binding of steroid hormones or analogues. Following ligand binding and 
release from the chaperones hsp70 and/or hsp90 (163), ER dimers (middle grey striped oval 
circle) translocate to the nucleus where they regulate target genes, resulting in specific 
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cellular outcomes. In addition, membrane associated ER can signal via a rapid response 
leading to cellular fates. ER membrane association can occur following different membrane 
receptor activations, like IGF-1R, EGFR or Her2 via PI3-K (p85 and p110) (grey stick 
receptor) and lead to further signal transduction of AKT or with Shc via MAPK pathway. In 
addition, palmitoylated was also found at specific membrane domains, called caveolae (far 
right) associated with caveolin 1 (CAV1), which inhibits adenocyclase (AC) via Gα1 and 
results in ER dissociation from the membrane after ligand binding through de-palmitoylation 
(164). Black diamond E2, cross palmitoylation, P phosphorylation, IRS Insulin receptor 
substrate, PM plasma membrane (148). 
 
 
Nongenomic estrogen signalling 
 
The model of nongenomic responses arose from studies demonstrating that 
E2 repeatedly exerted effects that were too fast to be based on transcriptional 
events. The ER membrane form is predicted to be a full length ER (165), an isoform 
(166), or a completely distinct receptor (167). ERs harbour neither transmembrane 
nor intrinsic kinase domains, which could explain membranous signalling events, 
thus specific modifications like myristoylation, palmitoylation and protein interactions 
are most likely involved to target and maintain ER at the plasma membrane. The 
adaptor protein Shc and the Insulin-like growth factor 1 receptor (IGF-1R) were 
shown necessary for membrane localization of ER by siRNA knock-down assays 
(168).  
 In endothelial cells, as in other cell types, ER was shown to target lipid rafts 
within the plasma membrane (caveolae) by interaction with caveolin-1, where it 
activates endothelial nitric oxide synthase (eNOS) through protein kinase-mediated 
phosphorylation (169). Caveolae facilitate signal transduction by providing a location 
for various signalling molecules (170). 
Activation of ER by phosphorylation was demonstrated in a hormone-
dependent as well as hormone-independent manner and is an integral regulatory 
mechanism of nongenomic responses (Figure 15). Martin et al. demonstrated for the 
first time the involvement of AKT, also called Protein Kinase B, in phosphorylation of 
ERα (171). AKT becomes activated by growth factors binding to tyrosine-kinase 
receptors which signal via phosphatidylinositol 3-kinase (PI3K). Major regulatory 
proteins for AKT regulation in the signalling pathway are phosphatase with tensin 
 51
homology (PTEN) and target of Rapamycin (mTOR). PTEN is a lipid phosphatase 
specific for 3’phosphorylated inositol phosphates and inhibits AKT, whereas the 
mTOR kinase is essential for AKT phosphorylation (172). Upon phosphorylation and 
activation AKT functions in two ways, on the one hand augments transcription of 
ERα, and on the other hand increases ER activity by phosphorylating AF1 on 
different residues. Increased protein phosphorylation of both AKT and PTEN along 
with PTEN gene mutations, deletions or loss of expression have been detected in 
hormone responsive tumours, which would lead to an enhancement of ER signalling. 
Protein Kinase A (PKA) is also involved in regulating ERα transcriptional 
activity by phosphorylation of ER S236 in one zinc finger of the DBD, this 
modification was found to inhibit dimerization and DNA-binding and had attenuating 
effects. Cholera toxin, a G-protein activator, in combination with 3-isobutyl-1-
methylxanthine, a phosphodiesterase inhibitor, and Dopamine have all been 
demonstrated to increase intracellular cAMP levels and activate PKA (173). 
 
 
Caveolins 
 
 
Caveolin proteins are primary structural components of caveolae, which form 
50-100nm plasma membrane invaginations in various cell types (174). Caveolae are 
involved in several cellular processes including cholesterol homeostasis, vesicular 
transport and regulation of signal transduction (175). There are three known caveolin 
proteins caveolin-1 (CAV1) (176), caveolin-2 (CAV2) (177), and caveolin-3 (CAV3) 
(178). CAV1 and CAV2 are expressed in a variety of tissues, including endothelial 
(179), epithelial (180), and neuronal (181), and have overlapping expression in most 
tissues. CAV3 is expressed mainly in skeletal and smooth muscles (178) and the 
nervous system (181). While ablation of CAV1 and CAV3 resulted in a complete loss 
of caveolae formation (182, 183), disruption of CAV2 did not seem to affect caveolae 
formation (184).  
The plasma membrane invagination structure of caveolae supports functional 
protein-protein interactions and cluster of several discrete signalling pathways. Thus, 
caveolae are thought to integrate interactions of receptors and signalling molecules 
in the plasma membrane, resulting in rapid and specific signal transduction (175). 
The caveolin scaffolding domain (CSD) of CAV1 binds numerous signalling 
 52
molecules, including Src family kinases, c-Neu, H-Ras, EGFR, eNOS, and G-protein 
coupled receptors (GPCRs). Interaction of the CSD domain with these signalling 
molecules holds them in an inactive state, which is released upon activation by the 
appropriate stimuli (185). 
The ability of CAV1 to hold and orchestrate the spatio-temporal pairing of 
membrane localized ERα with its effectors makes CAV1 an important scaffolding 
protein mediating membrane ERα actions. CAV1 is required for estrogen-mediated 
ERα-dependent eNOS production in endothelial cells (186). In MCF-7 breast cancer 
cells and in vascular smooth muscle cells, overexpression of CAV1 increases 
estrogen-dependent ERα translocation to the cell membrane and potentiates nuclear 
ERα-mediated gene expression (187). 
More recently, CAV1 has also been shown to interact with the WD-repeat 
protein striatin, which has been shown to be a key intermediary of the effects of 
steroid receptors, specifically estrogen receptor-α (ER) (188). Lu et al provided 
evidence that striatin´s N-terminal segment interacts with the DNA binding domain of 
ER in the immortalized human endothelial cell line, EA.hy926 cells. This interaction 
organizes the ERα-eNOS membrane signalling leading to rapid nongenomic 
activation of downstream signalling pathways including ERK and eNOS in endothelial 
cells.  
 
WD-repeat proteins: Striatin, Zinedin and SG2NA 
 
The WD-repeat-containing family of proteins is defined by two main 
characteristic features: a lack of intrinsic catalytic activity and repeated units of beta-
sheet motifs that are arranged into a beta-propeller structure to form a platform on 
which multiple protein complexes can dynamically assemble. In this way WD repeat 
containing proteins play a major role in cellular events by mediating important 
protein-protein interactions by providing a permissive scaffold for the anchorage of 
several diverse molecules that are important in cellular signalling, cytoskeletal 
assembly and vesicular trafficking.   
 
Striatin, zinedin and SG2NA are three distinct but structurally related WD-
repeat proteins that share high protein sequence homology within both C- and N-
terminal domains.   
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Figure 18.  Schematic representation of protein-protein interaction domains present in the 
WD-repeat proteins, striatin, zinedin and SG2NA.  Percentage homology within the mapped 
interaction domains (black boxes) are indicated.  Gray boxes represent poorly conserved 
regions between the three proteins and may contribute to differential functions of these 
molecules.  The respective amino acid length of each protein is also noted.  The arrow head 
indicates the position of an additional amino acid present in SG2NA  (189). 
 
 Striatin, which comprises 780 amino acids and weighs 110 kDa, was first 
isolated from brain synaptomes as a calmodulin-binding protein. It contains at least 
four protein-protein interaction domains (see Figure 18), including caveolin-binding, 
coiled-coil, and Ca2+-calmodulin (CaM) binding at the N-terminus, and a series of 
eight WD repeat domains at the C-terminus (190). Overexpression of striatin in 
endothelial cells resulted in an increase in ERα localization within membrane-
enriched fractions containing EGFR and IGF-1 receptor and a slight decrease in the 
presence of nuclear ERα suggesting that it plays a role in the cellular distribution of 
ER bringing it in close proximity to membrane receptors where it can potentially be 
involved in cellular signalling (188). In this way, the N-terminus of striatin (amino 
acids 1-203) has been found interact with the N-terminus of ERα (amino acids 185-
253) while the C-terminal WD repeat domain binds the GPCR (Gαi) complex. 
Therefore, striatin serves as a scaffold directing ERα to the plasma membrane and 
bridges ERα with the GPCR (Gαi) complex to facilitate assembly of a membrane 
signalling complexes required for rapid estrogen extra-nuclear activation of MAPK, 
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Akt, and eNOS in endothelial cells (188). Interestingly, disruption of the striatin-ERα 
interaction had no effect on estrogen-mediated gene transcription suggesting that 
striatin specifically mediates ERα extra-nuclear signalling independent of ERα 
nuclear actions.  
Phylogenetic analysis of the WD proteins striatin, zinedin and SG2NA suggest 
that are derived from an ancestral gene through gene duplication to explain their 
similar gene and protein characteristics.  Furthermore, tissue expression; at least in 
the mouse, overlap and appear to be localized within the same tissue types.  In this 
way, these three WD protein members may potentially play an important and 
functional role in mediating steroid receptor dependent signalling.  
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Materials and Methods 
 
Cell Lines and Cell Culture 
 
During the course of this work two cell lines were used: EA.hy926 and IMR90.  
 
EA.hy926 
Immortalized endothelial cell lines are very often used as a model of 
endothelium for studies of various processes connected with its functions. Among the 
hybrid cells, the EA.hy926 cell line, derived by the fusion of HUVECs with the 
continuous human lung carcinoma cell line A549, is presently the best characterized 
macro-vascular endothelial cell line (191). The EA.hy926 cells used in these 
experiments were a kind gift from Dr. Cora J Edgell and were obtained from the 
Tissue Culture Facility at the University of North Carolina Lineberger Comprehensive 
Cancer Centre. 
Cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) media 
(DMEM 4,5g/L Glucose with L-Glutamine and sodium pyruvate by Cellgro, Manassas, 
USA) complemented with 10% Fetal Bovine Serum (FBS) (Gibco, Invitrogen, 
Carlsbad, USA) and 1% Pencilin/Streptomycin solution (100U/ml penicillin, 100g 
streptomycin; Gibco, Invitrogen, Carlsbad, USA. 
Cells were kept at low passages (1-13) due to informal reports by other groups, 
stating that the expression of certain proteins was lost or diminished if the cells were 
used past after passage 16. Cells were passaged at a 1 to 16 ratio (4500 cells/cm2). 
 
IMR90 
 The IMR90 cell line is a human diploid fibroblast strain derived by W.W. 
Nichols and associates from the lungs of a 16-week female foetus (192).  
The division potential, viral susceptibilities and other properties have been thoroughly 
studied such that the line may be considered as an alternate for WI-38 and other 
standard human lung cell strains. The cells have been reported to be capable of 
attaining 58 population doublings before the onset of senescence. 
The IMR90 cells used were acquired from the American Type Culture 
Collection (catalogue number CCL-186™) (ATCC, Manassas, VA, USA) and 
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maintained until population doubling (PDL) 48. IMR90 cells were grown and 
passaged in MCDB 131 media (Gibco, Invitrogen, Carlsbad, USA) complemented 
with 10% FBS and 1% Pencilin/Streptomycin solution. Cells were passaged at a 1 to 
6 ratio (4000 cells/cm2). 
 
Primary Cell Culture 
 
 Primary cells are thus called because they are derived directly from a living 
organism. In the case of the work here presented healthy C57BL/6 mice were used 
to collect aortic endothelial cells. 
 The advantages of primary cultures are that the cells have not been “modified” 
in any way (other than the enzymatic or physical dissociation necessary to obtain 
them), and that allows for study conditions as close as possible to in vivo. The 
disadvantages of these cultures are the mixed nature of each preparation, limited 
lifespan of the culture and the potential contamination problems. 
 
Mouse Aortic Endothelial Cells 
 
Aortic endothelial cells were isolated under sterile conditions as previously 
described by Kobayashi et al. in 2005 (193).  
The animals were sacrificed under deep inhalatory anaesthesia with isoflurane 
and cleaned with a 70% solution on ethanol. An incision was made vertically from the 
mid abdomen to the neck. The rib cage was cracked and removed as were the lungs 
to expose the aorta. Fat surrounding the aortic vase was removed using a scalpel. 
The lower extremity of the thoracic aorta was clipped to release the blood and 
subsequently perfused with 1 ml PBS (Gibco, Invitrogen, Carlsbad, USA) 
containing 1,000 U/ml heparin (Sigma-Aldrich, St. Louis, MO) from the left ventricle.  
The heart was removed and a 23G needle was inserted in the aorta and the 
top part was tied using surgical thread. The aorta was perfused with DMEM media 
and the lower end equally tied using surgical thread. The aortas was then dissected 
out and placed in a Petri dish (no coating) containing 20% FBS-DMEM with 1000 
U/ml heparin.  
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Using a syringe, the isolated aorta was washed in serum-free DMEM and filled 
with a 2 mg/ml collagenase II solution (Sigma-Aldrich, St. Louis, USA). The aorta was 
placed in a clean Petri dish that went in a 37ºC, 5% CO2 incubator. After 45min 
incubation, endothelial cells were flushed into a conical tube with 5 ml of 20% FBS-
DMEM.  
The cells collected were then centrifuged (1200 rpm for 5 minutes), 
resuspended and cultured in 5 ml 20% FBS-DMEM in type I collagen-coated T25 
flasks (Corning, New York, USA). Cells were incubated for 2 hr at 37ºC. The media 
was then removed and the cells resuspended in 20% FBS-DMEM containing: 
100U/ml penicillin, 100g streptomycin, 2mM L-glutamine (Gibco, Invitrogen, 
Carlsbad, USA), 1% MEM amino acids (Gibco, Invitrogen, Carlsbad, USA), 1% 
sodium pyruvate (Gibco, Invitrogen, Carlsbad, USA), 100 /ml heparin, 100 g/ml 
endothelial cell growth supplements (Sigma-Aldrich, St. Louis, MO) and incubated in 
5% CO2 at 37°C in a humidified atmosphere. The cells were used at passages 2-3. 
The purity of the primary cultures was confirmed by the specific monoclonal 
antibodies raised against vWF and PECAM-1. 
 
FBS Selection and Growth Curve 
 
 As many scientists who work with cells on a regular basis know, there are 
some batches of FBS that seem to work better than others. FBS is not a man made 
product and hence its ingredients/components may vary not only in quality as in 
quantity. This way, and because the cells used for experiments revealed to be 
sensitive to such changes, it was decided to test different batches of FBS opting for 
one with which all of the necessary experiments would be ran. 
  
Using the service Batch Testing with Reserves provided by Gibco, which 
allows customers to obtain a sample for testing in their own application with a reserve 
held on that batch, 5 different serum lots were received and further tested: 
 
Lot 1- 1355888 
Lot 2- 1355891 
Lot 3- 1389439 
Lot 4- 1365490 
Lot 5- 1385397 
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Seven T25 flasks were seeded with the same amount of cells for both the 
EA.hy926 and IMR90 cells. Counts were taken (at the same hour) everyday for 7 
days  using a Neubaüer counting chamber and Trypan Blue Stain (Gibco, 
Invitrogen, Carlsbad, USA) for cell viability purposes. Plating day was considered 
day 1. Cells were allowed to attach for three hours before the first count was taken. 
EA.hy926 cells were used at Passage 13 and IMR90 cells at PDL 26. 
 
 
Immunofluorescence Staining 
 
In order to confirm the endothelial nature and purity of the primary cell cultures  
used in this thesis specific monoclonal antibodies raised against different endothelial 
cell markers were used (Von Willebrand Factor (VWF, Santa Cruz #sc-8068) and 
CD31 (PECAM-1, BD Pharmingen #5502741.50)) in conjunction with 
immunofluorescence techniques.  
Briefly EA.hy926, IMR90 and Mouse Aortic Endothelial Cells were grown in 
microscope coverslips. When cell confluence reached about 70% the coverslips were 
washed twice with PBS to remove any media residues. After the wash cells were 
fixed using 1ml of a 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO) solution 
prepared in PBS per slide and incubated for 15 minutes at room temperature. 
Following fixation, the slides were washed three times with PBS to remove any 
leftover paraformaldehyde residues. 
In order for the antibodies to reach the cells, these have to be permeablized 
after fixated. A solution of 15% Triton X-100 (Sigma-Aldrich, St. Louis, MO) prepared 
in PBS was used. Cells were incubated at room temperature for 15 minutes, 
following a blocking step using a 1% BSA (Sigma-Aldrich, St. Louis, MO) solution 
prepared in PBS for 30 minutes again at room temperature. 
After the cells were prepped the primary antibody was applied. The specific 
antibody was diluted in blocking solution (1% BSA in PBS) and left overnight at 4ºC. 
The following antibodies and dilutions were used: 
 
- Purified Rat anti-mouse CD31 (PECAM-1) Monoclonal antibody; BD 
Pharmingen (San Diego, CA, USA) cat.no. 550274; 1:50 dilution. 
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- Von Willebrand Factor, Goat polyclonal anti-vWF (c-20) Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA, USA) cat.no. sc8068; 1:100 dilution. 
- 1E12 concentrate Iowa Hybridoma Bank Smooth Muscle Actin anti-mouse, 
1:50 dilution. 
 
Once the incubation time is over the coverslips are washed three times with a 0,1% 
Triton X-100 solution in PBS for 5 minutes per wash. 
  
Since the primary antibody is not linked to any fluorochrome its necessary to 
apply a secondary antibody in order to be able to visualize the cell markers under the 
fluorescence microscope. The following secondary antibodies were respectively 
applied for 1 hour at 37ºC in blocking solution: 
- Alexa Fluor 488 donkey anti-rat IgG, Molecular Probes #A-21208, 1:200 
dilution. 
- Alexa Fluor 488 donkey anti-goat IgG, Molecular Probes #A-11055, 1:200 
dilution. 
- Alexa Fluor 568 goat anti-mouse IgG, Molecular Probes #A-11004, 1:200 
dilution. 
 
Once the one hour incubation time is over the coverslips are again washed three 
times with a 0.1% Triton X-100 solution in PBS (5 minutes per wash). The final step 
consists on dipping the slides into water twice and letting them air dry. 
 Finally VECTASHIELD® Mounting Medium with DAPI (Vector Laboratories, 
Burlingame, USA) was applied to preserve fluorescence and counterstain DNA and 
the coverslips mounted on microscope slides (the coverslip was kept in place using 
nail polish). The Nikon Eclipse 90i Fluorescence Roper Scientific Microscope was 
used to analyze the resulting cell staining.  
 
Electron Microscopy 
 
 After having confirmed the endothelial nature of the cells in use, electron 
microscopy was used to confirm the presence of caveolae in the cell membrane of 
the same cells. Both EA.hy926 and Mouse Aortic Endothelial Cells were tested as 
well as Mouse Aortic Endothelial Cells from a CAV1 deficient animal. 
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Briefly, cells were fixed in 2.0% glutaraldehyde in 0.1 mol/L sodium cacodylate 
buffer, pH 7.4 (Electron Microscopy Sciences, Hatfield, PA) overnight at 4ºC.  Cells 
were then rinsed in 0.1 mol/L sodium cacodylate buffer, post-fixed in 1.0% osmium 
tetroxide (in cacodylate buffer) for one hour at room temperature, rinsed in buffer 
again, then in distilled water and stained, en bloc, in an aqueous solution of 2.0% 
uranyl acetate for one hour at room temperature.   
Cells were subsequently rinsed in distilled water and embedded in 2.0% 
agarose for ease of handling before being dehydrated through a graded series of 
ethanol to 100%.  Cells were then infiltrated with Epon resin (Ted Pella, Redding, 
CA) in a 1:1 solution of Epon:ethanol.  The following day they were placed in fresh 
Epon for several hours and then embedded in Epon overnight at 60 ºC.  Thin 
sections were cut on a Reichert Ultracut E ultramicrotome, collected on formvar-
coated grids, stained with uranyl acetate and lead citrate and examined in a JEOL 
JEM 1011 transmission electron microscope at 80 kV.  Images were collected using 
an AMT digital imaging system (Advanced Microscopy Techniques, Danvers, MA).  
Electron microscopy was performed in the Microscopy Core of the Centre for 
Systems Biology/Program in Membrane Biology, which is partially supported by an 
Inflammatory Bowel Disease Grant DK43351 and a Boston Area Diabetes and 
Endocrinology Research Centre Award DK57521. 
 
Western Blot (Electrophoresis and Immunoblot) 
 
Western blot, also know as protein immunoblot, is a widely used analytical 
technique used to detect specific proteins in a sample of tissue homogenate or cell 
extract. It uses gel electrophoresis to separate native proteins by 3D structure or 
denatured proteins by the length of the polypeptide. The proteins are then transferred 
to a membrane (typically nitrocellulose or PVDF), where they are probed (detected) 
using antibodies specific to the target protein (194, 195). 
 
Tissue preparation 
 
Samples can not be taken from whole tissue or from cell culture. Solid tissues 
are first broken down mechanically using a homogenizer and cells broken open by 
use of a sonicator. Assorted detergents, salts, and buffers are employed to 
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encourage lysis of cells and to solubilize proteins. Protease and phosphatase 
inhibitors are added to prevent the digestion of the sample by its own enzymes. 
Tissue preparation is done at cold temperatures to avoid protein denaturing and 
degradation. 
 
 
Figure 19 - Sample preparation for Western Blot technique. 
 
 
In brief the cells/tissues were homogenized in RIPA 
(Radioimmunoprecipitation Assay) Lysis Buffer System (#sc-24948 Santa Cruz 
Biotechnology Inc, Santa Cruz, USA) containing Triton X-100 (detergent) and 
protease/phosphatase inhibitors (PMSF, sodium orthovanadate and protease 
inhibitor cocktail). If phospo-proteins were being studied PhosphoStop (Cat. No. 04 
906 837 001, Roche, Mannheim, Germany) was added to the RIPA Buffer in order to 
inhibit phosphatase activity that would degrade the samples. When the sample of 
interest was a tissue sample (heart, aorta, etc) a homogenizer was used to break the 
collected tissue down but, in most cases, the samples were resultant from a cell 
based experiments. In this case, the cells were collected (scrapped) using the RIPA 
Lysis Buffer System and incubated on ice for 30 minutes. After the incubation, the 
cells were sonicated (30V, 10 seconds, 3 times) and spun down. 
The resulting protein extracts were quantified using the Coomassie (Bradford) 
protein assay (#23200, Thermo Fisher Scientific, Rockford, USA). The Bradford 
assay is a colorimetric protein assay based on an absorbance shift of the dye 
Coomassie Brilliant Blue G-250, in which, under acidic conditions the red form of the 
dye is converted into its bluer form to bind to the protein being assayed. The binding 
of the protein stabilizes the blue form of the Coomassie dye; thus the amount of the 
complex present in solution is a measure for the protein concentration, and can be 
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estimated by use of an absorbance reading. The (bound) form of the dye has an 
absorption spectrum maximum historically held to be at 595 nm. The increase of 
absorbance at 595 nm is proportional to the amount of bound dye, and thus to the 
amount (concentration) of protein present in the sample. 
Protein extracts (10-20 μg) were combined with an equal volume of 2X 
Laemmli Sample Buffer (Bio-Rad, Hercules, USA) (containing 5% 2-
mercaptoethanol), boiled for 5 minutes at 95ºC, and size-fractionated by 
electrophoresis on 7.5%-12.5% SDS-polyacrylamide gels.  
 
 
Gel Electrophoresis 
 
The sample proteins are separated using gel electrophoresis. The most 
common type of gel electrophoresis employs polyacrylamide gels and buffers loaded 
with sodium dodecyl sulfate (SDS). SDS-PAGE (SDS polyacrylamide gel 
electrophoresis) maintains polypeptides in a denatured state once they have been 
treated with strong reducing agents (2-mercaptoethanol) to remove secondary and 
tertiary structure and thus allows separation of proteins by their molecular weight. 
Sampled proteins become covered in the negatively charged SDS and move to the 
positively charged electrode through the acrylamide mesh of the gel. Smaller proteins 
migrate faster through this mesh and the proteins are thus separated according to 
size (usually measured in kilodaltons, kDa). The concentration of acrylamide 
determines the resolution of the gel - the greater the acrylamide concentration the 
better the resolution of lower molecular weight proteins. The lower the acrylamide 
concentration the better the resolution of higher molecular weight proteins.  
Samples are loaded into wells in the gel. One lane is usually reserved for a 
marker or ladder, a commercially available mixture of proteins having defined 
molecular weights, typically stained so as to form visible, coloured bands. Bio-rad 
kaleidoscope pre-stained standards (Bio-Rad, Hercules, USA) where use as control 
for molecular weight. When voltage is applied along the gel, proteins migrate into it at 
different speeds and separate into bands within each lane. 
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Figure 20 - SDS-Page Electrophoresis Gel System. 
 
Transfer  
 
In order to allow for antibody detection, the proteins are moved from within the 
gel onto a membrane made of cellulose. The membrane is placed on top of the gel 
carefully avoiding air bubbles to form and a stack of filter papers placed on top of that. 
The entire stack is then dipped in a buffer solution. The method used for transferring 
the proteins is called electroblotting and uses an electric current to pull proteins from 
the gel into the  nitrocellulose membrane. The proteins move from within the gel onto 
the membrane while maintaining the organization they had in the gel. As a result of 
this "blotting" process, the proteins are exposed on a thin surface layer for detection 
(see below). Throughout the experiments 0.2 m nitrocellulose membrane from Bio-
rad (Bio-Rad, Hercules, USA) was used. 
 
 
Figure 21 - Western Blot Transfer System (Electrobloting). 
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The uniformity and overall effectiveness of the transfer process was checked 
by  staining the membrane with a Ponceau S dye (Sigma-Aldrich, St. Louis, MO, 
USA) solution (0,1% w/v in 5% acetic acid). 
 
Blocking 
 
Since the membrane has been chosen for its ability to bind protein and as both 
antibodies and the target are proteins, steps must be taken to prevent interactions 
between the membrane and the antibody used for detection of the target protein. 
Blocking of non-specific binding is achieved by placing the membrane in a dilute 
solution of protein - typically 3-5% Bovine serum albumin (BSA) or non-fat dry milk  in 
Tris-Buffered Saline (TBS), with a minute percentage of detergent such as Tween 20 
or Triton X-100. The protein in the dilute solution attaches to the membrane in all 
places where the target proteins have not attached. Thus, when the antibody is 
added, there is no room on the membrane for it to attach other than on the binding 
sites of the specific target protein. This reduces "noise" in the final product of the 
western blot, leading to clearer results, and eliminates false positives. 
For the purpose of the experiments TBS-Tween (USB Corporation, Cleveland, 
OH) was used together with Blotting Grade Blocker Non Fat Dry Milk (Bio-Rad, 
Hercules, USA) usually in the form of a 5% solution employed for 1 hour at room 
temperature with gentle agitation.  
 
Detection 
 
During the detection process the membrane is "probed" for the protein of 
interest with a modified antibody which is linked to a reporter enzyme; when exposed 
to an appropriate substrate this enzyme drives a colorimetric reaction and produces a 
colour. This traditionally takes place in a two-step process. 
 
Primary antibody 
 
Primary antibodies are generated when a host species or immune cell culture 
is exposed to the protein of interest. Normally, this is part of the immune response, 
whereas here they are harvested and used as sensitive and specific detection tools 
that bind the protein directly. After blocking, a dilute solution of primary antibody is 
incubated with the membrane under gentle agitation. Typically, the solution is the 
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same as the one used for blocking the membrane. The antibody solution and the 
membrane can be sealed and incubated together for anywhere from 30 minutes to 
overnight. It can also be incubated at different temperatures, with warmer 
temperatures being associated with more binding, both specific (to the target protein, 
the "signal") and non-specific ("noise"). 
Primary antibodies were from BD Transduction Laboratories (San Diego, CA, 
USA): mouse anti- striatin (catalogue no. 610838, 1:1000), mouse anti-eNOS 
(catalogue no. 610297, 1:2500), anti-CAV1 (clone 2297, catalogue no. 610406, 
1:1000), and mouse anti-ERK1/2 (catalogue no. 610124, 1:5000); Cell Signalling 
Technology (Danvers, MA, USA): rabbit anti-phospho-eNOS (peNOS) (catalogue no. 
9571, 1:1000), rabbit anti-phospho-p44/42 MAPK (pERK 1/2) (catalogue no 4377, 
1:1000); and Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) rabbit anti-MR 
(catalogue no. sc11412, 1:1000).  Primary antibodies were typically left to incubate 
overnight at 4ºC with gentle agitation.  
 
Secondary antibody 
 
 
 
After rinsing the membrane to remove unbound primary antibody, the 
membrane is exposed to another antibody, directed at a species-specific portion of 
the primary antibody. Antibodies come from animal sources; anti-mouse secondary 
will bind to almost any mouse-sourced primary antibody, which allows some cost 
savings by allowing an entire lab to share a single source of mass-produced antibody, 
and provides far more consistent results. This is known as a secondary antibody, and 
due to its targeting properties, tends to be referred to as "anti-mouse," "anti-goat," etc. 
The secondary antibody is usually linked to biotin or to a reporter enzyme such as 
alkaline phosphatase or horseradish peroxidase. Most commonly, a horseradish 
peroxidase-linked secondary is used to cleave a chemiluminescent agent, and the 
reaction product produces luminescence in proportion to the amount of protein. A 
sensitive sheet of photographic film is placed against the membrane, and exposure 
to the light from the reaction creates an image of the antibodies bound to the blot. 
 
Secondary antibodies used were from Sigma-Aldrich company (St. Louis, MO, 
USA): Anti-Mouse IgG (Fab specific)–Peroxidase antibody produced in goat 
(catalogue no. A9917, 1:10,000) and Anti-Rabbit IgG (whole molecule)–Peroxidase 
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antibody produced in goat (catalogue no. A0545, 1:10,000). Secondary antibodies 
were incubated for 1 hour at room temperature with gentle agitation. 
 
Figure 22 - Two step detection process  for Western Blot analysis. 
 
Analysis 
 
After the unbound probes are washed away, the western blot is ready for 
detection of the probes that are labelled and bound to the protein of interest. In 
practical terms, not all westerns reveal protein only at one band in a membrane. Size 
approximations are taken by comparing the stained bands to that of the marker or 
ladder loaded during electrophoresis. The process is repeated for a structural protein, 
such as actin or tubulin, that should not change between samples. The amount of 
target protein is normalized to the structural protein to control between groups. This 
practice ensures correction for the amount of total protein on the membrane in case 
of errors or incomplete transfers. 
After the initial detection of the target protein the membranes were stripped 
using Stripping Buffer (Boston BioProducts, Asland, MA, USA) and subsequently re-
probed for -actin. The results were normalized to -actin to correct for loading. 
Quantitative data are presented as fold change relative to controls 
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Chemiluminescent detection 
 
 
Chemiluminescent detection methods depend on incubation of the western 
blot membrane with a substrate that will luminesce when exposed to the reporter on 
the secondary antibody. The light is then detected by photographic film, and more 
recently by CCD cameras which capture a digital image of the western blot. The 
image is analysed by densitometry, which evaluates the relative amount of protein 
staining and quantifies the results in terms of optical density. Newer software allows 
further data analysis such as molecular weight analysis if appropriate standards are 
used. 
 
Figure 23 - Chemiluminescence detection used in Western Blot analysis. 
Enhanced Chemiluminescence Reagent (Perkin-Elmer Life Sciences, Boston, MA) 
was used before the membranes were exposed and developed on CL-XPosure Film 
(Thermo Scientific, Chicago, IL, USA). 
 
Co-Immunoprecipitation (Co-IP) 
 
Co-immunoprecipitation was used as a tool to try to establish if there were any 
protein-protein interactions or if the proteins were organized as protein complex.  
Immunoprecipitation of intact protein complexes (i.e. antigen along with any 
proteins or ligands that are bound to it) is known as co-immunoprecipitation (Co-IP). 
Co-IP works by selecting an antibody that targets a known protein that is believed to 
be a member of a larger complex of proteins. By targeting this known member with 
an antibody it may become possible to pull the entire protein complex out of solution 
and thereby identify unknown members of the complex. This works when the proteins 
involved in the complex bind to each other tightly, making it possible to pull multiple 
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members of the complex out of solution by latching onto one member with an 
antibody. This concept of pulling protein complexes out of solution is sometimes 
referred to as a "pull-down".  
Identifying the members of protein complexes may require several rounds of 
precipitation with different antibodies for a number of reasons: 
 
 A particular antibody often selects for a subpopulation of its target protein that 
has the epitope exposed, thus failing to identify any proteins in complexes that 
hide the epitope.  
 The first round of IP will often result in the identification of many new proteins 
that are putative members of the complex being studied. The researcher will then 
obtain antibodies that specifically target one of the newly identified proteins and 
repeat the entire immunoprecipitation experiment. This second round of 
precipitation may result in the recovery of additional new members of a complex. 
The identified proteins may not ever exist in a single complex at a given time, but 
may instead represent a network of proteins interacting with one another at 
different times for different purposes. 
 Repeating the experiment by targeting different members of the protein 
complex allows the researcher to double-check the result. Each round of pull-
downs should result in the recovery of both the original known protein as well as 
other previously identified members of the complex (and even new additional 
members). By repeating the immunoprecipitation in this way, the researcher 
verifies that each identified member of the protein complex was a valid 
identification. If a particular protein can only be recovered by targeting one of the 
known members but not by targeting other of the known members then that 
protein's status as a member of the complex may be subject to question. 
 
In brief the cells were collected (scrapped) and homogenized in 
immunoprecipitation buffer (RIPA Buffer, Santa Cruz Biotechnology Inc.), the cell 
lysate sonicated for 20 seconds (30 Volts) and incubated for 30 min at 4 ºC. Next, 
the lysate was centrifuged at 10,000g for 10 minutes, and protein content determined 
by colorimetric assay (Micro BCA protein kit, Thermo Scientific, Chicago, IL, USA). 
The protein extract (500 g) was incubated with 1-2 g of monoclonal or polyclonal 
antibodies for 1-2 hours at 4 ºC together with 50-100 l of protein G or A/G 
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MicroBeads (Miltenyi Biotec, Auburn, CA, USA). The Microbeads, antibody and cell 
lysate mix were separated using MACSmini columns and respective magnetic stand, 
according to the manufacturers protocol (described bellow). Finally the beads were 
washed with RIPA buffer and the bound immuno-complexes eluted using boiling 
loading dye and assessed by Western Blot analysis.  
The antibodies used were from BD Transduction Laboratories (San Diego, 
CA): mouse anti- striatin (catalogue no. 610838), mouse anti-CAV1 (catalogue no. 
611338) and Santa Cruz Biotechnology Inc.: rabbit anti-MR (catalogue no. sc11412), 
rabbit anti- CAV1 (catalogue no. sc 894). The specificity of the rabbit anti-MR was 
assessed by comparison by those provided by Dr. Gomez-Sanchez (University of 
Mississippi Medical Centre, Jackson, MS, USA) (196). 
 
 Immunopurification using μ Columns and μMACS™ Separator 
 
Before starting the heating block was heated to 95ºC. The (Column is placed 
in the magnetic field of the μMACS™ Separator with a suitable waste container 
under it. The column is prepared by rinsing it with 200 (L of lysis buffer. The elution 
buffer is placed in the pre-heated block (90 (L should be pre-heated for each 
separation column). The cell lysate is applied onto the column and allowed to run 
through. The non-bound fraction can be collected in a fresh tube for analysis. 
Columns are “flow stop” and do not run dry. Magnetically labelled protein is retained 
in the μ Columns. The column is then rinsed with 4 x 200 (L of a suitable buffer (RIPA 
buffer). Finally, 20 μL of pre-heated (95 °C) 1× SDS gel loading buffer are applied 
onto the column matrix using a fresh pipette tip for each column and incubated for 5 
minutes at room temperature (if a drop is present on the column tip, this should be 
removed by contacting the column tip with the waste tube or by using a fresh pipette 
tip). A fresh collection tube is placed under the μColumn and 50 μL of pre-heated 
(95 °C) SDS gel loading buffer are applied onto the column matrix using a fresh 
pipette tip for each column. If a drop is present on the column tip, this should also be 
collected by contacting the column tip with the tube or by using a pipette, ensuring 
thereby, a reproducible elution volume. The eluted immunoprecipitate can now be 
analyzed by SDS-PAGE. 
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Figure 24 – Schematic protocol for Immunopurification using μ Columns and μMACS™ 
Separator. 
 
MACS Technology was selected for this application due to its sensitivity, 
specificity and speed. Immunoprecipitation with μMACS Protein A/G MicroBeads 
does not involve a centrifugation step. Instead, after a short incubation of cleared 
lysate with the MicroBeads- coated with the specific antibody- the magnetizable 
immune complex is passed over a separation column placed in the magnetic field of 
a MACS Separator. The labelled complex is retained within the column while other 
proteins are efficiently washed away. For SDS-PAGE analysis, the 
immunoprecipitated protein is eluted from the column with SDS gel loading buffer. 
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Alternatively, enzymatic reactions with the precipitated immune complex can be 
performed on the separation columns. 
μMACS™ Protein A and μMACS Protein G MicroBeads are colloidal, super-
paramagnetic MicroBeads, which are conjugated to Protein A or Protein G, 
respectively. Protein A is a 42 kDa protein component of the cell wall of 
Staphylococcus aureus while Protein G is a 33 kDa cell surface protein of the group 
G streptococci. Both of these proteins bind to the Fc region of IgG with high affinity 
and avidity, leaving the Fab region of the antibody free for interaction with its antigen; 
thus, resulting in the formation of multimeric complexes between antigen, antibody, 
and MicroBeads. The binding specificities of Protein A and G for immunoglobins 
differ depending on the subclass and origin of the antibody. The extremely small 
MicroBeads, 50 nm in diameter, allow fast reaction kinetics while the column 
technology provides effective washing steps to minimize contaminations. 
 
 
RNA Extraction 
 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen Sciences, 
Valencia, CA, USA) following the manufacturer’s instructions. The RNeasy procedure 
represents a well-established technology for RNA purification. This technology 
combines the selective binding properties of a silica-based membrane with the speed 
of microspin technology. A specialized high-salt buffer system allows up to 100 μg of 
RNA longer than 200 bases to bind to the RNeasy silica membrane. Biological 
samples are first lysed and homogenized in the presence of a highly denaturing 
guanidine-thiocyanate–containing buffer, which immediately inactivates RNases to 
ensure purification of intact RNA. Ethanol is added to provide appropriate binding 
conditions, and the sample is then applied to an RNeasy Mini spin column, where the 
total RNA binds to the membrane and contaminants are efficiently washed away. 
High-quality RNA is then eluted in 30–100 μl water. With the RNeasy procedure, all 
RNA molecules longer than 200 nucleotides are purified. The procedure provides an 
enrichment for mRNA since most RNAs <200 nucleotides (such as 5.8S rRNA, 5S 
rRNA, and tRNAs, which together comprise 15–20% of total RNA) are selectively 
excluded.  
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Protocol: Purification of Total RNA from Animal Cells Using Spin Technology 
 
It is essential to use the correct amount of starting material in order to obtain 
optimal RNA yield and purity. The minimum amount is generally 100 cells, while the 
maximum amount of starting material should not exceed 1 x 107 cells. All steps of the 
procedure are performed at room temperature. Before starting the procedure it is 
recommended to add -mercaptoethanol (-ME) to Buffer RLT, 10 μl -ME should be 
added per 1 ml of Buffer RLT.  
For cells grown in a monolayer (EA.hy926 cells) and in a surface area of under 
10 cm2 (6 well plate) it is advised to lyse the cells directly in the cell culture vessel. 
The cell-culture medium should be removed using aspiration (without touching the 
cell layer) and the cells rinsed with PBS before lysis in order to remove any leftover 
media which could reduce the RNA yield. Cells are disrupted by adding 350 l of 
Buffer RLT and scraping with an appropriate cell scrapper. The lysate is transferred 
to a microcentrifuge tube and vortexed to mix the cell pellet. No cell clumps should 
be visible before the homogenization step. 
When processing a number of cells under 1x105, homogenization can be 
achieved by vortexing the cell pellet at high speed for 1 minute. After this step, 350 l 
of 70% Ethanol are added and mixed by pippeting up and down several times. This 
solution is transferred to an RNeasy spin column placed in a 2 ml collection tube and 
centrifuged for 15 seconds at 10,000 rpm. The resulting flow-through is discarded 
and the collection tube re-used. Next, 700 l of Buffer RW1 are added to the spin 
column followed by centrifugation at 10,000 rpm for another 15 seconds.  The flow-
through is again discarded and the collection tube re-used. 500 μl RPE Buffer are 
added to the RNeasy spin column followed by centrifugation at 10,000 rpm 15 
seconds. The flow-through is discarded and the step repeated with a 2 minute 
centrifugation to wash the spin column membrane before the final step. 
After centrifugation, the RNeasy spin column is carefully removed from the 
collection tube so that the column does not contact the flow-through. The RNeasy 
spin column is placed in a new 1.5 ml collection tube and 30–50 μl RNase-free water 
is added directly to the spin column membrane. Next, the tube is centrifuged for one 
minute at 10,000 rpm to elute the RNA. The resulting RNA is pure enough to use for 
reverse-transcription. 
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Following extraction, the RNA yield was measured using spectrophotometric 
analysis. Nucleic acids absorb ultraviolet light in a specific pattern. In a 
spectrophotometer, a sample is exposed to ultraviolet light at 260 nm, and a photo-
detector measures the light that passes through the sample. The more light absorbed 
by the sample, the higher the nucleic acid concentration in the sample. Using the 
Beer-Lambert Law it is possible to relate the amount of light absorbed to the 
concentration of the absorbing molecule. At a wavelength of 260 nm, the average 
extinction coefficient  for single-stranded RNA it is 0.025 (μg/ml)-1 cm-1 . Thus, an 
optical density (or "OD") of 1 corresponds to a concentration of 40 μg/ml for single-
stranded RNA. This method of calculation is valid for up to an OD of at least 2 (197). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 - Schematic protocol for RNA 
extraction using RNeasy Mini Kit. 
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Reverse Transcription (RT) 
 
 cDNA was synthesized from 3 g total RNA with the First Strand cDNA 
Synthesis Kit (Amersham, Buckinghamshire, UK). Reverse transcription is a 
laboratory technique commonly used in molecular biology where a RNA strand is 
reverse transcribed into its DNA complement (complementary DNA, or cDNA) using 
the enzyme reverse transcriptase. First-strand cDNA synthesis is catalyzed by 
Moloney Murine Leukaemia Virus (M-MuLV) reverse transcriptase. The conditions of 
this reaction have been optimized to permit full-length transcription of RNAs 7 
kilobases or more in length. The preassembled bulk firststrand cDNA reaction mixes 
require only the addition of DTT, RNA, and a primer of choice. The first-strand 
reaction may be primed with either of the primers provided with the kit: the Not I-
d(T)18 bifunctional primer or pd(N)6 primer. Custom primers complementary to a 
specific mRNA sequence may also be used to prime first-strand synthesis. Following 
synthesis of the first-strand cDNA, the resulting doublestranded RNA:cDNA 
heteroduplex can be used directly for second-strand cDNA synthesis. Alternatively, 
the completed first-strand reaction may be amplified directly by PCR (198-200). 
Depending on the intended use of the first-strand cDNA, synthesis may be 
performed using different volumes of bulk first-strand cDNA mix, and different types 
and amounts of primer and RNA. If the cDNA is to be amplified, either 5 μl or 11 μl of 
the bulk reaction mix may be used, and 1–5 μg of total RNA, or 20–150 ng of mRNA, 
are sufficient. For the purposes of the experiments conducted, 5 μl of bulk reaction 
mix were used together with 3 μg of total RNA diluted in a total of 8 μl of RNAse-free 
water. 
The RNA sample is placed in a microcentrifuge tube and RNAse-free water 
added, if necessary, to bring the RNA to the appropriate volume (either 8 μl or 20 μl). 
The RNA solution is heated to 65ºC for 10 minutes and then chilled on ice. The bulk 
first-strand cDNA reaction mix is gently pipetted to obtain a uniform suspension and 
the appropriate volume of the bulk first-strand cDNA reaction mix (either 5 μl or 11 μl) 
is added to a sterile 1,5 or 0,5 ml microcentrifuge tube. To this tube are added 1 μl of 
DTT solution, 1 μl of primer at the appropriate concentration, and the heat-denatured 
RNA. The solution is pipetted up and down several times to mix and incubated at 
 75
37°C for 1 hour. The completed first-strand cDNA reaction product is now ready for 
immediate PCR amplification. 
 
Quantitative Real-Time Polymerase Chain Reaction (qPCR) 
 
In molecular biology, quantitative real time polymerase chain reaction (qPCR) 
is a technique based on PCR, which is used to amplify a targeted DNA sequence. 
For one or more specific sequences in a DNA sample, qPCR enables both detection 
and quantification. The quantity can either be an absolute number of copies or a 
relative amount when normalized to DNA input and/or additional normalizing genes.  
The procedure follows the general principle of PCR; its key feature is that the 
amplified DNA is detected as the reaction progresses in real time. Two common 
methods for detection of products in real-time PCR are: (1) non-specific fluorescent 
dyes that intercalate with any double-stranded DNA, and (2) sequence-specific DNA 
probes consisting of oligonucleotides that are labelled with a fluorescent reporter 
which permits detection only after hybridization of the probe with its complementary 
DNA target. 
A DNA-binding dye binds to all double-stranded (ds)DNA in PCR, causing 
fluorescence of the dye. An increase in DNA product during PCR therefore leads to 
an increase in fluorescence intensity and is measured at each cycle, thus allowing 
DNA concentrations to be quantified. However, dsDNA dyes such as SYBR Green 
will bind to all dsDNA PCR products, including non-specific PCR products (such as 
primer dimer). This can potentially interfere with, or prevent, accurate quantification 
of the intended target sequence. 
Fluorescent reporter probes detect only the DNA containing the probe 
sequence; therefore, use of the reporter probe significantly increases specificity, and 
enables quantification even in the presence of non-specific DNA amplification. 
Fluorescent probes can be used in multiplex assays—for detection of several genes 
in the same reaction—based on specific probes with different-coloured labels, 
provided that all targeted genes are amplified with similar efficiency. The specificity of 
fluorescent reporter probes also prevents interference of measurements caused by 
primer dimers, which are undesirable potential by-products in PCR. The method 
relies on a DNA-based probe (e.g. Taqman probes) with a fluorescent reporter at one 
end and a quencher of fluorescence at the opposite end of the probe. The close 
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proximity of the reporter to the quencher prevents detection of its fluorescence; 
breakdown of the probe by the 5' to 3' exonuclease activity of the Taq polymerase 
breaks the reporter-quencher proximity and thus allows unquenched emission of 
fluorescence, which can be detected after excitation with a laser. An increase in the 
product targeted by the reporter probe at each PCR cycle therefore causes a 
proportional increase in fluorescence due to the breakdown of the probe and release 
of the reporter. 
 
Figure 26 – DNA quantification using fluorescent reporter probes. (1) In intact probes, 
reporter fluorescence is quenched. (2) Probes and the complementary DNA strand are 
hybridized and reporter fluorescence is still quenched. (3) During PCR, the probe is 
degraded by the Taq polymerase and the fluorescent reporter released. 
 
 
Real-time PCR can be used to quantify DNA sequences by two methods: 
relative quantification and absolute quantification. Relative quantification is based on 
internal reference genes to determine fold-differences in expression of the target 
gene. Absolute quantification gives the exact number of target DNA molecules by 
comparison with DNA standards (201). The general principle of DNA quantification by 
real-time PCR relies on plotting fluorescence against the number of cycles on a 
logarithmic scale. A threshold for detection of DNA-based fluorescence is set slightly 
above background. The number of cycles at which the fluorescence exceeds the 
threshold is called the cycle threshold, Ct. During the exponential amplification phase, 
the sequence of the DNA target doubles every cycle. For example, a DNA sample 
whose Ct precedes that of another sample by 3 cycles contained 23 = 8 times more 
template. However, the efficiency of amplification is often variable among primers 
and templates. Therefore, the efficiency of a primer-template combination is 
assessed in a titration experiment with serial dilutions of DNA template to create a 
standard curve of the change in Ct with each dilution. The slope of the linear 
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regression is then used to determine the efficiency of amplification, which is 100% if 
a dilution of 1:2 results in a Ct difference of 1. For commercially available probes 
such experiments are no longer necessary since the manufacturer has already 
optimized the performance of the primers for each target sequence. 
To quantify gene expression, the Ct for an RNA or DNA from the gene of 
interest is divided by Ct of RNA/DNA from a housekeeping gene in the same sample 
to normalize for variation in the amount and quality of RNA between different 
samples. This normalization procedure is commonly called the ΔΔCt-method (202), 
and permits comparison of expression of a gene of interest among different samples. 
However, for such comparison, expression of the normalizing reference gene needs 
to be very similar across all the samples. Choosing a reference gene fulfilling this 
criterion is therefore of high importance, and often challenging, because only very 
few genes show equal levels of expression across a range of different conditions or 
tissues (203, 204).  
 
Polymerase Chain Reaction amplification reactions were performed with 
Taqman gene expression assays in duplicate with the use of the ABI Prism 7000 
Sequence Detection System (Applied Biosystems, Foster City Calif.). The  cycle 
(CT) threshold method was used to determine mRNA levels. Target gene expression 
was normalized to 18S rRNA levels. Probes used: zinedin (STRN4, 
Hs00183850_m1), SG2NA (STRN3, Hs00205827_m1), striatin (STRN, 
Hs00162404_m1), lysine deficient protein kinase 4 (WNK4, Hs00260769_m1), serum 
glucocorticoid regulated kinase 1 (SGK1, Hs00178612_m1), prostaglandin I2 (PTGIS, 
Hs00919949_m1) and prostaglandin-endoperoxide synthase 1 (PTGS1, 
Hs00168776_m1). 
 
siRNA knockdown of striatin 
 
Small interfering RNA (siRNA), sometimes known as short interfering RNA or 
silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in 
length, that play a variety of roles in biology. The most notable role of siRNA is its 
involvement in the RNA interference (RNAi) pathway, where it interferes with the 
expression of a specific gene. In addition to its role in the RNAi pathway, siRNA also 
 78
acts in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the 
chromatin structure of a genome; the complexity of these pathways is only now being 
elucidated.  
siRNAs were first discovered by David Baulcombe's group at the Sainsbury 
Laboratory in Norwich, England, as part of post-transcriptional gene silencing (PTGS) 
in plants. The group published their findings in Science in a 1999 paper titled "A 
species of small antisense RNA in posttranscriptional gene silencing in plants" (205). 
Shortly thereafter, in 2001, synthetic siRNAs were shown to be able to induce RNAi 
in mammalian cells by Thomas Tuschl, and colleagues in a paper published in 
Nature (206). This discovery led to a surge in interest in harnessing RNAi for 
biomedical research and drug development. 
siRNAs have a well-defined structure: a short (usually 21-nt) double-strand 
RNA (dsRNA) with 2-nt 3' overhangs on either end: 
 
 
Figure 27- Schematic representation of a siRNA molecule. 
 
Each strand has a 5' phosphatase group and a 3' hydroxyl (-OH) group.  This 
structure is the result of processing by dicer, an enzyme that converts either long 
dsRNAs or small hairpin RNAs into siRNAs (207). siRNAs can also be exogenously 
(artificially) introduced into cells by various transfection methods to bring about the 
specific knockdown of a gene of interest.  In essence, any gene whose sequence is 
known can, thus, be targeted based on sequence complementarity with an 
appropriately tailored siRNA.  This has made siRNAs an important tool for gene 
function and drug target validation studies in the post-genomic era. Transfection of 
an exogenous siRNA can, sometimes, prove to be problematic because the gene 
knockdown effect is only transient, in particular, in rapidly dividing cells. 
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EA.hy926 cells were transfected with ON-TARGETplus siRNA pre-designed 
duplex specific for striatin (J-019572-09-0050) obtained from Dharmacon RNAi 
Technologies, Thermo Scientific (Chicago, IL, USA). Control/blank siRNA (D-001810-
01-05) was transfected in parallel with striatin siRNA following the manufacturer’s 
protocols and using the Dharmafect 1 siRNA Transfection Reagent (T-2001-03) from 
Dharmacon RNAi Technologies. The cells were then harvested for Western blot 
analysis 48 hours post-transfection.  
 
siRNA Transfection Protocol 
 
All steps of protocol should be performed in a laminar flow cell culture hood 
using sterile techniques. Cells were plated at a density of 700,000 cells per well of a 
six well plate in antibiotic-free media, the day before the experiment and left to 
incubate overnight at 37°C with 5 % CO2. Before transfection, a 5 μM siRNA solution 
is prepared in 1X siRNA buffer. 
In separate tubes, the siRNA (10 l of siRNA, 5 M per well) and the 
DharmaFECT transfection reagent (2 l per well) are diluted with serum-free media 
to a total volume of 200 l per well. The components of each tube are gently mixed 
by pipetting up and down followed by a 5 minute incubation at room temperature. 
The contents of tube 1 and 2 are added together and mixed by pipetting up and down, 
followed by 20 minutes incubation at room temperature. 
 The culture medium is removed from the cell culture well and 400 l of the 
previous mixture are added. Another 1,6 ml of antibiotic-free media are added to 
each well to fulfil the 2 ml recommended volume per well. The plates are gently 
swirled to ensure appropriate distribution of the transfection reagents. The cells are 
incubated at 37°C in 5 % CO2 for 24–48 hours (for mRNA analysis) or 48–96 hours 
(for protein analysis). In order to reduce cytotoxicity, the transfection medium is 
replaced by regular culture medium after 24 hours of incubation. 
 
 Before selecting the concentrations of transfection reagents to use as well as 
which reagents to use several optimization experiments were conducted.  
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Animals 
 
The present studies followed the guidelines approval from the Institutional 
Animal Care and Use Committee at Harvard Medical School and conforms to the 
Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, revised 1996). Male mice (C57Bl/6J) 
from Jackson Laboratory (Bar Harbour, ME) were selected for experiments. All 
animals were housed in a room lighted 12 h/day at an ambient temperature of 22 ± 
1ºC. Animals were allowed 1-3 weeks to recover after arrival and had free access to 
Purina Lab Chow 5001 (Ralston Purina Co., St. Louis, MO) and tap water until the 
initiation of the experiment unless otherwise stated.  
 
General Cell Culture Experimentation Protocol 
 
EA.hy926 cells were maintained in DMEM with 10% FBS. Twelve hours before 
treatment, cells were switched to DMEM without FBS. At the time of treatment, cells 
were incubated with vehicle, aldosterone (10-8 mol/L; Acros Organics, Geel, Belgium), 
or aldosterone (10-8 mol/L) plus the MR antagonist canrenoate (10-6 mol/L; Sigma-
Aldrich, St. Louis, USA) in DMEM without FBS. For the Estrogen experiments cells 
were grown is Estrogen Deficient (ED) phenol free media (Gibco) prepared with 
charcoal striped FBS (208). Twelve hours before treatment, cells were switched to 
DMEM without FBS. At the time of treatment, cells were incubated with vehicle, 
estrogen (5 x 10-8 mol/L; Sigma-Aldrich, St. Louis, USA), or estrogen (5 x 10-8 mol/L) 
plus aldosterone (10-8 mol/L) in DMEM without FBS. 
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Results 
 
 
 
A significant part of the research shown here was based on cell culture of 
established immortalized cell lines and it is crucial to keep the culture conditions as 
homogenous as possible, so that, this is not one more variable that needs to be 
taken into account when analyzing the results of the experiments carried out with 
these cells. Since the culture media itself has a controlled formulation the major 
source of variation comes from additives that are not standardized such as, foetal 
bovine serum (FBS). To reduce such variation, FBS from a single manufacturer’s lot 
was selected after rigorous screening, and subsequently used throughout the 
duration of the experimental phase of the work presented herein. As part of this 
screening cell number and viability were measured as well as the pERK protein 
response to aldosterone stimulation. 
 
FBS is the sterile liquid that is obtained from the clotted blood of the bovine 
foetus. It contains numerous growth factors that are needed for the survival and 
propagation of mammalian cells in culture and for this reason was introduced early in 
cell biology research, subsequent to initial studies with hen and sheep sera (209-
212). Already in the 1950s profound differences for cellular growth between human 
serum and FBS were described and first attempts were made to culture cells in 
serum-free media (212, 213). Despite advances in the fabrication of standardized 
serum-free media over the last decades (214), FBS still remains the most widely 
used cell culture medium supplement in cell biology.  
 
FBS is commercially available from numerous manufacturers and researchers 
typically choose their sera batches based on price, good viability and function of their 
cell cultures, or cloning efficiency. However, few researchers study the composition 
of their FBS batches and these sera therefore remain a major black box in cellular 
experiments. It was previously reported that different sera contain distinct 
compositions of fatty acids, including arachidonic acid (215), and that these lipids can 
directly influence cellular experiments (216, 217). More recently, it was shown that 
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FBS can contain unknown factors that are able to inhibit Toll-like receptor (TLR) 
activation under certain circumstances (218). Although it is generally accepted that 
the composition of FBS may directly influence the outcome of cellular experiments, 
relatively little is known about the impact of lipids and other sera components. 
 
FBS Selection and Growth Curve 
 
Using the service Batch Testing with Reserves provided by Gibco, 5 different 
lots of serum were tested: 
 
Lot 1- 1355888     
Lot 2- 1355891     
Lot 3- 1389439 
Lot 4- 1365490 
Lot 5- 1385397 
  
 
 
Seven T25 flasks were seeded with the same amount of cells for both the 
EA.hy926 and IMR90 cells. Counts were taken (at the same hour) everyday for 7 
days using a Neubaüer counting chamber and Trypan Blue Stain (Sigma-Aldrich) for 
cell viability purposes. Plating day was considered day 1.   
 
 
 
Table 1- EA.hy926 Cell Growth Study for FBS lot Selection. 
Day Cell number (x105) Cell Viability (%) Cell Density (%) Lot 
1 2.0 x 105 100% 10% 
2 1.0 x 105 100% 20% 
3 2.0 x 105 100% 40% 
4 3.0 x 105 100% 40% 
5 2.0 x 105 100% 30% 
6 5.0 x 105 100% 60% 
7 8.0 x 105 100% 80% 
Lot 1- 1355888 
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Day Cell number (x105) Cell Viability (%) Cell Density (%) Lot 
1 2.0 x 105 100% 20% 
2 1.0 x 105 100% 20% 
3 2.0 x 105 100% 40% 
4 3.0 x 105 100% 40% 
5 8.0 x 105 87.5% 80% 
6 8.0 x 105 100% 100% 
7 20 x 105 100% 100% 
Lot 2- 1355891 
1 2.0 x 105 100% 15% 
2 1.0 x 105 100% 20% 
3 2.0 x 105 100% 30% 
4 5.0 x 105 100% 60% 
5 6.0 x 105 83.3% 70% 
6 9.0 x 105 88.9% 100% 
7 15 x 105 100% 100% (secondary) 
Lot 3- 1389439 
1 3.0 x 105 100% 20% 
2 2.0 x 105 100% 40% 
3 4.0 x 105 100% 60% 
4 8.0 x 105 100% 75% 
5 10 x 105 100% 90% 
6 15 x 105 100% 100% (secondary) 
7 20 x 105 85% 100% (secondary) 
Lot 4- 1365490 
1 2.0 x 105 100% 20% 
2 1.0 x 105 100% 30% 
3 3.0 x 105 100% 40% 
4 4.0 x 105 100% 60% 
5 7.0 x 105 100% 60% 
6 11.0 x 105 81.8% 90% 
7 14 x 105 100% 100% 
Lot 5- 1385397 
 
 Before the FBS lot was selected, media samples were sent to a core facility 
part of Harvard University in order to measure the aldosterone levels present in each 
lot. After measurement aldosterone levels were considered too low to cause any 
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interference in the experiments being carried out with the FBS since they were not 
detectable using a sensitive radioactive assay. 
 
Graphic 1- FBS Growth Study using EA.hy926 cells. 
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After analyzing the growth study results for all lots it became apparent that    
lot 1 did not present the necessary conditions for optimal growth of the cells due to 
poor cell growth, lots 2-4 showed consistent results with a exponential trend as 
desired but, lot number 4 did better overall not only showing a more consistent 
growth trend than the other lots but also a faster growth achieving full confluency 
sooner than other lots. Further testing was done to determine if this lot was suitable 
for the experiments planned although, at this stage, lot 4 was considered the most 
promising and the specific growth rate for these cells was calculated using data from 
lot number 4 growth curve.  
 The most well know form of the growth equation is as follows: 
 
N = N0.eμ t 
 
This equation allows scientists to calculate the approximate number of cells (N) that 
will be present at a time t, provided that the initial number of cells plated (N0) is 
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known. μ is termed the specific growth rate or often simply growth rate, (unit: d-1, 
h−1, or min−1) and can be calculated using the following formula: 
 
ln (x2/x1) = (t2-t1) 
 
The specific growth rate for EA.hy926 cells using FBS lot number 4 was calculated to 
be 0.0289 h−1. The doubling time for this cell line is between 24 and 48 hours 
depending on which phase of the growth curve the cells are in. 
 FBS lot 4 was the best choice for growing EA.hy926 cells but, what about 
IMR90 cells? 
 
Table 2- IMR90 Cell Growth Study for FBS lot Selection. 
Day Cell number (x105) Cell Viability (%) Cell Density (%) Lot 
1 2.0 x 105 100% 10% 
2 1.0 x 105 100% 10% 
3 2.0 x 105 100% 15% 
4 3.0 x 105 100% 40% 
5 6.0 x 105 100% 50% 
6 7.0 x 105 100% 70% 
7 8.0 x 105 100% 70% 
Lot 1- 1355888 
1 2.0 x 105 50% 10% 
2 2.0 x 105 100% 15% 
3 3.0 x 105 100% 20% 
4 3.0 x 105 100% 40% 
5 7.0 x 105 100% 60% 
6 7.0 x 105 100% 70% 
7 7.0 x 105 100% 60% 
Lot 2- 1355891 
1 2.0 x 105 50% 10% 
2 3.0 x 105 66.7% 10% 
3 2.0 x 105 100% 20% 
4 6.0 x 105 83.3% 50% 
5 11.0 x 105 90.9% 50% 
6 8.0 x 105 100% 60% 
7 9.0 x 105 88.9% 70% 
Lot 3- 1389439 
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Day Cell number (x105) Cell Viability (%) Cell Density (%) Lot 
1 2.0 x 105 100% 10% 
2 2.0 x 105 100% 10% 
3 3.0 x 105 100% 30% 
4 4.0 x 105 100% 60% 
5 9.0 x 105 100% 60% 
6 7.0 x 105 100% 70% 
7 10 x 105 100% 70% 
Lot 4- 1365490 
1 2.0 x 105 100% 10% 
2 2.0 x 105 100% 20% 
3 2.0 x 105 100% 40% 
4 3.0 x 105 100% 40% 
5 4.0 x 105 100% 40% 
6 4.0 x 105 100% 50% 
7 6.0 x 105 100% 60% 
Lot 5- 1385397 
 
Graphic 2- FBS Growth Study using IMR90 cells. 
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Analyzing the results shown on the table and graph depicted above it is easy 
to ascertain that the IMR90 cell line presents a very different growth pattern from the 
EA.hy926 cell line. The cell numbers achieve are lower and full confluency is never 
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achieved which is in keeping with the fact that these fibroblasts suffer from contact 
inhibition and hence need to be passaged before reaching full confluency. An 
example of that contact inhibition can be seen with lots 3 and 4 where cells peak at 
96 hours but subsequently reduce in number. The growth also seems slower with a 
doubling time closer to 48 hours. 
 In terms of FBS batches, once again three different groups can be 
distinguished according with their general effectiveness. Lot number 5 was 
considered the worse FBS for culturing the IMR90 cell line due to a very poor growth 
rate.  Lot number 1 and number 2 achieved better growth rates and could potentially 
be used but, it was lot number 3 and lot number 4 that delivered the best growth. Of 
all the lots tested, number 3 seems to have faired the best displaying a perfect 
exponential trend with higher number of cells. However, because this is not the only 
cell line used for experimental procedures and, furthermore, the main cell lines used 
are endothelial in nature, lot number 4 was elected the best fit for the work to be 
developed ahead, providing the best results for EA.hy926 cells and good results with 
IMR90 cells. 
 The specific growth rate for IMR90 cells using FBS lot number 4 was 
calculated to be 0.0338 h−1. The doubling time for this cell line is between 24 and 48 
hours depending on which phase of the growth curve the cells are in. 
 
Endothelial Cell Phenotyping 
 
 Optimal cell culture conditions are very important to maintain the growing 
variables such as time and cell number present as stable as possible but, even more 
important is to make sure that the cells used have the right characteristics for the 
designed experiments. In the case of the experimental work developed for this thesis, 
the elected cell lines were selected in order to try and mimic the endothelial layer 
(endothelium) of the cells and arteries present in the cardiovascular system. As 
mentioned before and amongst the hybrid cells, the EA.hy926 cell line, derived by 
the fusion of HUVECs with the continuous human lung carcinoma cell line A549, is 
presently the best characterized macro-vascular endothelial cell line (191). Although 
these cells have been described it is still necessary to confirm its properties under 
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our culture conditions and also to make sure that the proteins of interest for this study 
are indeed present in these cells.  
 However, for the purpose of writing this thesis not only immortalized cell lines 
were used but also a primary cell line. The advantages of primary cultures are that 
the cells have not been “modified” in any way (other than the enzymatic or physical 
dissociation necessary to obtain them), and that allows for study conditions as close 
as possible to in vivo. The disadvantages of these cultures are the mixed nature of 
each preparation, limited lifespan of the culture and the potential contamination 
problems. For all of these reasons several tests have to be performed before any 
conclusions can be derived from the experiments designed using these cells. 
 
Morphological Analysis 
 
 One of the first and easiest phenotypic analysis that can be performed is to 
evaluate the morphology of the experimental cells. The American Type Culture 
Collection (ATCC) is a non-profit bioresource centre which has been preserving, 
growing and distributing cultures for almost 80 years. ATCC is the largest biological 
resource centre in the world with the most comprehensive source of reference 
cultures and reagents. Since 1925, this company has set the standard for 
authentication and distribution of biological reference materials and it is easy to 
access its library to get the technical information relating to the cell type you might be 
working with. The following figures are representative images of EA.hy926 cells 
maintained and sold by ATCC that can be used as reference when evaluating the 
morphology of these cells. 
 EA.hy926 cells display a “triangular” shape at a low density and eventually 
evolve to cobblestone morphology when they are maintained in culture on a plastic 
support. They do not form multiple layers but a uniform cobblestone like monolayer at 
full confluency (219). Since the primary cultures used in these studies are also 
endothelial nature, it is expected they would exhibit a similar morphology and growth 
pattern to EA.hy926 cells. 
 Below are electron micrographs photos showing EA.hy926 cells (figure 29) 
used in the laboratory as well as Mouse Endothelial Cells (figure 30) at different 
culture densities.  
 89
 
Figure 28- Light microscope photographs showing EA.hy926 cells at different  
culture densities. 
 
 
  
 
 
 
 
 
 
Figure 29- Light microscope photographs showing EA.hy926 used for experiments.  
Pictures taken using 200x magnification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30- Light microscope photographs showing Mouse Aortic Endothelial Cells used for 
experiments. Pictures taken using 200x magnification. 
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Comparing the images supplied by ATCC (figure 28) to the images obtained 
by photographing the cells in culture in the laboratory (figure 29) it is easy to see 
morphological similarities. When the cells are less confluent it is possible to 
distinguish the triangular shape typical for these cells and, when the cells become 
confluent they evolve to form the monolayer cobblestone pattern as specified by 
ATCC. 
Mouse Aortic Endothelial Cells electron micrographs depicted show a striking 
similarity to EA.hy926 cells. In low densities the cultured cells show several shapes 
ranging from fusiform to the typical more triangular shape. From observational 
studies it was possible to distinguish different stages of growth from the shape the 
cells take. When the cells first attach to the collagen matrix with which the flasks 
were treated they are spherical. After adhering onto the matrix, the cells start 
“stretching” and taking a more fusiform shape. On the next stage, pseudopods or 
“feet” start forming and evolve until the shape takes the more triangular and typical 
endothelial cell shape. At full confluency these cells show a tight cobblestone pattern 
similar to the EA.hy926 cells but it is also possible to see a couple scattered cells on 
top of the monolayer. All in all the primary cultures used for experiments show 
(through morphological analysis) a high degree of purity. 
 
Immunofluorescence Staining 
 
In order to confirm the endothelial nature and purity of the primary cell cultures 
used, specific monoclonal antibodies raised against different endothelial cell markers 
were used (Von Willebrand Factor (VWF) and CD31 (PECAM-1)) (220, 221) in 
conjunction with immunofluorescence techniques.  
Briefly EA.hy926, IMR90 and Mouse Aortic Endothelial Cells were grown in 
microscope coverslips. When cell confluence reached about 70% the cells were fixed 
using paraformaldehyde and permeablized with a solution of 15% Triton X-100 
detergent. After the cells were prepped the primary antibody was applied. The 
specific antibody was diluted in blocking solution (1% BSA in PBS) and left overnight 
at 4ºC. Since the primary antibody is not linked to any fluorochrome its necessary to 
apply a secondary antibody in order to be able to visualize the cell markers under the 
fluorescence microscope. Fluorescent green and red antibodies were used to label 
the VWF, CD31 and alpha smooth muscle actin (-SMA), respectively. 
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VECTASHIELD® Mounting Medium with DAPI was applied to preserve fluorescence 
and counterstain DNA (stains the DNA blue) and the coverslips mounted on 
microscope slides. The Nikon Eclipse 90i Fluorescence Roper Scientific Microscope 
was used to analyze the resulting cell staining.  
 Both EA.hy926 and Mouse Aortic cells are expected to stain positive to 
endothelial cell markers CD31 and VWF but negative to -SMA, whereas IMR90 
cells, being fibroblasts are expected to stain positive to -SMA (222), but negative to 
the other two markers. 
 EA.hy926 cells were used at passages 12 and 13, Mouse Aortic Endothelial 
cells were used at passages 3 and 4 and derived from different isolation experiments 
and finally IMR90 cells were used at different PDLs and were included in most 
immunofluorescence staining experiments as a negative control. 
 
 
Figure 31- EA.hy926 and IMR90 cells stained with CD31 (green) or -SMA (red) antibodies. 
Nuclear DNA stained blue with DAPI. Images shown with a 400x magnification (10x ocular, 
40x lens) (A, D): EA.hy926 cells stained with CD31 antibody shown in green; (B, E): 
EA.hy926 cell nuclear DNA stained blue with DAPI; (C, F): EA.hy926 cells show negative 
staining for -SMA (red). (G): IMR90 cells show negative staining for CD31 (green); (H): 
IMR90 cell nuclear stained blue with DAPI; (I): IMR90 cells stained with -SMA shown in red. 
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 Results shown above confirm that these cells are viable models t study 
cardiovascular function. EA.hy926 cells stained positive for CD31 confirming its 
endothelial nature. Further proof came from the negative staining for -SMA. 
Contrary to EAhy.926 cells, IMR90 fibroblasts stained positive for -SMA and 
negative to CD31. This result indicates that these cells are a good negative control 
and demonstrates that the immunofluorescence staining is extremely sensitive, with 
very low background and non-specific staining levels. Nuclear DNA staining, 
highlighted by DAPI shows that the cells have maintained their integrity and depict 
optimal levels of fixation and permeabilization as well as the quality of the mounting 
medium used. 
 
Figure 32- EA.hy926 and IMR90 cells stained with VWF (green) or -SMA (red) antibodies.  
Images shown with a 400x magnification (10x ocular, 40x lens) (A, C): EA.hy926 cells 
stained with VWF antibody shown in green; (B, D): EA.hy926 cells show negative staining for 
-SMA (red). (E): IMR90 cells show negative staining for VWF (green); (F): IMR90 cells 
stained with -SMA shown in red. 
 
 93
Once again results shown above are in agreement with expectations. 
EA.hy926 cells stained positive for VWF confirming its endothelial nature with further 
proof derived from the negative staining for -SMA. IMR90 fibroblasts stained 
positive for -SMA and negative to VWF, again as expected.  
Another piece of evidence demonstrating that the immunofluorescence 
staining was a success is the even distribution of the colour in the cells. This shows 
that the antibody displays little non-specific binding and the cells were prepared 
properly for the staining. 
 
 
Figure 33- Mouse Aortic Endothelial cells stained with VWF (green) or -SMA (red) 
antibodies. Nuclear DNA stained blue with DAPI. Images shown with a 400x magnification 
(10x ocular, 40x lens) (A, D): Mouse Aortic cells stained with VWF antibody shown in green;     
(B, E): Mouse Aortic cells nuclear DNA stained blue with DAPI; (C, F): Mouse Aortic cells 
show negative staining for -SMA (red).  
 
 Due to the isolation method, these primary cells have a considerable chance 
of containing a mixture of more than one cell type, making the immunofluorescence 
staining results particularly important to determine if this is a viable method for future 
use in experimental procedures or if further purification of these primary cells is 
required.  
 
 Results depicted above point to the presence of a cell population of 100% 
endothelial cells suggesting that no further purification of these cells is required. 
Images show that even at higher levels of confluency all cells stain positive for VWF, 
 94
a specific marker for endothelial cells. Like EA.hy926 cells, Mouse Aortic Endothelial 
cells are also negative for -SMA, confirming its endothelial nature. It is possible to 
see some background staining but comparatively to the staining seen in fibroblast 
cells, it is too low to be considered positive. Nuclear DNA, as measured by DAPI 
staining, indicates that these cells withstood fixation and permeabilization well and 
the primary antibodies were allowed to penetrate and stain the cell throughout.  
 
 
Figure 34- Mouse Aortic cells and IMR90 cells stained with CD31 (green) or -SMA (red) 
antibodies.  Images shown with a 400x magnification (10x ocular, 40x lens) (A, C): Mouse 
Aortic cells stained with CD31 antibody shown in green; (B, D): Mouse Aortic cells show 
negative staining for -SMA (red). (E): IMR90 cells show negative staining for CD31 (green); 
(F): IMR90 cells stained with -SMA shown in red. 
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Results shown above are in agreement with what was observed in EA.hy926 
cells. Mouse Aortic cells stained positive for CD31 antibody confirming its endothelial 
nature with further proof derived from the negative staining for -SMA. Also as 
expected, IMR90 fibroblasts stained positive for -SMA and negative to CD31.  
  
These results, together with the VWF staining results, indicate that the Mouse 
Aortic cells are indeed endothelial and, therefore, can be used for further 
experiments without any concerns for purity. Both isolation experiments resulted in a 
pure endothelial cell population viable for experimentation. 
 
As mentioned previously in the introductory chapter, in endothelial cells ER 
was shown to target lipid rafts within the plasma membrane (caveolae) by interaction 
with caveolin-1, where it activates endothelial nitric oxide synthase (eNOS) through 
protein kinase-mediated phosphorylation (169). Caveolae facilitate signal 
transduction by providing a location for various signalling molecules (170). Activation 
of ER by phosphorylation has been demonstrated to occur in both a hormone-
dependent as well as hormone-independent manner and is an integral regulatory 
mechanism of nongenomic responses.  
The plasma membrane invagination structure of caveolae supports functional 
protein-protein interactions and cluster of several discrete signalling pathways. Thus, 
caveolae are thought to integrate interactions of receptors and signalling molecules 
in the plasma membrane, resulting in rapid and specific signal transduction (175). 
The caveolin scaffolding domain (CSD) of CAV1 binds numerous signalling 
molecules, including Src family kinases, c-Neu, H-Ras, EGFR, eNOS, and G-protein 
coupled receptors (GPCRs). The ability of CAV1 to hold and orchestrate the spatio-
temporal pairing of membrane localized ERα with its effectors makes CAV1 an 
important scaffolding protein mediating membrane ERα actions. CAV1 is required for 
estrogen-mediated ERα-dependent eNOS production in endothelial cells (186).  
More recently, CAV1 has also been shown to interact with the protein striatin, 
which has been shown to be a key intermediary of the effects of steroid receptors, 
specifically estrogen receptor-α (ER) (188). Lu et al provided evidence that striatin´s 
N-terminal segment interacts with the DNA binding domain of ER in the 
immortalized human endothelial cell line, EA.hy926 cells. This interaction organizes 
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the ERα-eNOS membrane signalling leading to rapid nongenomic activation of 
downstream signalling pathways including ERK and eNOS in endothelial cells. 
Interestingly, disruption of the striatin-ERα interaction had no effect on estrogen-
mediated gene transcription suggesting that striatin specifically mediates ERα extra-
nuclear signalling independent of ERα nuclear actions.  
 
 Results demonstrated for ERα by other groups and mentioned above served 
as the basis for this thesis. Being part of the same family of steroid receptors and 
having in common its method of action it is possible that MR also shares this form of 
nongenomic/rapid signalling with ERα. Having established the endothelial nature of 
both the EA.hy926 and mouse aortic primary cells, the next logical step was to make 
sure that the proteins of interest (MR, striatin and caveolin 1) were present in the 
cells to be used in experimental studies.  
 
Protein Determination by Western Blot Analysis 
 
 Since the subject of this study is the nongenomic action of MR, it is only 
natural to investigate MR expression in EA.hy926 and mouse aortic cells. According 
to the proteomic information repository website UniProtKB/Swiss-Prot, MR protein is 
expected to have a molecular weight of 107 kDa. UniProt is a comprehensive, high-
quality and freely accessible database of protein sequence and functional 
information, many entries being derived from genome sequencing projects. It 
contains a large amount of information about the biological function of proteins 
derived from the research literature and is a good place to look for reliable 
information on molecular weights and protein isoforms. 
 The antibody selected for this study was Santa Cruz’s rabbit polyclonal 
antibody raised against amino acids 1-300 of the human MR protein (catalogue 
number sc-11412). The main reason for selecting this antibody was the fact that it 
had been used before in the laboratory (223), providing consistent results. Below is 
the image provided by the manufacturer for the band size to expect. 
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 Analyzing the image it is possible to see several bands. One faint band over 
113 kDa which one can speculate might either be non specific or, due to post-
translational modification of the MR protein. The strong intensity band at around    
107 kDa can be assumed to be MR and finally, an even stronger intensity band at 
around 75-80 kDa which could potentially be an MR isoform that lacks steroid-
binding activity and acts as ligand-independent transactivator (52). Bearing in mind 
that the manufacturer itself does not offer any explanation for the multiple bands 
present, this explanation is only one of many possible. 
 
 Both Mouse Aortic Endothelial cells (MAEC) and EA.hy926 cells were tested 
for MR protein. Mouse heart tissue was also used to ascertain if there was any MR 
present in this tissue. 
 
 
 
 
 
Figure 36 – Western blot membrane showing the presence of MR protein in Mouse Aortic 
Endothelial cells (MAEC), EA.hy926 cells (EA.hy) and Mouse heart tissue (Heart). 
 
Figure 35 – Image provided by 
Santa Cruz Technology for cat. 
no. sc-11412 MR antibody. 
107 kDa 
MAEC  EA.hy  Heart
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 The size of the bands shown in this western blot membrane was estimated 
from the relative position of the bands to the Kaleidoscope Precision western blot 
marker manufactured by BioRad. The bands were positioned slightly above the 100 
kDa marker, making the 107 kDa a very likely weight.  
 Results show a strong presence of the protein in both MAEC and EA.hy926 
cells, being the later where the highest abundance can be found. There are several 
reports pointing to the presence of MR in cardiac tissue (224, 225). It has also been 
established that the presence of MR in cardiac tissue tends to increase with 
inflammation and fibrosis, being higher in disease models (226). Western blot results 
above show the presence of MR in mouse cardiac tissue although not in very high 
amounts as seen in the endothelial cells tested alongside in the same membrane. 
These results are consistent with the literature and would indicate a healthy rodent. 
The different bands seen in the image provided by the manufacturer were not 
present in the western blots carried out with our samples.  
 
The next protein that was looked at was striatin since it plays a key role in the 
nongenomic actions of ER and may possibly be involved in the nongenomic actions 
of MR if the initial hypothesis for this work is correct.  
 
The UniProtKB/Swiss-Prot website predicts the molecular weight of the striatin 
protein to be around 86 kDa. The antibody selected for this study was BD 
Bioscience’s mouse monoclonal antibody raised against amino acids 450-600 of the 
rat striatin protein (catalogue number 610838). Below is the image provided by the 
manufacturer for the band size to expect. 
 
 
 
 
 
 
 
 
 
 
Figure 37 – Image provided by 
BD Biosciences for cat. no. 
610838 striatin antibody. 
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The expected molecular weight differs significantly from the predicted weight 
but, it is in accordance with results obtained for other antibodies available in the 
market which strongly points to the possibility that striatin undergoes a post-
translational modification. In light of the available information on this protein, the most 
probable modification appears to be phosphorylation and there is some evidence in 
the literature (227) that seems to corroborate this hypothesis. Unfortunately, there 
isn’t a commercially available antibody that can be used to prove such a theory.  
 
 Again, both endothelial cell lines were tested for striatin protein, alongside 
mouse heart tissue. Results obtained are depicted below.  
 
 
 
 
 
Figure 38 – Western blot membrane showing the presence of striatin protein in Mouse Aortic 
Endothelial cells (MAEC), EA.hy926 cells (EA.hy) and Mouse heart tissue (Heart). 
 
Once again, the size of the bands shown in this western blot membrane was 
estimated from the relative position of the bands to the Kaleidoscope Precision 
western blot marker. The bands were positioned a little above the 100 kDa marker, 
pointing to the 110 kDa weight.  
 Results show the presence of the protein in all the samples tested, MAEC, 
EA.hy926 cells and Mouse heart tissue. Samples show an even amount of striatin 
protein present, although the strongest band can be seen for the EA.hy926 cell line, 
making it an ideal cell line to study this thesis hypothesis.  
 
 Finally, the samples were tested for the presence of the protein caveolin 1.The 
UniProtKB/Swiss-Prot website predicts the molecular weight of the caveolin 1 protein 
to be around 20/21 kDa, having an alpha and a beta isoform. The antibody chosen 
for this study was BD Transduction Laboratories mouse monoclonal antibody 
developed using amino acids 1-178 of Rous Sarcoma Virus Transformed-Chick 
Embryo Fibroblasts (RSV-CEF) and purified from tissue culture supernatant or 
ascites using affinity chromatography (catalogue number 610406). Below is the 
image provided by the manufacturer for the western blot results that can be expected. 
110 kDa 
MAEC EA.hy Heart 
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 The manufacturers western blot results show a single band which they place 
at 24 KDa. This result is in agreement with the expected molecular weight for the 
alpha isoform of this protein (20/21 KDa). Although there is a discrepancy, the 
variation does not seem to indicate that there is any post-translational modification or 
that it can be a different protein. 
 
Both endothelial cell lines used in this study were tested as well as a mouse 
heart sample. Western blot was carried out using the standard protocol for the 
laboratory and following the manufacturer’s instructions. Results obtained are 
depicted below. 
 
 
 
 
 
Figure 40 – Western blot membrane showing the presence of caveolin 1 protein in Mouse 
Aortic Endothelial cells (MAEC), EA.hy926 cells (EA.hy) and Mouse heart tissue (Heart). 
  
Figure 39 – Image provided by 
BD Transduction Laboratories for 
cat. no. 610406 caveolin 1. 
antibody. 
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Results obtained in the lab show the presence of one or two bands around the 
22/24 KDa weight. It is also possible that there were two bands for EA.hy926 cells 
and/or heart tissue but, there is so much of the protein that the potential two bands 
appear as one. The bands all came under the 25 KDa Kaleidoscope weight marker. 
Mouse endothelial cells show 2 distinct bands which were attributed to a possible 
phosphorylated form of the protein. Results seen are in line with what the 
manufacturer predicts. The highest level of caveolin 1 protein is seen in the mouse 
heart tissue sample, followed by the EA.hy926 endothelial cell line.  
 
The results from all the western blot tests carried out confirm the choice of the 
EA.hy926 immortalized endothelial cell line as a good model to study this work’s 
hypothesis.  
In addition to western blot analysis, the presence of MR and striatin protein in 
mouse aortic endothelial cells was also detected using immunofluorescence 
techniques. 
 
 
Figure 41 – Mouse Aortic Endothelial cells stained with striatin (green, A) antibody and MR 
(red, B) antibody. Cells were used at passage 4. Images shown with a 400x magnification. 
 
The presence of the protein caveolin 1 in the cell lines studied is a good 
indication of the existence of caveolae rafts in the cell membrane but, in order to be 
sure of their presence and, because it’s a fundamental point in the hypothesis, it was 
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decided to send the cells to be tested by electron microscopy to confirm the presence 
or absence of the caveolae.  
 
Determination of the Presence/Absence of caveolae rafts by Electron Microscopy 
 
The plasma membrane is a biological membrane that separates the interior of 
all cells from the outside environment. It is selectively permeable to ions and organic 
molecules and controls the movement of substances in and out of cells, protecting 
them from outside sources. But, the plasma membrane is not a homogenous 
structure. Specifically, the plasmalemma typically contains numerous small lipid 
patches enriched for cholesterol and glycosphingolipids, commonly referred to as 
lipid rafts. Lipid rafts may function to bring different proteins into proximity and thus 
promote interactions between receptors and signalling proteins and among different 
signalling receptors, allowing for receptor cross-talk (228). In certain cell types, 
plasmalemmal lipid rafts can be clustered and organized by a scaffolding composed 
of the intracytoplasmatic cholesterol-binding proteins caveolin 1, 2, or (in muscle 
cells) 3 into 50- to 100-nm flask shaped invaginations called caveolae (229). These 
organelles were originally discovered in the early 1950s by electron microscopic 
analysis of vascular endothelial cells (230) and of bladder epithelium (231). Caveolae 
have since been observed in many cell types although adipocytes, fibroblast, muscle 
cells and endothelial cells show the greatest abundance. Caveolae function to permit 
transcytosis of macromolecules across an endothelial cell barrier such as that found 
in brain capillaries. More recently, it has been appreciated that caveolae may also 
play a key role in cell signalling. This is because caveolins, especially caveolin 1, can 
bind to several types of plasma membrane receptor proteins and concentrate these 
molecules within the caveolae (232). This clustering of disparate receptor types 
further facilitates receptor cross-talk, allowing one type of ligand-occupied receptor to 
activate the downstream signalling pathways normally initiated by a different receptor 
type (185, 229). In other words, in addition to their role in transcytosis, caveolae 
appear to function as highly efficient lipid rafts. 
 It is know that caveolae are abundant in endothelial cells (ECs) in situ but 
markedly diminished in cultured cells, making it difficult to assess their role in 
signalling. For the particular immortalized cell line used in this study (EA.hy926) there 
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is some preliminary data that demonstrates the presence of caveolae on the cell 
membrane of these cells (see figure 42). D’Alessio et al (229), used Transmission 
Electron Microscopy (Phillips CM 100 electron microscope at an accelerating voltage 
of 80 kV) to demonstrate the presence of these structures in EA.hy926 cells. 
 
 
 
Results obtained by this group show the presence of caveolae in resting 
EA.hy926 cells that, disappear when these cells are treated with methyl-β-
cyclodextrin which acts as a disruptor of lipids rafts. These results are a very good 
indication of what can be expected from the cells used in this thesis sent for EM 
analysis. 
 
EA.hy926 cells were sent for EM analysis together with mouse aortic 
endothelial cells (wild type and caveolin 1 knock-out) and a potentially negative cell 
line (HEPG2 liver hepatocyte cell line). After fixation in the laboratory, thin sections 
were cut on a Reichert Ultracut E ultramicrotome, collected on formvar-coated grids, 
stained with uranyl acetate and lead citrate and examined in a JEOL JEM 1011 
transmission electron microscope at 80 kV.  Images were collected using an AMT 
digital imaging system (Advanced Microscopy Techniques, Danvers, MA). Electron 
microscopy was performed in the Microscopy Core of the Centre for Systems 
Biology/Program in Membrane Biology at the Massachusetts General Hospital in 
Boston. Results obtained can be seen in the figures presented below.   
 
 
Figure 42- A: Transmission electron 
microscopy reveals caveolae, 
indicated by arrowheads, in resting 
EA.hy926 cells.  
B: Electron Microscopy analysis of 
methyl-β-cyclodextrin (MβCD) treated 
cells showing the disappearance of 
caveolae network (28). 
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Figure 43 – Transmission electron micrographs depicting EA.hy926 cells. Caveolae can be 
seen on the cell membrane (refer to arrows). Images shown at 40000x magnification. Scale 
bar shown on right bottom below the image. 
 
Figure 44 – Transmission electron micrographs depicting mouse aortic endothelial cells. 
Caveolae can be seen on the cell membrane (refer to arrows). Images shown at 40000x 
magnification. Scale bar shown on right bottom below the image. 
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Figure 45 – Transmission electron micrographs depicting HEPG2 hepatocyte cells. 
 No caveolae can be seen on the cell membrane. Images shown at 40000x magnification. 
Scale bar shown on right bottom below the image. 
 
  
EA.hy926 cells shown in figure 43 clearly show the presence of caveolae in 
the cell membrane. The flask-shape invaginations are present all along the cell 
membrane of different cells and are accompanied by signs of endocytosis. There are 
several endocytic vesicles in the vicinity of the cell membrane thought to be result of 
the intake of molecules by the caveolae to be transported to different locations in the 
cell, namely the nucleus. The results depicted are very similar to what had been 
published before (229) not only in the number and shape of the caveolae seen but 
are also in keep with the expected size of 50- to 100 nm. 
 
Mouse aortic endothelial cells were collected from animal vessels and 
perpetuated in culture for several passages. Although they are closer to the in vivo 
conditions, it is still possible for them to lose characteristics when placed in culture 
conditions, hence it is very important to look for caveolae presence in these cells 
before proceeding to more experiments.  Results shown in figure 44 are very similar 
to the ones observed for EA.hy926 cells. Cell membranes show a high number of 
invaginations consistent with the presence of caveolae in these cells together with 
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endocytic vesicles concurrent with the engulfing of molecules from the outside 
environment of the cells to be “delivered” to different destinations within the cellular 
milieu. The main differences that can be seen between the mouse aortic endothelial 
cells and the immortalized endothelial cell line EA.hy926 are that the size of the 
caveolae appears to be smaller in the mouse cells and these also appear to be more 
distant between themselves. It is difficult to discern if this is result of culturing the 
cells or a characteristic intrinsic to the cells. What can be said is that the presence of 
the endocytic vesicles is a positive sign of the working order of the caveolae present 
and hence makes these cells adequate for further experiments on the potential 
function of the caveolae in cell signalling. 
 
Contrary to the endothelial cells seen in figure 43 and 44, the hepatocyte cell 
line HEPG2 electron micrographs shown on figure 45 depict a very smooth cell 
membrane without any invaginations resembling the shape of caveolae seen before. 
There are also no endocytic vesicles which is in keep with the lack of endocytosis 
carried out by the caveolae. It is possible to discern a few “dimples” on the cell 
membrane that show heavy staining. These are clathrin-coated pits which tend to be 
bigger than the caveolae and are present in virtually every type of cells. These pits 
are also present in the endothelial cells shown and can be easily differentiated from 
the caveolae due to their heavy staining and bigger size, they also do not have the 
flask shape associated with the caveolae. 
 
 All in all these results are very positive, endothelial cells shown, both 
immortalized and primary cultures, depict a strong caveolae presence on their cell 
membrane confirming their promise as a good study tool to potentially answer the 
questions asked during this experimental project. 
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Figure 46 – Transmission electron micrographs depicting mouse aortic endothelial cells from 
CAV1 WT animals. Caveolae can be seen on the cell membrane (refer to arrows). Images 
shown at 40000x magnification. Scale bar shown on right bottom below the image. 
 
Figure 47 – Transmission electron micrographs depicting mouse aortic endothelial cells from 
CAV1 KO animals. No caveolae can be seen on the cell membrane. Images shown at 
40000x magnification. Scale bar shown on right bottom below the image. 
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 Figures 46 and 47 show electron micrographs of mouse aortic endothelial cells 
resultant from primary cell culture of aortic cells collected from CR57BL6 mice that 
lack the caveolin 1 gene (CAV1 KO animals) or their wild type counterparts. The 
reason why we look at the wild type mouse once again is due to the fact that different 
species were being used. Whereas the original mouse aortic endothelial cells were 
collected from CD1 mice (the regular white or brown laboratory mouse), which is a 
cheaper animal model, the CAV1 KO wild type animal comes from a different species 
of mouse, the black 6 model that has some genetic differences. Hence the only way 
to make sure that the cells collected from these different animals displayed the same 
basic characteristics was to submit both cell cultures to be analyzed by electron 
transmission microscopy and compare the photographic results obtained. 
 
 Looking at figure 46 it is easy to spot differences between these cells and the 
ones shown in figure 44. The caveolae are present but are more difficult to spot on 
the cell membrane due to their size. The membrane has the same general reticulated 
aspect as the previous mouse aortic endothelial cells but the invaginations 
themselves are much smaller in size making them harder to distinguish against the 
general background of the cell cytoplasm. There is some evidence of endocytic 
vesicles but again not as pronounce as what was observed before. Figure 47 derives 
from a CAV1 KO animal and shows smoother cell surface with clathrin-coated pits 
visible but no apparent caveolae or endocytic vesicles.  
 
 Although the results are in keeping with what was expected, they are not 
believed to be very clear. The size of the caveolae is much smaller than what was 
observed before and they are difficult to distinguish in the cell membrane. In this way 
judgment was reserved until further experiments were undertaken about the 
presence/absence of caveolae in these cells. 
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Aldosterone-Response Studies 
 
 This work is based on the premise that aldosterone rapid signalling via the 
mineralocorticoid receptor may function in a similar way to what has been described 
for the estrogen receptor alpha (188). To explore this hypothesis it is important to 
select a signalling molecule to focus on and test in order to investigate whether the 
action of this molecule is enhanced when the cells are stimulated with aldosterone. 
The authors of the paper mentioned above, used mitogen activated protein kinases 
(MAPK), specifically ERK1/2 kinases as target molecules and tested if its 
phosphorylation was enhanced when the cells were stimulated with estrogen. After 
careful consideration, literature review and previous results analyzed, it was decided 
to study ERK1/2 from the MAPK family as possible important players in the 
aldosterone nongenomic signalling cascade. This decision was greatly aided by the 
literature where several sources referred to an increase in pERK activity (118, 233, 
234) but also by previous results observed within the research group (235).  
 Male C57BL/6 on a 3% NaCl (salt) diet were injected intraperitoneally with 
either 10 µg/kg of aldosterone (experimental group) or vehicle (control group) and 
killed at different time points after injection (0, 0.5, 1, 2, 3, 4, 5 and 12h). Plasma 
aldosterone levels reached a peak (290 ng/dl) at 30 minutes, returning to baseline at 
3 hours. Total RNA was extracted from whole hearts and used in microarray studies 
to analyze the gene expression profiles in the heart. Animal models of 
mineralocorticoid excess demonstrate cardiac damage (107, 236, 237), and human 
clinical trials offer evidence that blockade of the mineralocorticoid receptor can 
decrease morbidity and mortality in patients with heart failure (103, 104). The 
experiment was designed to focus on the genetic effects of aldosterone that could 
potentially mediate empirically observed myocardial injury. In rodent models, 
uninephrectomy and high-salt diet are necessary for demonstration of 
mineralocorticoid-mediated cardiac damage (107, 110, 111). Whereas the duration of 
this particular experiment was too short to observe myocardial injury, experimental 
conditions were designed to replicate the physiological conditions that have been 
shown to lead to cardiac damage. Several of the genes whose expression level was 
affected by aldosterone are known to play a role in steroid signalling: dual specificity 
phosphatase 7 dephosphorylates ERK (238), and protein phosphatase 5 may be 
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involved in glucocorticoid receptor signalling (239). Several groups have reported an 
increase in phosphorylation of ERK1/2 within several minutes after aldosterone 
administration that is not blocked by inhibitors of transcription and translation (240, 
241), implying a nongenomic mechanism. These findings possibly indicate a second, 
genomic pathway leading to ERK1/2 phosphorylation (by decreasing the expression 
of the enzyme responsible for ERK1/2 dephosphorylation), after a longer period of 
time.  
 With reports of increases in phosphorylation as early as 5 minutes after 
stimulation with aldosterone, it was felt that the best course of action was a short-
time aldosterone stimulation study to pinpoint when the endothelial cells used in the 
laboratory achieve a peak in ERK1/2 phosphorylation. 
 
Graph 3: Aldosterone short-time stimulation study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 EA.hy926 cells were grown in 10% FBS DMEM media until reaching about 
70% confluency. At that stage the cells were stepped-down to 0,4% FBS DMEM to 
keep the environment stimulation to a minimum. Although the aldosterone levels in 
FBS were measured and considered to be negligent, this is still a very rich media and 
it is difficult to assess if the growth factors and cytokines present influence the 
signalling pathway under study, hence by keeping their levels to the minimum to 
ensure cell viability the chance of external factors influencing the outcome of the 
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experiments is highly diminished. Cells were kept in the step-down media overnight 
and then stimulated with 10 nM aldosterone or vehicle (ethanol solution used to 
dissolve the aldosterone chemical) for different periods of time. Cells were then 
washed in PBS and collected in RIPA buffer for western blot analysis. 
Phosphorylated ERK1/2 protein levels were measured and normalized to ERK1/2. 
Results are shown on graph 3 and it is easy to identify two distinct peaks of activity 
for phospho-ERK after EA.hy926 cells are stimulated with aldosterone. The first peak 
is quite steep and observed at 15 minutes of aldosterone treatment. Although the 
short length of time of treatment leads to the very tempting conclusion that this might 
be a nongenomic effect of aldosterone signalling, it is not possible to correctly 
ascertain if this is the case without performing further experiments. The second peak 
can be seen at 5 hours of treatment. Due to the relatively long period of time of 
treatment, this peak is believed to be due to genomic effects of aldosterone and 
further experiments were undertaken to confirm this hypothesis. Statistical results 
shown on graph 3 were obtained by one-way ANOVA followed by post-hoc Mann-
Whitney t-test comparison for selected time-points.  
 
Graph 4: Aldosterone short-time stimulation study. 
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and 5 hours with the highest being at 15 minutes with an almost doubling of ERK 
phosphorylation. Once more, statistical results shown on graph 4 were obtained by 
one-way ANOVA followed by post-hoc Mann-Whitney t-test comparison for selected 
time-points.  
 
 When it comes to what aldosterone dose to use for cell stimulation authors 
seem to be divided. When looking at the literature it is possible to find values going 
from 0,1 to 100nM of aldosterone being used to stimulate cells. For the first 
experiments carried out with the EA.hy926 cells, 10nM aldosterone was the selected 
concentration for time course studies. Although cells responded well to this 
concentration, it was felt that a dose response study was necessary to determinate if 
this was the best concentration to use with these cells. 
 
Graph 5: Aldosterone dose response study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48 – Western blot depicting the results shown on graph 5. 
Numbers shown above the photo represent the aldosterone dose in nM. 
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aldosterone dose at 15 minutes of stimulation leading up to a 2-fold response when a 
1µM aldosterone dose is used. * represents a p < 0,05 when compared to vehicle (0 
nM). Although it is tempting to select the dose that delivers the highest response in 
terms of ERK phosphorylation and, hence, cell signalling, it is important to consider 
the physiological relevance of the dose used in cell experiments, making it possible 
to compare to situations of high aldosterone levels in medical science. 
 Primary hyperaldosteronism (PHA) is recognized as the most common 
endocrine form of secondary hypertension (242-247) with an estimated prevalence 
between 5% and 15% in the hypertensive population (248). Primary aldosteronism, 
also known as primary hyperaldosteronism, is characterized by the overproduction of 
aldosterone by the adrenal glands without the expected excessive renin secretion, 
making the ratio of plasma aldosterone concentration to plasma renin activity the 
most common screening test for this condition. Aldosterone causes increase in 
sodium and water retention and potassium excretion in the kidneys, leading to 
arterial hypertension. PHA has many causes, including adrenal hyperplasia and 
adrenal carcinoma. When it occurs due to a solitary aldosterone-secreting adrenal 
carcinoma (a type of benign tumour), it is known as Conn’s syndrome (249). Plasma 
aldosterone levels vary considerably, even for normotensive individuals. A study 
conducted in 76 healthy individuals and 28 confirmed PHA patients resulted in 
plasma aldosterone values of 0,033 to 1,930 nM for healthy subjects and 0,158 to 
5,012 nM for PHA patients (250). 
 These values, especially the top value for PHA patients seems to validate the 
choice of 10nM aldosterone as a valid one both for cell studies as for a possible 
comparison with pathophysiological states in humans as it is within the same order of 
magnitude, although higher. This way although 10nM aldosterone cannot be called a 
pathophysiological dose, it is still an acceptable pharmacological dose for 
comparison with disease states in humans. In addition, clinical results collected by 
other investigators in the group over the past 30 years (HyperPATH cohort) show 
that in 828 hypertensive subjects the circulating aldosterone levels ranged between 
0,05 and 11,53 nmol/L (Mean= 1,37 ± 0,94 nmol/L [Std Dev]; Median 1,13 nmol/L). 
Furthermore, aldosterone levels over 100 nmol/L have been observed in heart failure 
patients (251, 252), reinforcing the fact that high levels of aldosterone play a part in 
the pathophysiology of cardiovascular failure. 
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Aldosterone’s nongenomic effects 
 
 Having focused on making sure that everything is in place for the key 
experiments, the aldosterone short-time study was repeated with cells grown in the 
selected FBS batch media and a mineralocorticoid receptor inhibitor. EA.hy926 cells 
were grown until about 70% confluency in 10% FBS media and then stepped-down 
to 0,4% FBS media overnight before the experiments took place. Each treatment was 
applied in triplicate and each experiment repeated three times. 
 Potassium canrenoate is the potassium salt of canrenoic acid, an antagonist of 
aldosterone action. Like spironolactone, it is a prodrug, which is metabolized to 
canrenone in the body. Spironolactone and its active metabolites canrenone and 
potassium canrenoate are normally used as hypertensive drugs but, their mechanism 
 
Figure 49 – Potassium canrenoate. 
Systematic IUPAC name: potassium 3-
[(8R,9S,10R,13S,14S,17R)-17-hydroxy-10,13-
dimethyl – 3 – oxo - 2, 8, 9, 11, 12, 14, 15, 16 
– octahydro - 1H – cyclopenta [a] 
phenanthren -17-yl] propanoate. 
 
of action is not fully understood. It is known that it initially inhibits sodium 
reabsorption and secondarily potassium excretion in the distal tubule of nephrons but 
little is known about how it acts in the cardiovascular system. A study conducted in 
aortic rings suggests that canrenoate might exert this action through an inhibition of 
voltage-dependent Ca2+ channels (253). 
 There were several reasons for selecting canrenoic acid as the inhibitor of 
choice for aldosterone in these studies, most of them due to practicality. Canrenoic 
acid is readily available from chemical suppliers like Sigma-Aldrich whereas 
eplerenone and especially spironolactone are more difficult to get hold of in pure form. 
Canrenoic acid is also water soluble making it a perfect inhibitor for use in cell based 
assays. In contrast, both spironolactone and eplerenone need to be dissolved in 
ethanol making them more toxic for cells. 
 As previously described, cells were plated in 6 well plates at a density of         
5 x 105 cells/well and allowed to reach 70% confluency before the media was 
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changed from DMEM 10% FBS (selected batch) to DMEM 0,4% FBS and left 
overnight. Canrenoic acid was used at a concentration of 1µM (100 times the 
aldosterone concentration) to ensure an efficient inhibition.  
 
Graph 6: Aldosterone short-time course with antagonist. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50 – Western blot illustrating the results shown on graph 6. 
Letters shown above the photo represent the treatment  
(V- vehicle, A- aldosterone, MRA- mineralocorticoid antagonist). 
 
 Just as seen before, EA.hy926 cells show an increase in ERK1/2 
phosphorylation when stimulated with 10nM aldosterone for 15 minutes. This result is 
in agreement with has been observed before with these cells with a 2,5 fold increase 
in pERK (p  0,01 when compared to 5 minutes). When the mineralocorticoid 
antagonist canrenoic acid (MRA) is used in conjunction with the aldosterone 
treatment, the increase in ERK phosphorylation is abrogated, thus confirming that the 
5 15 30 60 15
0
1
2
3
4
* p  0.01 ** p  0.01
+ MRATreatment time (min.)
pE
R
K
/E
R
K
 P
ro
te
in
 L
ev
el
s
(a
rb
itr
ar
y 
un
its
)
 V     A V     A V     A V     A 
pERK 
MRA 
5 Min. 15 Min. 30 Min. 60 Min. 
ERK 
 116
increase in pERK observed is indeed due to an effect of aldosterone acting through 
the mineralocorticoid receptor. 
 
This result is by itself promising, especially because it is consistent with 
previous experiments and thus would appear to be a true biological observation and 
not an artefact of the experimental paradigm. Although promising, more experiments 
are necessary before claiming any physiological significance for this result. One of 
the easiest critiques is that the cell line used is not only an immortalized cell line but 
also not of cardiovascular origin, making the conclusions drawn from these results of 
lesser interest and significance in the study of cardiovascular relevance of 
aldosterone nongenomic actions. In order to add relevance to the results observed in 
EA.hy926 cells, experiments were repeated using early culture mouse aortic 
endothelial cells collected from healthy mice. Cells were isolated from the pulmonary 
section of mice aortas and grown in DMEM, 20% FBS with the addition of 1% MEM 
amino acids, 1% sodium pyruvate, 100 /ml heparin, 100 g/ml endothelial cell growth 
supplements (Sigma-Aldrich, St. Louis, MO) and incubated in 5% CO2 at 37°C in a 
humidified atmosphere. The cells were used at passages 2-3. The purity of the 
primary cultures was confirmed by the specific monoclonal antibodies raised against 
VWF and PECAM-1 previous to use in experiments. 
 
  Because each individual aorta yields a small number of cells, it was 
necessary to combine cells from more than one aorta for these experiments. All 
aortas were collected at the same time and processed using the same experimental 
protocol and reagents. Cells were cultured in collagen coated 6 well plates till 
confluency and then passaged to collagen coated t-flasks to expand previous to use 
in aldosterone experiments. Cells were first used at passage 2 and for no longer than 
4 passages total. As with EA.hy926 cells, mouse aortic endothelial cells were 
stepped-down previous to use in experiments. Due to the fact that these cells are 
grown in double the amount of FBS as the EA.hy926 cells it took to stepping-down 
phases, from 20% FBS to 10% FBS and then to 0,4% FBS, to allow the cells to get 
used to less nutrients without entering senescence.  
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Graph 7: Aldosterone short-time stimulation study using Mouse Aortic Endothelial cells. 
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Figure 51 – Western blot illustrating the results shown on graph 7. Treatments were done in 
triplicate using 10nM aldosterone for different periods of time. 
 
 Each treatment was done in triplicate and the experiment itself repeated at 
least 3 times. 6 mice were sacrificed per experiment and the cells collected pooled 
together in order to have the necessary number of cells per experiment.  
 Results show a significant increase in pERK protein levels at 15 minutes of 
aldosterone, confirming previous observations with the EA.hy926 cells line. The 
magnitude of the increase in protein levels is smaller than the one observed before 
but more consistent between experiments as indicated by a smaller error bar (see 
graphs 6 and 7). Seeing that these cells were isolated from the aorta of healthy 
rodents, the results observed are in all probability closer to physiological relevance in 
humans. They also confirm that the EA.hy926 cell line as a good model for 
endothelial cell action. 
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 Combined together, the results from short-time aldosterone stimulation studies 
with EA.hy926 endothelial cells and mouse aortic endothelial cells start to piece 
together a convincing amount of evidence pointing to a newly described nongenomic 
action of aldosterone in endothelial cells. Although the observed results can be 
considered as a rapid action of aldosterone, in order to call it a nongenomic action, 
first it is necessary to demonstrate that no gene translation is occurring in the 15 
minutes of aldosterone action.  
 EAhy.926 cells were stimulated with 10nM aldosterone for 15 minutes and 5 
hours and then collected for mRNA extraction. After mRNA was purified and 
quantified, a reverse-transcription kit was used to obtain cDNA that was then used in 
Real-Time PCR gene expression experiments. The 5 hour time-point was used as a 
measure of positive genomic action. Aldosterone is known to change the expression 
of several different genes being it by increasing or reducing it (254). 4 different genes 
were selected for quantification in aldosterone stimulated EA.hy926 cells but only 2 
showed the expected results with an increase/decrease at 5 hours and no change at 
15 minutes. Although all the genes studied showed no change at 15 minutes, NOS 
and aldolase, did not show a sufficient change at 5 hours to make it significant 
evidence of a genomic effect of aldosterone, only being slightly elevated when 
compared to control.  
 
 The mechanisms behind aldosterone action have been extensively 
characterized, particularly in the kidney collecting duct (CD).  In intact CD or cultured 
CD cells, the response to aldosterone can be divided into main phases- early and 
late –that differ significantly, although both require changes in gene transcription 
(255). The principal early action of aldosterone in CD cells (after 30-45 minutes) is to 
increase apical membrane permeability by increasing Na+ transport through ENaC 
(96). In most cases, the ENaC-mediated early effect of aldosterone accounts for 
more than 60% of the total increase in Na+ current and, importantly without changes 
in ENaC gene transcription (77). These observations suggest that MR regulates the 
transcription of a regulatory protein that increases the plasma membrane localization 
and/or activity of existing ENaC protein. The early effects of aldosterone are potent, 
rapid and largely limited to changes in ENaC-mediated Na+ transport, with other 
effects such as proliferation, occurring later (256). Thus, the mRNA levels of a 
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mediator of the early response should increase markedly and rapidly and the 
mediator of the early response should, in turn, strongly stimulate ENaC activity. 
SGK1 (Serum/glucocorticoid regulated kinase 1) has been shown to be such an 
aldosterone-stimulated regulator of ENaC activity (79, 257, 258).  
 SGK1 mRNA is rapidly increased by 
aldosterone and, when expressed in Xenopus 
oocytes, SGK1 strongly and selectively stimulates 
ENaC-mediated Na+ transport in addition to 
localizing ENaC to the membrane (255). Most 
studies regarding aldosterone action concern the 
renal system where its action is most important, 
indeed, one study using cardiomyocytes has shown 
that some of the genes whose expression is 
affected by aldosterone in the collecting duct are 
also increased in the cardiovascular system. 
Results of this study showed a 2.5 fold increase in 
SGK1 mRNA (259), other genes were found to be 
up-regulated by aldosterone action, including several connected to inflammation and 
fibrosis like   PAI-1 and ADAMTS1. 
 
Graph 8: SGK1 mRNA levels in EA.hy926 cells after stimulation with aldosterone. 
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Figure 52- Crystal structure of Serum 
Glucocorticoid Regulated Kinase 1, 
adapted from the Protein Data Base 
(PDB 2R5T). 
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Consistent with the observations for cardiomyocytes, EA.hy926 cells 
stimulated with aldosterone showed an increase in SGK1 mRNA levels. SGK1 went 
up by about 2,5 fold after 5 hours of 10nM aldosterone treatment (p 0,001 when 
compared to 15 minutes). Contrary to the 5 hour time-point that displays a classic 
genomic action of aldosterone with a significant increase in SGK1 mRNA levels, the 
15 minute time-point did not show any significant change supporting the hypothesis 
that the increase in pERK protein levels is indeed a nongenomic effect of aldosterone 
action at this time-point. In order to take into account differences between samples, 
SGK1 mRNA levels were normalized using the housekeeping ribosomal gene 18S. 
 
Graph 9: WNK4 mRNA levels in EA.hy926 cells after stimulation with aldosterone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serine/threonine-protein kinase WNK4 also known as WNK lysine deficient 
protein kinase 4 or WNK4, is an enzyme that in humans is encoded by the WNK4 
gene (260). The WNK4 gene encodes a serine-threonine kinase expressed in distal 
nephron. Its primary role in renal physiology is as a molecular switch between the 
angiotensin II-aldosterone mediated volume retention and the aldosterone mediated 
potassium wasting. This is achieved by regulating the sodium-chloride symporter 
(NCC), that is uniquely expressed in the distal nephron and is sensitive to thiazide 
type diuretics (261). Under basal conditions (low circulating Ang II and low 
Aldosterone), WNK4 will inhibit NCC function. It has been proposed that in the event 
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of hyperkalemia and an increased secretion of aldosterone (which will upregulate 
both ENaC and the renal outer medullary potassium channel (ROMK)), this inhibition 
of NCC, will allow an increase in the arrival of sodium to the distal nephron (rich in 
ENaC and ROMK) which will allow the exchange of sodium for potassium ions, 
thereby reducing plasma potassium levels, without increasing sodium chloride 
retention (which is always accompanied by volume expansion). Mutations in NCC 
regulators WNK1 and WNK4 cause Type II pseudohypoaldosteronism (PHA2), also 
known as Gordon’s syndrome, an autosomal dominant disease in which there is an 
increase in NCC activity leading to short stature, increased blood pressure, increased 
serum K+ levels, increased urinary calcium excretion and hyperchloremic metabolic 
acidosis. 
 
It was thought that aldosterone required the presence of angiotensin II to 
activate the WNK4 regulator but, recently, it was shown that in the presence of 
losartan (an angiotensin II inhibitor), aldosterone was still capable of increasing total 
and phosphorylated NCC twofold to threefold. The kinases WNK4 and SPAK 
(STE20/SPS1-related proline/alanine-rich kinase) also increased with aldosterone 
and losartan. Furthermore, a dose-dependent relationship between aldosterone and 
NCC, SPAK and WNK4 was identified, suggesting that these are aldosterone-
sensitive proteins (262). 
 
In keeping with these observations, EA.hy926 cells stimulated with 
aldosterone showed an increase in WNK4 mRNA levels. WNK4 increased by about 
3.5 fold after 5 hours of 10nM aldosterone treatment (p 0,001 when compared to 15 
minutes). Although the 5 hour time-point displayed a classic genomic action of 
aldosterone with a significant increase in WNK4 mRNA levels, the 15 minute time-
point again did not show any significant change reinforcing the idea that the increase 
in pERK protein levels is a nongenomic effect of aldosterone action. In order to take 
into account differences between samples, WNK4 mRNA levels were normalized 
using the housekeeping ribosomal gene 18S. 
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Aldosterone’s genomic effects 
 
 Having so far concentrated on the nongenomic effects of aldosterone and 
having established that there is a significant increase of pERK due to aldosterone 
stimulation both in EA.hy926 cells and mouse aortic endothelial cells, it was 
necessary to investigate if striatin and the caveolae play a role in this action as seen 
for estrogen’s nongenomic actions.  
 The first question asked was if aldosterone influences striatin in any way and 
in order to answer that question, EA.hy926 cells were stimulated with 10nM 
aldosterone for different periods of time conducive to a potential genomic effect. As 
before cells were stepped-down the day before the experiment. After stimulation, 
cells were collected for western blot analysis and striatin protein levels measured. 
 
Graph 10: Striatin protein levels in EA.hy926 cells after stimulation with aldosterone (ALDO). 
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 Results showed a significant increase in striatin protein at 5 hours of 
aldosterone stimulation, consistent with the second increase in ERK1/2 
phosphorylation observed before, leading to the possibility that these two effects 
might, somehow, be linked. This result was unexpected, since striatin is believed to 
be a chaperone protein, facilitating the interactions between different signalling 
proteins. The increase in striatin takes place at 5 hours of aldosterone stimulation 
which, as shown before, is in agreement of other genomic actions of aldosterone. 
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However, this increase seems to be an acute event that occurs only at 5 hours of 
stimulation and is not sustained further. Striatin protein levels were normalized to     
β-actin to account for possible variations in the amount of protein loaded in each well. 
  In order to determine if this is indeed an effect of mineralocorticoid activation, 
further experiments were carried out using the MR antagonist canrenoic acid. 
EA.hy926 cells were treated with, vehicle, 10nM aldosterone or 1µM canrenoic acid 
for 5 and 24 hours. 
 
Graph 11: Striatin protein levels in EA.hy926 cells after MR activation/inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 Results show that the aldosterone-induced increases in striatin expression are 
mediated via the activation of the mineralocorticoid receptor in EA.hy926 cells since 
canrenoic acid effectively inhibited the increase in striatin protein levels. Consistent 
with the previous experiments, striatin protein levels (after normalization to β-actin) 
went up by about two fold (*p < 0.05 vs. vehicle-treated cells). In the graph ALDO 
stands for 10nM aldosterone treatment and MRA for 1µM canrenoic acid treatment. 
 
 Although it was established that the observed effect is a consequence of 
mineralocorticoid receptor activation, it is still to be determined if this is in fact a 
genomic action of aldosterone. To determine if this is the case, EA.hy926 cells were 
stimulated with 10nM aldosterone ± canrenoic acid for 5 and 24 hours. After 
stimulation, cells were harvested for mRNA isolation and quantification of striatin 
mRNA using Real-Time PCR.  
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Graph 12: Striatin mRNA levels in EA.hy926 cells after MR activation/inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 Results observed are consistent with the observed increase in striatin protein 
levels seen at 5 hours of aldosterone stimulation and supports the hypothesis that 
aldosterone is exerting a genomic effect on the EA.hy926 cells studied and that 
striatin is an aldosterone-sensitive protein. Striatin mRNA levels (after normalization 
to 18S) went up by about two fold (*p < 0.05 vs. vehicle-treated cells). In the graph 
ALDO stands for 10nM aldosterone treatment and MRA for 1µM canrenoic acid 
treatment. 
  
 Because the increase in striatin protein was an unexpected find, experiments 
were repeated using mouse aortic endothelial cells to ensure that this was not an 
artefact due to using an immortalized cell line as a model. As before cells were 
stepped-down to 0,4% FBS media and left overnight to quiesce. The following day 
cells were treated with 10nM aldosterone in the presence/absence of the 
mineralocorticoid inhibitor canrenoic acid (1µM). After 5 hours of treatment, cells 
were rinsed and collected in RIPA buffer for subsequent western blot analysis. Each 
treatment was carried out in triplicate wells and, every experiment executed three 
times for statistical analysis. 
 
 
 
 
 125
Graph 13: Striatin protein levels in MAEC cells after MR activation/inhibition. 
 
 
 
Figure 53 – Western blot illustrating the results shown on graph 13. ALDO stands for 10nM 
aldosterone treatment and CA for 1µM canrenoic acid. 
 
 Results obtained with MAEC are very similar to previous observations with 
EA.hy926 cells. Striatin protein levels went up by about two-fold confirming that 
striatin is indeed an aldosterone-sensitive protein and leading to more questions 
about the consequences of this discovery. Although striatin protein was increased at 
five hours in these cells, there wasn’t an increase in the mRNA levels, leading us to 
believe that the peak of stimulation does not occur at the same time as was observed 
with EA.hy926 cells or the increase in mRNA levels is not as noticeable as with 
EA.hy926 cells making the differences more difficult to detect. 
 Results obtained in animal studies seem to confirm the observations from the 
cell experiments carried out. An experimental study with animals showed that dietary 
sodium restriction increased striatin levels in mouse hearts and aorta. A sodium 
restricted mouse model was studied which is known to have increased aldosterone 
levels (263). Mice were given a low sodium (LS) diet for 11 days which led to a 
significantly higher plasma aldosterone level (64,18 ± 14,30 ng/dl; (n=6)) than their 
cohort study companions on a (HS) high sodium diet (34,26 ± 4,99 ng/dl (n=7)) for 
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the same amount of time. Heart tissue as well as aorta was isolated upon animal 
sacrifice and protein isolated and measured by western blot analysis. Striatin levels 
were significantly higher in mice on a low sodium diet than the mice on higher sodium 
levels. 
 
Graph 14: Heart tissue striatin protein levels in mice on a high sodium or low sodium diet. 
 
 
 Results show on graph 14 depict a near two-fold increase in striatin protein 
levels in animals on a low sodium diet, consistent with the higher plasma aldosterone 
levels and previous results obtained in experimental endothelial cell studies. Higher 
striatin protein levels were also observed in aortic tissue collected from these animals. 
 
Graph 15: Aorta striatin protein levels in mice on a high sodium or low sodium diet. 
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 As with heart tissue, striatin protein levels were significantly higher in aortas 
from LS mice when compared to HS mice by about two-fold once again, consistently 
with the higher striatin protein levels observed in mouse aortic endothelial cells 
treated with aldosterone. Blood pressure levels were also measured in these animals 
using the tail cuff method (264). As shown previously under these conditions, low 
sodium was associated with lower blood pressure than high sodium (108,8 ± 2,8 mm 
Hg vs. 114,7 ± 3,1 mm Hg, LS vs. HS respectively, mean ± standard deviation, p < 
0,03) (264). 
 
 In order to characterize the in vivo relevance of these findings, the effects of 
aldosterone on striatin levels was studied in mouse heart by using additional models 
of mineralocorticoid activation. The effects of an acute in vivo aldosterone 
administration on striatin levels in the heart were analysed. A vehicle injection was 
included at each time point in order to distinguish the effects caused by the injection 
from the ones due to a response to aldosterone stimulation. Male C57BL/6 mice on a 
3% NaCl diet were injected intraperitoneally (IP) with either 10 µg/kg of aldosterone 
or vehicle and sacrificed at the following time-points after injection: 0 hours (no 
injection), 1, 2 and 3 hours. Five mice were sacrificed in each group at each 
individual time-point.  
 
Graph 16: Striatin protein levels in mice injected with aldosterone or vehicle. 
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Figure 54 – Western blot illustrating the results shown on graph 16.  
Sham stands for vehicle injection. 
 
 It was observed (in heart tissue) that striatin levels increased in aldosterone-
treated mice when compared to vehicle injected animals (sham). Plasma aldosterone 
concentrations were determined in each animal as reported previously (235) and, as 
expected, plasma aldosterone levels only increased in the aldosterone injected 
group, reaching its highest level at 30 minutes with a concentration of 280 ng/dl. 
Although the results shown are not statistically significant due to high error values, 
the overall result confirms previous results obtained and adds physiological 
relevance to them. The big difference being that, in the case of an acute injection it 
seems that the increase in striatin protein occurs more quickly than in in vitro studies. 
This can be due to many factors but it is believed to be mainly due to the fact that we 
are working with a bigger mass of cells as well as interactions (including feedback 
mechanisms) and crosstalk of other tissue types that are intact within the whole 
animal, instead of a monolayer of cultured endothelial cells. 
 
 Finally, a previous studied animal model of acute, generalized, multiple organ 
injury secondary to vascular inflammation (109, 110) was used to assess the 
interaction of mineralocorticoid activation on striatin. In this model, animals are 
treated with the nitric oxide synthase inhibitor, L-NG-Nitroarginine Methyl Ester (L-
NAME), in combination with angiotensin II. The treatment induces myocardial 
damage initiated at the vascular level which can be prevented by MR blockade or by 
adrenalectomy (109, 110). Knowing this, the      AngII/L-NAME model was used as a 
“stressor” model to ascertain if an increase in mineralocorticoid activation would also 
lead to an increase in striatin levels. 
 Results show that AngII/L-NAME treatment is associated with increased 
striatin levels both in heart and kidney tissues when compared to vehicle treated 
control. In these studies, AngII/L-NAME treatment increased aldosterone circulating 
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levels (122,1 ± 34,1 ng/dl (n= 6)) when compared to vehicle treatment (34,26 ± 4,99 
ng/dl (n =7); p= 0,008). In addition, blood pressure levels were also measured in 
these animals and, as shown previously, AngII/L-NAME treatment was associated 
with increased blood pressure levels vs. vehicle treated mice (120 ± 3,8 mm Hg vs. 
161 ± 23 mm Hg, vehicle vs. AngII/L-NAME respectively, mean ± standard deviation, 
p < 0,04) (265). 
 
Graph 17: Heart striatin protein levels in mice treated with AngII/L-NAME or vehicle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph 18: Kidney striatin protein levels in mice treated with AngII/L-NAME or vehicle. 
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 All the data obtained from these different animal experiments consolidates the 
previous results generated by the endothelial cell studies. Although unexpected, the 
finding that aldosterone levels seem to influence striatin protein levels is an important 
one and might change the way this protein is viewed by other investigators as well as 
add to its functions. 
 
 After establishing that aldosterone has both genomic and nongenomic effects 
in the endothelial cells studied and, the presence of striatin in the same cells, it is 
now necessary to ascertain if the presence of striatin is necessary for the 
nongenomic effects to occur and, if higher striatin levels will change the way the 
mineralocorticoid signalling occurs in these cells. In order to establish if striatin is a 
necessary player in the nongenomic rise of pERK levels in the endothelial cells 
studied it was decided to employ siRNA technology to knock-down striatin in these 
cells followed by aldosterone stimulation to confirm if the nongenomic effects had 
changed in any way. 
 
Striatin knock-down using siRNA 
 
Small interfering RNA (siRNA), sometimes known as short interfering RNA or 
silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in 
length, that play a variety of roles in biology. The most notable role of siRNA is its 
involvement in the RNA interference (RNAi) pathway, where it interferes with the 
expression of a specific gene. In addition to its role in the RNAi pathway, siRNA also 
acts in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the 
chromatin structure of a genome; the complexity of these pathways is only now being 
elucidated.  
siRNAs have a well-defined structure: a short (usually 21-nt) double-strand 
RNA (dsRNA) with 2-nt 3' overhangs on either end. Each strand has a 5' 
phosphatase group and a 3' hydroxyl (-OH) group.  siRNAs can also be exogenously 
(artificially) introduced into cells by various transfection methods to bring about the 
specific knockdown of a gene of interest.  In essence, any gene whose sequence is 
known can, thus, be targeted based on sequence complementarity with an 
appropriately tailored siRNA.  This has made siRNAs an important tool for gene 
function and drug target validation studies in the post-genomic era. Transfection of 
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an exogenous siRNA can, sometimes, prove to be problematic because the gene 
knockdown effect is only transient, in particular, in rapidly dividing cells. 
EA.hy926 cells were transfected with ON-TARGETplus siRNA pre-designed 
duplex specific for striatin obtained from Dharmacon RNAi Technologies in parallel 
with Control/blank siRNA following the manufacturer’s protocols and using the 
Dharmafect 1 siRNA Transfection Reagent. The cells were then harvested for 
Western blot analysis 48 hours post-transfection.  
 
 The goal for the siRNA experiments was to significantly decrease the amount 
of striatin protein being produced in these cells without affecting the normal 
functioning of the cells. Because it was the first time this technology was employed in 
the laboratory, there were several rounds of optimization experiments before the 
suitable conditions were achieved. 
 Since each cell line reacts differently to a siRNA duplex, it was decided to 
order 4 different duplexes and test which one functioned better with the EA.hy926 
endothelial cell line.  Transfection was executed according to the manufacturer’s 
protocols. Cells were transfected for 24 hours for mRNA collection and 48 hours for 
western blot analysis. Each time transfection media was replaced by normal growth 
media after 24 hours to prevent cell toxicity and death. Different transfection 
conditions like solution concentrations and transfection length were also optimized 
but are not shown here. 
 
Graph 19: Striatin mRNA levels in EA.hy926 cells transfected with siRNA duplexes. 
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 Real-time PCR results showed that transfection with duplexes 1-3 resulted in a 
significant decrease in striatin mRNA levels to about 25% when compared to an 
untransfected control. Each experiment was carried out in triplicate wells. 
 
 Since a decrease in mRNA is not sufficient proof that striatin protein was 
indeed reduced, experiments were repeated and the transfection extended to 48 
hours to induce protein reduction. Cells were then collected for western blot analysis. 
 
Graph 20: Striatin protein levels in EA.hy926 cells transfected with siRNA duplexes. 
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 Western blot results confirmed that there was a significant reduction in striatin 
protein levels by about 75% compared to untransfected control when duplexes 1-3 
where employed. Again duplex 4 did not knockdown striatin protein levels with 
respect to control, confirming that each cell line reacts differently and reinforcing the 
need to perform optimization steps prior to experimentation. Different combinations of 
two duplexes where also tried but not shown here. Results obtained where very 
similar to the ones yielded by individual duplexes and therefore not an improvement 
and was not pursued further. 
 Striatin is not the only member of its family; Zinedin and SG2NA are two other 
family members with similar structure and sequence homology which could 
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potentially be affected by the siRNA gene expression inhibition. In this way cells 
transfected with the 4 duplexes for 24 hours where analysed by Real-Time PCR 
quantification to determine if other family members, besides striatin, had their mRNA 
levels significantly reduced. 
 
Graph 21: SG2NA mRNA levels in EA.hy926 cells transfected with siRNA duplexes. 
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Graph 22: Zinedin mRNA levels in EA.hy926 cells transfected with siRNA duplexes. 
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 Results showed that SG2NA levels did not seem to be affected by the 
transfection with siRNA duplexes designed to interfere with striatin gene expression 
but, it was a different case with Zinedin. Duplex 1 and 2 where significantly reduced 
after 25 hours of transfection, making then unviable reagents to use in future 
experiments due to the fact that more than one striatin family member is being 
affected and, in this way, making conclusions about the specific role of striatin in 
future siRNA experiments limited.  
 After all the results where analysed it was decided to selected duplex 3 for use 
in future experimental paradigms since it complied with all the necessary 
requirements, specifically targeted knockdown of striatin expression without off target 
effects of related family proteins.  
 
 Having established the optimal conditions for striatin knock-down experiments 
using siRNA technology, previous experiments where now repeated. Before 
employing the siRNA technology to the cells, the first critical experiment was once 
more repeated to ensure consistency of the results and also to use the same cell 
batch and passage for all of the knock-down experiments. 
 
Graph 23: ERK protein phosphorylation levels in EA.hy926 cells stimulated with aldosterone. 
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**p < 0.05 vs. Aldosterone). MRA stands for mineralocorticoid receptor antagonist 
and represents treatment with 10M canrenoic acid. These results are consistent 
with what was previously shown and demonstrate that the cells are responsive to 
aldosterone stimulation. 
 
Graph 24: ERK protein phosphorylation levels in EA.hy926 cells transfected with striatin 
siRNA and subsequently stimulated with aldosterone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The rapid increase in pERK levels, observed in the previous graphic, is 
abolished when the EA.hy926 cells are transfected with striatin siRNA (* p < 0.01 vs. 
Control). Control represents untransfected cells, all of the “transfection” procedure 
was carried out but the duplex was absent from the mix effectively making it a mock 
transfection. MRA stands for mineralocorticoid receptor antagonist and represents 
treatment with 10M canrenoic acid. Results show that the rapid rise in pERK levels 
is abolished but also, the overall phosphorylation levels seem to be lower in the 
transfected cells. By comparison, though, ERK protein levels seem to be elevated in 
the transfected cells, perhaps justifying the decrease in phosphorylation levels as it is 
showed has a ratio between pERK and total ERK. 
 In order to establish that the scrambled (control) sequence does not affect the 
cell signalling, the first experiment was repeated in cells transfected with the control 
duplex and results compared.  
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Graph 25: ERK protein phosphorylation levels in EA.hy926 cells transfected with striatin 
control siRNA and subsequently stimulated with aldosterone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Cells transfected with scrambled siRNA show a significant increase in ERK 
phosphorylation levels (* p < 0,05 vs. Control; **p < 0,05 vs. Aldosterone). Results 
shown on graph 25 clearly confirm that the scrambled control sequence does not 
affect the way these cells signal. The rapid increase in ERK phosphorylation is 
present in comparable levels to what has been shown previously and is abrogated 
when the cells are treated with canrenoic acid (MRA). 
 
Graph 26: WNK4 mRNA levels in EA.hy926 cells transfected/untransfected with striatin 
siRNA and subsequently stimulated with aldosterone. 
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 Finally, EA.hy926 cells, transfected with striatin siRNA or controls 
(untransfected) were treated with aldosterone (10nM) and mRNA levels of WNK4 
and SGK1 were measured to establish if a decrease in striatin gene expression 
influenced aldosterone’s known genomic responses. Results show that in both cases 
the genomic signalling is not affected, there is no significant change between 
transfected and untransfected cells while, at 5 hours of aldosterone stimulation, a 
genomic effect is still visible and significant (WNK4, p< 0,05 vs. control and SGK1, 
p<0,001 vs. control). 
 
Graph 27: SGK1 mRNA levels in EA.hy926 cells transfected/untransfected with striatin 
siRNA and subsequently stimulated with aldosterone. 
 
 
 
 
 
 
 
 
 
 
 
All combined these results indicate that striatin is a necessary player in 
aldosterone’s nongenomic effects and that when it is not present such effects 
(increase in ERK phosphorylation levels at 15 minutes) do not occur. They also 
indicate that striatin does not seem to be necessary for the classical, genomic effects 
to occur, pointing to the possibility that different pathways are in play here. 
 
Having established that striatin is a key player in aldosterone’s nongenomic 
effects via the mineralocorticoid receptor it remains to study the importance of the 
caveolae in this process. It is known that striatin contains four protein-protein 
interaction domains, including a caveolin-binding domain (190) and that, CAV1 has  
been shown to interact with the protein striatin.  
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Striatin seems to be a key intermediary of the effects of steroid receptors, 
specifically estrogen receptor-α (ER) (188). Lu et al provided evidence that striatin´s 
N-terminal segment interacts with the DNA binding domain of ER in EA.hy926 cells. 
This interaction organizes the ERα-eNOS membrane signalling leading to rapid 
nongenomic activation of downstream signalling pathways including ERK and eNOS 
in endothelial cells. Taking these previous observations into account it is important to 
investigate the possible connection between MR, striatin and caveolin 1. 
 
Interactions between MR, Striatin and CAV1 
 
 
In order to detect any possible interaction between these 3 proteins of interest 
it was decided to employ co-immunoprecipitation (Co-IP) as a tool to try to establish if 
there were any protein-protein interactions or if they were organized as protein 
complex. Co-IP works by selecting an antibody that targets a known protein that is 
believed to be a member of a larger complex of proteins. By targeting this known 
member with an antibody it may become possible to pull the entire protein complex 
out of solution and thereby identify unknown members of the complex. This works 
when the proteins involved in the complex bind to each other tightly, making it 
possible to pull multiple members of the complex out of solution by latching onto one 
member with an antibody. This concept of pulling protein complexes out of solution is 
also referred to as a "pull-down".  
 If MR, striatin and CAV1 are interacting closely, it will be possible to “pull” one 
of these proteins down and use a different antibody to detect the other protein. In 
brief, endothelial cells were collected (scrapped) and homogenized in RIPA Buffer 
and protein content determined by colorimetric assay. The protein extract (500 g) 
was incubated with 1-2 g of monoclonal or polyclonal antibodies for 1-2 hours at     
4 ºC together with 50-100 l of protein G or A/G MicroBeads. The Microbeads, 
antibody and cell lysate mix were separated using MACSmini columns and 
respective magnetic stand, according to the manufacturers protocol. Finally the 
beads were washed with RIPA buffer and the bound immuno-complexes eluted using 
boiling loading dye and assessed by Western Blot analysis.  
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Figure 55 – Western blot illustrating the presence of CAV1 protein after striatin “pull-down”.  
MAEC stands for mouse aortic endothelial cells and EAhy for EA.hy926 cells. 
 
In the first Co-IP, striatin was targeted to be pulled down and the resulting 
elution studied for the presence of CAV1 protein. Results show that there seems to 
be an interaction between striatin and caveolin 1 in mouse aortic endothelial cells, 
EA.hy926 cells and mouse heart tissue. This result was not unexpected since it is 
known that striatin has a caveolin-binding domain but, it was necessary to establish 
such a fact in our cells of interest and it also goes to demonstrate that the Co-IP 
technique chosen to look at possible interactions is an efficient study tool.  
 
 
 
 
 
 
 
Figure 56 – Western blot illustrating the presence of striatin protein after CAV1 “pull-down”.  
Input stands unprecipitated cell extract and EAhy for EA.hy926 cells. 
 
To prevent any possible artefacts resulting from the technique used, the 
reverse Co-IP was always performed. The figure shows that when CAV1 is the target 
of the “pull-down”, striatin is presence is detected in the resulting cell elution. This 
confirms the previous result and demonstrates a close interaction between caveolin 1 
and striatin proteins. Input represents a cell extract that did not go through the Co-IP 
process, and serves as a control for the antibody used in western-blot analysis since 
it hadn’t been used in Co-IP studies previously.  
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 140
 
 
 
 
 
 
Figure 57 – Western blot illustrating the presence of CAV1 protein after MR “pull-down”.  
MAEC stands for mouse aortic endothelial cells and EAhy for EA.hy926 cells. 
 
The next round of Co-IPs connects the mineralocorticoid receptor to caveolin 1 
and the caveolae.  When the MR is captured by the beads treated with MR-specific 
antibody it is possible to detect the presence of CAV1 in the resulting elution. This 
means that MR and CAV1 have a close interaction and potentially places the 
mineralocorticoid in the caveolae structure located in the cell membrane. Results 
shown for heart tissue depict two different bands that correspond to the alpha and 
beta isoforms of caveolin 1, known to be expressed in cardiomyocytes (266). 
 
 
 
 
 
 
Figure 58 – Western blot illustrating the presence of MR protein after CAV1 “pull-down”.  
EAhy stands for EA.hy926 cells. 
 
Once again, the reverse Co-IP confirms the results shown before and points to 
the presence of the mineralocorticoid receptor in the cell membrane in the caveolae 
structures or connected to them via CAV1 protein. Due to a smaller amount of CAV1 
protein present in the EA.hy926 cells when compared to whole heart tissue, the 
resulting MR band appears faint but with enough definition to be considered a 
positive result. 
The next possible interaction studied was that between striatin and MR. It was 
already known that MR needs striatin to exert its nongenomic effects so this 
interaction is expected to be strong. 
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Figure 59 – Western blot illustrating the presence of MR protein after striatin “pull-down”.  
MAEC stands for mouse aortic endothelial cells and EAhy for EA.hy926 cells. 
 
As expected, when striatin is precipitated with A/G beads conjugated to striatin 
antibody, the resulting elution contains a high amount of mineralocorticoid receptor, 
demonstrating and confirming the predicted close interaction between the two 
proteins.  
 
 
 
 
 
 
 
Figure 60 – Western blot illustrating the presence of striatin protein after MR “pull-down”.  
Input stands for unprecipitated cell extract and EAhy for EA.hy926 cells. 
 
The reverse Co-IP confirms the interaction between striatin and MR and 
seems to point to the presence of two striatin isoforms in EA.hy926 cells. According 
to Swiss-Prot striatin has two different isoforms although isoform I is the one that is 
commonly reported and referred to.  Isoform I has 780 amino acid and weighs about 
86.13 KDa, whereas isoform II has 731 amino acids and weighs about 80.76 KDa. 
The different in expected weight and the results obtained with the antibody used 
might be due to a post-translational modification as has been referred previously 
when phenotyping the EA.hy926 cells. 
 These Co-IP results show a strong interaction between MR, striatin and CAV1 
and seem to indicate the formation of a possible triple complex between these three 
proteins, most likely modulated by CAV1 since it has a known role in binding the 
IP: Striatin
WB: MR
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MAEC EAhy Heart
110 kDa
IP: MR
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Input    EAhy
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striatin protein and would likely also serve to anchor the MR to the cell membrane, 
keeping it in place for further interactions with other molecules to occur and leading 
to rapid, nongenomic effects of MR activation. To test this hypothesis mouse aortic 
endothelial cells were collected from wild-type and CAV1 knock-out animals. These 
cells were expended and used at passage 3 and 4. Just like the previous studies, 
cells were collected in RIPA buffer, processed and used for Co-IP studies. 
 
 
  
 
 
 
 
Figure 61 – Western blot illustrating the presence/absence of striatin protein after MR     
“pull-down” in MAEC. WT stands for wild-type animals and KO for knock-out. 
 
Results show that in the absence of CAV1, the mineralocorticoid receptor does 
not seem to interact with striatin or, there interaction is weakened and cannot be 
detected using co-immunoprecipitation techniques. The reverse Co-IP was also 
executed in order to confirm this theory. 
 
 
 
 
 
 
 
Figure 62 – Western blot illustrating the presence/absence of MR protein after striatin     
“pull-down” in MAEC. WT stands for wild-type animals and KO for knock-out. 
 
Likewise and, as expected, the reverse Co-IP showed that in the absence of 
CAV1 Striatin does not seem to interact with the mineralocorticoid receptor. These 
results are very important and seem to strengthen the existence of a triple complex 
between MR, striatin and CAV1, with caveolin 1 as the intermediary between the 
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other the proteins. These results also point to an important role being played by the 
caveolae in providing a prime spot for protein interactions and cell signalling to take 
place. To test if the caveolae are indeed pivotal in MR activation and aldosterone’s 
nongenomic signalling, EA.hy926 cells were treated with lipid-raft disruptors 
(cyclodextrin and -Methylcyclodextrin) and subsequently treated with 10nM 
aldosterone for 15 minutes. 
 
Graph 28: ERK phosphorylation levels in EA.hy926 cells treated with lipid raft disrupting 
chemicals and subsequently stimulated with aldosterone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EA.hy926 cells were pre-incubated overnight with two lipid raft disrupting 
chemicals and then treated with 10nM aldosterone for 15 minutes. As is shown in the 
above graphic, aldosterone had no effect on pERK in the presence of either chemical.  
Although these results are not quite significant due to a low number of repeats, the 
general trend which they demonstrate seems to confirm the caveolae as having a 
facilitating role is aldosterone’s nongenomic effects by providing a place for MR to 
interact with other players in this cell signalling pathway.  
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Further experiments (results not shown) carried out with mouse aortic 
endothelial cells collected form wild-type and CAV1 knock-out animals seemed to 
indicate that the lack of caveolin 1 did not affect the genomic effects of aldosterone 
with a visible peak in striatin protein levels still being observed after 5 hours of 
aldosterone stimulation. This result, albeit not significant, might indicate that 
aldosterone and striatin are playing more than one role in these endothelial cells and 
the striatin protein peak observed at 5 hours of aldosterone might prove to be 
important on its own.  
 
Aldosterone’s influence on Estrogen’s nongenomic actions 
 
 Lu et al identified striatin as a scaffold protein that promotes localization of 
ER to the plasma membrane and assembly of the signalling complex of ER and Gi 
that is required for ER-dependent activation of MAPK, phosphatidylinositol 3–Akt 
kinase, and eNOS, a critical regulator of many physiologic and pathophysiological 
processes (188). Their results show a peak in eNOS phosphorylation at 15 minutes 
of estrogen stimulation that is abrogated if striatin is disrupted (using a blocking 
peptide). They also show that overexpression of striatin markedly changes the 
distribution of ER by substantially increasing the proportion of ER that is 
distributed along the plasma membrane. These results combined with the information 
that the binding of estrogen (E2) to the membrane has been confirmed, in addition to 
the presence of ER and caveolin in plasmalemmal caveolae and, their connection 
to nongenomic and short-term effect of E2 on endothelial NO release (186) led to the 
possibility of a an interaction/cross-talk relationship between aldosterone and 
estrogen signalling in endothelial cells. 
 
 The first step taken was to ascertain if, like aldosterone, estrogen treatment 
stimulated the production of striatin protein. EA.hy926 cells were treated with either 
10nM aldosterone or 50nM estrogen for 5 hours. Aldosterone but not estrogen 
treatment increases striatin protein levels. Cells used for experiments with estrogen 
stimulation were grown in Estrogen-Deficient media which is achieved by charcoal-
stripping the FBS used in the media preparation. 
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Graph 29: Striatin protein levels in EA.hy926 cells treated with aldosterone (10nM)              
or estrogen (50nM) for 5 hours. 
 
 
 
 
 
 
 
 
 
 
 Results show that the increase in striatin protein seems to be specific to 
aldosterone’s MR activation and does not occur with estrogen stimulation. The next 
logical step was then to reproduce the estrogen action previously observed by Lu et 
al and introduce aldosterone in the mix to determine if the presence of more striatin 
protein at a given time in these cells affected the way nongenomic actions of 
estrogen occurred. 
  
Graph 30: eNOS phosphorylation levels in EA.hy926 cells treated with estrogen (50nM) for 
short periods of time with/without aldosterone (10nM) pre-treatment for 5 hours. 
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 EA.hy926 cells were pre-treated with or without aldosterone (10nM) for 5 
hours. peNOS/eNOS levels were then measured in response to estrogen (50nM) 
stimulation were measured at 5, 15 and 30 minutes. Pre-treatment with aldosterone 
enhanced estrogen’s nongenomic response.  
 The graphic depicted above shows that results previously obtained by Lu et al 
were successfully replicated. There was a peak in eNOS phosphorylation which 
occurred at 15 minutes of estrogen stimulation ( *p<0,015 vs. vehicle). This peak is 
smaller than previously observed and the estrogen dose employed higher which can 
be justified by the absence of overexpression of striatin protein in cells used. 
 When an aldosterone pre-treatment is added to the treatment conditions, a 
very interesting event occurs. There is a shift in the peNOS peak observed; it not 
only increases its levels but it also occurs sooner (#p<0,032 vs. 15 minutes with no 
pre-treatmen; **p<0,02 vs. vehicle). This is not an experimental artefact as this 
experiment was repeated six times always in triplicate wells and the results obtained 
consistent with some variation in the peNOS levels achieved. 
 This is a novel result and might prove to change the way steroid signalling is 
viewed, adding a new level of complexity concerning crosstalk between different 
receptors. Although Lu et al had already showed that the peak observed in eNOS 
phosphorylation disappears when striatin action is blocked by a specifically designed 
peptide; they had not attempted to knock-down striatin levels to confirm this 
conclusion. 
 
Graph 31: peNOS levels in EA.hy926 cells transfected with striatin scramble/siRNA and 
treated with estrogen for 15 minutes with/without aldosterone pre-treatment. 
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 EA.hy926 cells grown in estrogen deprived media were transfected with 
striatin scrambled sequence or striatin siRNA for a period of 48 hours. After 
transfection cells were made quiescent by stepping-down serum levels to 0,4% FBS 
overnight. Cells were then treated with 50nM estrogen for 15 minutes with/without a 
pre-treatment with 10nM aldosterone for a period of 5 hours. Results shown confirm 
the previous observations and confirm striatin has a key player in estrogen signalling. 
Cells transfected with striatin scrambled sequence (control) show a 2 fold peak in 
eNOS phosphorylation levels at 15 minutes of estrogen treatment. This peak 
increases when the same cells were subjected to a 5 hour pre-treatment step with 
10nM aldosterone. When the cells are transfected with striatin siRNA, the response 
to estrogen stimulation is completely abrogated, even when pre-treatment with 
aldosterone is employed.  
 
 Because the results showed so far indicate a potential cross-talk between 
estrogen and aldosterone signalling pathways, it was important to study the effect of 
estrogen on ERK phosphorylation. Since aldosterone pre-treatment enhances eNOS 
phosphorylation levels when cells are stimulated with estrogen, it is possible that 
estrogen pre-treatment might influence ERK phosphorylation levels when cells are 
stimulated with aldosterone. 
 
Graph 32: ERK phosphorylation levels in EA.hy926 cells treated with aldosterone (10nM) for 
short periods of time with/without estrogen (50nM) pre-treatment for 5 hours. 
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 Results show that, contrary to what was observed with aldosterone, estrogen 
pre-treatment does not increase pERK levels in EA.hy926 cells. Aldosterone 
stimulation for 15 minutes caused a peak in pERK levels, consistent with has been 
shown here before but, pre-treatment with 50nM estrogen for 5 hours did not 
increase this peak, showing no significant change from cells untreated with estrogen. 
 
 Striatin has been proven to be involved in rapid signalling events in the cells 
studied but, results observed so far do not seem to indicate that the same is true for 
the more classical genomic effects of steroid action. Striatin siRNA did not damper 
the genomic effects of aldosterone stimulation but, it remains to be seen if the same 
is true for estrogen action. PTGIS or prostaglandin I2 (prostacyclin) synthase, 
together with PTGS1 or prostaglandin-endoperoxide synthase 1 were selected as 
targets to study the effects of striatin knock-down on estrogen’s genomic actions. 
 
 Prostaglandin-I synthase (EC 5.3.99.4) also known as prostaglandin I2 
(prostacyclin) synthase (PTGIS) or CYP8A1 is an enzyme involved in prostanoid 
biosynthesis that in humans is encoded by the PTGIS gene (267). This enzyme 
belongs to the family of cytochrome P450 isomerases. This endoplasmic reticulum 
membrane protein catalyzes the conversion of prostaglandin H2 to prostacyclin 
(prostaglandin I2), a potent vasodilator and inhibitor of platelet aggregation. An 
imbalance of prostacyclin and its physiological antagonist thromboxane A2 contribute 
to the development of myocardial infarction, stroke, and atherosclerosis (268). 
Recent studies have shown that in human umbilical vein endothelial cells (HUVEC), 
treatment with estrogen (1-100nM) caused a dose-dependent increase in 
prostaglandin I2 synthase protein production, up to 50% and PTGIS gene expression 
levels were also increased by 50% after exposure to estrogen (269). 
  
PTGIS expression levels were measured by Real-Time PCR in EA.hy926 cells 
transfected/untransfected with striatin siRNA and subsequently treated with 50nM 
estrogen for 15 minutes and 5 hours. 
 
 
 149
Graph 33: PTGIS mRNA levels in EA.hy926 cells transfected/untransfected with striatin 
siRNA and stimulated with 50nM estrogen for 15 minutes and 5 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Results show that, as expected and described in the literature, treatment with 
estrogen stimulated PTGIS expression in the endothelial cells studied (p<0,05 vs. 
vehicle). Transfection with striatin siRNA, did not affect this genomic action, with 
similar levels of mRNA observed for both untransfected and transfected cells. 
 
Graph 34: PTGS1 mRNA levels in EA.hy926 cells transfected/untransfected with striatin 
siRNA and stimulated with 50nM estrogen for 15 minutes and 5 hours. 
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Cyclooxygenase-1 (COX-1), also known as prostaglandin G/H synthase 1, 
prostaglandin-endoperoxide synthase 1 or prostaglandin H2 synthase 1, is an 
enzyme that in humans is encoded by the PTGS1 gene (270, 271). Prostaglandin-
endoperoxide synthase (PTGS), also known as cyclooxygenase (COX), is the key 
enzyme in prostaglandin biosynthesis. It converts free arachidonic acid, released 
from membrane phospholipids to prostaglandin (PG) H2. There are two isozymes of 
COX encoded by distinct gene products: a constitutive COX-1 (this enzyme) and an 
inducible COX-2, which differ in their regulation of expression and tissue distribution. 
The PTGS1 gene encodes COX-1, which regulates angiogenesis in endothelial cells. 
COX-1 is normally present in a variety of areas of the body, including not only the 
stomach but any site of inflammation and is inhibited by nonsteroidal anti-
inflammatory drugs (NSAIDs) such as aspirin. Estrogen is known to increase the 
expression of the PTGS1 gene in endothelial cells (272, 273). 
 
Results show that treatment with estrogen stimulated PTGS1 expression in 
the endothelial cells studied (p<0,05 vs. vehicle), consistent with the literature. 
Transfection with striatin siRNA, did not affect this genomic action in anyway, with 
similar levels of mRNA observed for both untransfected and transfected cells. 
 
 The fact that aldosterone has been shown to increase eNOS phosphorylation 
in EA.hy926 cells stimulated with estrogen might be viewed as a consequence of the 
use of an immortalized endothelial cell line as a study tool, this way previous key 
experiments were repeated in mouse aortic endothelial cells in an attempt to bring 
the results shown close to physiological relevance.  
  
Mouse aortic endothelial cells were collected from healthy animals and 
allowed to expand until passage 2 when a high enough number of cells was achieve 
in order to proceed with the cell studies. Cells were grown in estrogen deprived 
media and stepped-down to 0,4% FBS the night before in order to avoid the 
occurrence of any potential secondary stimulation by factors still present in the FBS.  
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Graph 35: eNOS phosphorylation levels in EA.hy926 cells treated with estrogen (50nM) for 
short periods of time. 
 
 
 
 
 
 
 
 
 
 
 
Graph 36: eNOS phosphorylation levels in EA.hy926 cells treated with estrogen (50nM) for 
short periods of time with aldosterone (10nM) pre-treatment for 5 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 Just as seen with EA.hy926 cells, pre-treatment with aldosterone enhanced 
estrogen’s nongenomic response. Graphic 33, depicted above, begins by showing 
that the results previously obtained in EA.hy926 cells where replicated. There was a 
peak in eNOS phosphorylation which occurred at 15 minutes of estrogen stimulation. 
The levels of phosphorylation achieved are also very similar to what as previously 
been observed for EA.hy926 cells (p<0,001 vs. vehicle). 
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 When an aldosterone pre-treatment is added to the treatment conditions, there 
is, once more, a shift in the peNOS peak observed. In the case of mouse aortic 
endothelial cells there doesn’t seem to be an increase in peNOS levels (as observed 
before) but, the nongenomic response to 5 minutes of estrogen stimulation is 
confirmed (p<0,01 vs. vehicle). Total protein lysates were immunoblotted for 
phospho-eNOS (peNOS) and normalized for the amount of total eNOS. These ratios 
were normalized to one for the vehicle-treated cells. 
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Discussion 
 
 
Aldosterone and MR: classic physiology and pathophysiology 
 
 Aldosterone was first isolated in 1953 and characterized as the major 
mineralocorticoid hormone on the basis of its potent effects on unidirectional 
transepithelial sodium transport (274). It is commonly thought that the major stimulus 
to its secretion is angiotensin (275, 276) and that the physiologic actions of 
aldosterone are homeostatic, preserving fluid and electrolyte status via a negative 
feedback loop - depletion of sodium or circulating volume leading to increased renin 
secretion, and the consequently increased angiotensin generation raising 
aldosterone secretion, which in turn increases Na+ and water retention via epithelial 
mineralocorticoid receptor (MR) activation to restore the status quo.  
 The MR is a member of a close subfamily, with glucocorticoid receptors, 
androgen receptors, and progesterone receptors. This receptor was first studied in 
classic aldosterone target tissues, such as the kidney, distal colon and salivary gland; 
subsequently, identical receptors were described in nonepithelial tissues such as 
hippocampus and heart, not commonly considered to be physiologic aldosterone 
target tissues (35, 277). In addition to the effects on gene expression, such receptors 
have increasingly been shown to have additional rapid nongenomic effects; although 
rapid nongenomic effects of aldosterone via MR activation have been clearly 
demonstrated experimentally, their physiologic roles remain to be established (278). 
Primary aldosteronism (Conn's syndrome) was first reported in 1954 by Dr 
Jerome Conn, who diagnosed aldosterone overproduction in a young woman with 
hypertension and hypokalemia, reversed by surgical removal of the affected adrenal 
(279). Inappropriately elevated aldosterone levels drive sodium and water retention, 
which increases circulatory volume and cardiac output; the latter, in turn, by reflex 
normalized by vasoconstriction, resulting in hypertension.  
Recently, evidence has been accumulating that aldosterone elicits additional, 
nonclassical effects. Besides experimental data, clinical studies like RALES, 
EPHESUS, and 4E (103, 104) convincingly demonstrate that aldosterone receptor      
(i.e. MR) antagonism protects against cardiovascular and renal remodelling 
independently of major alterations in blood pressure or NaCl homeostasis. The 
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model derived from these clinical trials and experimental animal studies suggests 
that activated mineralocorticoid receptor induces an inflammatory milieu with 
enhanced formation of reactive oxygen species and matrix proteins in the 
vasculature (107, 111, 280, 281). Subsequently, this vasculopathy leads to cardiac 
and renal damage. Although this model is now widely accepted, the individual steps 
in this pathophysiological network are only incompletely understood. 
 
Rapid, nongenomic actions of aldosterone 
 
After almost 30 years of research, the existence of nongenomic steroid actions 
is no longer disputed. The classical pathway of steroid action focuses on intracellular 
steroid receptors which modulate gene transcription by interacting with a transcription 
initiation complex and transcription factors (282); in addition, a direct interaction of 
steroids with nuclear DNA has been demonstrated (283). Besides these 
transcriptional actions, steroids mediate multiple other effects, through nongenomic 
mechanisms.  
The main feature of nongenomic steroid actions is the quick onset of their 
effects. Nongenomic effects have been assumed to originate at the cell membrane 
as most of the second messenger generating systems or the early steps in the 
kinase cascades, which are involved in rapid steroid actions, are organized and 
localized here to form functional signalling units. For the classical estrogen, 
glucocorticoid, androgen and progesterone receptors (ER, GR, AR and PR), 
localization at membranes has already been shown (284-286). In contrast to these 
receptors, the MR does not contain a palmitoylation motif which is usually involved in 
the membrane anchoring of steroid receptors. Interestingly, an interaction of the 
classical MR with the epidermal growth factor receptor (EGFR) at the membrane has 
been shown (287). 
At the cellular level, these rapid effects of aldosterone have not only been 
reported in renal and intestinal cells but also in cells from the cardiovascular system 
(278). In 1984, Moura and Worcel (288) showed a biphasic effect of aldosterone on 
Na efflux from arterial smooth muscle with a rapid component which they interpreted 
to be nongenomic, marking the beginning of the research on the nongenomic 
mechanisms of aldosterone. In vascular smooth muscle and endothelial cells, 
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activation of the above-described signalling pathways and the Na+/H+ exchanger 
has now been described by various studies (278, 289), although the functional 
significance has not yet been clarified. For cardiomyocytes, different rapid effects 
have been reported, including PKCɛ-mediated direct inhibition of Na+/K+-ATPase 
activity (278). Furthermore, activation of ERK1/2 had been observed after 30 minutes 
(233). 
 
Aldosterone-Response Studies 
 
 The work presented here is based on the hypothesis that nongenomic actions 
of the MR may function in a similar way to what has been described for the ER 
(188). To explore this hypothesis it was decided to study ERK1/2 from the MAPK 
family as a possible player in the aldosterone nongenomic signalling cascade. This 
decision was greatly aided by the literature where several sources referred to an 
increase in pERK levels suggesting higher MAPK activity (118, 233, 234) but also by 
previous results observed within the research group (235). Several groups have 
reported an increase in phosphorylation of ERK1/2 within several minutes after 
aldosterone administration that is not blocked by inhibitors of transcription and 
translation (240, 241), implying a nongenomic mechanism. With reports of increases 
in ERK phosphorylation as early as 5 minutes after stimulation with aldosterone, it 
was felt that the best course of action was a short-time aldosterone stimulation study 
to pinpoint when the endothelial cells used in the laboratory achieve a peak in 
ERK1/2 phosphorylation. 
 
 Two different types of endothelial cells were used in experiments EA.hy926 
and MAEC cells, both of which were extensively phenotyped. In addition, before each 
experiment cells were stepped-down to 0,4% FBS DMEM to keep the environment 
stimulation to a minimum, since it is impossible to determine which potential 
stimulating factors are present in the FBS.  
 
In order to select the adequate aldosterone dosage to use in experimentation, 
a dose response curve was generated. Results showed a dose-dependent response, 
with around 1,5 increase (30%) in ERK phosphorylation with a 10nM aldosterone 
dose at 15 minutes of stimulation leading up to a 2-fold response when a 1µM 
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aldosterone dose is used. Bearing in mind the potential physiological relevance of 
future results, 10nM aldosterone was the elected concentration for ensuing studies. 
Plasma aldosterone levels vary considerably. A study conducted in 76 healthy 
individuals and 28 confirmed primary hyperaldosteronism (PHA) patients resulted in 
plasma aldosterone values of 0,033 to 1,930 nM for healthy subjects and 0,158 to 
5,012 nM for PHA patients (250). In addition, clinical results collected by other 
investigators in the group over the past 30 years (HyperPATH cohort) show that in 
828 hypertensive subjects the circulating aldosterone levels ranged between 0.05 
and 11,53 nmol/L. Furthermore, aldosterone levels over 100 nmol/L have been 
observed in heart failure patients (251, 252). These values, especially the top value 
for PHA patients seems to validate the choice of 10nM aldosterone as a valid one 
both for cell studies as for a possible comparison with pathophysiological states in 
humans.  
 
A short-term study revealed two distinct peaks of activity for pERK after cells 
were stimulated with aldosterone. The first peak is observed at 15 minutes of 
aldosterone treatment and the second peak can be seen at 5 hours of treatment. 
These results were true for both cell lines used in the experimental design. Statistical 
results were obtained by one-way ANOVA followed by post-hoc Mann-Whitney t-test 
comparison for selected time-points.  
 
Aldosterone’s nongenomic effects 
 
 The short length of time of treatment needed to obtain the first peak in pERK 
lead to the hypothesis that this could be part of a nongenomic effect of aldosterone 
signalling. The second peak, seen at 5 hours of treatment was believed to be 
involved in genomic effects of aldosterone. 
 
Before further conclusions could be drawn, an antagonist of aldosterone action, 
potassium canrenoate, was used to ensure that the previously observed effects were 
due to MR activation and not an experimental artefact. Canrenoic acid was selected 
as inhibitor of choice for aldosterone due to practicality. Canrenoic acid is readily 
available from chemical suppliers is also water soluble making it a perfect inhibitor for 
use in cell based assays.  
 
 157
EA.hy926 stimulated with aldosterone with/without MR antagonist (MRA) 
showed an increase in ERK1/2 phosphorylation at 15 minutes of treatment, 
consistently with what has been observed before with these cells. When canrenoic 
acid was used in conjunction with the aldosterone treatment, the increase in ERK 
phosphorylation was abrogated, thus confirming that the increase in pERK observed 
is indeed due to an effect of aldosterone acting, at  least in part,  through MR. Put 
together, the results from short-time aldosterone stimulation studies point to a newly 
described nongenomic action of aldosterone in endothelial cells but, in order to call it 
a nongenomic action it was necessary to demonstrate that no gene translation was 
occurring in the 15 minutes of aldosterone action.  
 
 EAhy.926 cells were stimulated for 15 minutes and 5 hours and collected for 
mRNA extraction. After reverse-transcription, cDNA obtained was used for Real-Time 
PCR, the 5 hour time-point was used as a positive control for genomic action, based 
on previously published data. Aldosterone is known to increase or reduce the 
expression of several different genes (254), SGK1 has been shown to be one of 
these genes with a  2.5 fold increase in SGK1 mRNA after aldosterone stimulation 
(259) in cardiomyocytes. The kinase WNK4 has also been shown to have a dose-
dependent relationship with aldosterone, suggesting that it might be an aldosterone-
sensitive gene (262).  
 
Consistent with the observations for cardiomyocytes, EA.hy926 cells 
stimulated with aldosterone showed an increase in SGK1 mRNA levels of 2.5 times 
after 5 hours of aldosterone treatment. WNK4 mRNA levels also showed an increase 
of about 3.5 fold after 5 hours of treatment. Contrary to the 5 hour time-point that 
displays a classic genomic action of aldosterone with a significant increase in mRNA 
levels, the 15 minute time-point did not show any significant change supporting the 
hypothesis that the increase in pERK protein levels is indeed a nongenomic effect of 
aldosterone action at this time-point. In order to take into account differences 
between samples, mRNA levels were normalized using the housekeeping ribosomal 
gene 18S. 
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Aldosterone’s genomic effects 
 
Having established that there is a significant nongenomic increase of pERK 
due to aldosterone stimulation in endothelial cells, it was investigated if striatin and 
the caveolae played a role in this action as seen in estrogen’s nongenomic actions. 
To answer if aldosterone influenced striatin in any way, EA.hy926 cells were 
stimulated with aldosterone for periods of time conducive to a potential genomic 
effect. Results showed a significant increase in striatin protein at 5 hours of 
aldosterone stimulation, consistent with the second increase in pERK previously 
seen, hinting at the possibility that the two effects might be linked.  
 
This result was unexpected because striatin is believed to be a chaperone 
protein, facilitating the interactions between different signalling proteins. The increase 
in striatin took place at 5 hours of aldosterone treatment, similarly to other genomic 
actions of aldosterone. However, this increase seems to be an acute event occurring 
at 5 hours of stimulation. To determine if it was an effect of MR activation, 
experiments were carried out using canrenoic acid which, effectively inhibited the 
increase in striatin protein levels, thus establishing that the observed effect is a 
consequence of MR activation. 
 
Confirming the rise in striatin protein levels as a genomic consequence of MR 
activation, striatin mRNA levels (after normalization to 18S) went up by about two fold 
and did not occur in the presence of canrenoic acid. This result constitutes a novel 
genomic action of aldosterone and may have several implications linked to steroid 
hormone signalling, since striatin has been described as a necessary component in 
other steroid hormone pathways like estrogen (188). The increase in striatin protein 
levels at five hours of aldosterone treatment was confirmed in MAEC cells but, not 
the raise in mRNA levels, leading us to belief that the peak of stimulation does not 
occur at the same time as was observed with EA.hy926 cells or the increase is not as 
noticeable, making the differences more difficult to detect. 
 
 Results obtained in animal studies strengthened the observations derived from 
endothelial cell studies. An experimental study with animals showed that dietary 
sodium restriction increased striatin levels in mouse hearts and aorta. Striatin levels 
were significantly higher in mice on a low sodium diet; characterized as having higher 
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plasma aldosterone levels, than the mice on higher sodium levels. An acute in vivo 
aldosterone administration (IP) lead to an increase of striatin protein levels in mouse 
heart when compared to vehicle injected animals. Finally, animals treated with         
L-NAME, in combination with AngII; treatment which induces myocardial damage that 
can be prevented by MR blockade; showed increased striatin levels both in heart and 
kidney tissues when compared to vehicle treated control.  
Striatin and its family members zinedin and SG2NA are three distinct but 
structurally related WD-repeat proteins that share high protein sequence homology. 
The WD-repeat-containing family of proteins is defined by two main characteristic 
features: a lack of intrinsic catalytic activity and repeated units of beta-sheet motifs 
that are arranged into a beta-propeller structure to form a platform on which multiple 
protein complexes can dynamically assemble. In this way WD repeat containing 
proteins play a major role in cellular events by mediating important protein-protein 
interactions by providing a permissive scaffold for the anchorage of several diverse 
molecules that are important in cellular signalling, cytoskeletal assembly and 
vesicular trafficking.   
 
Striatin, which comprises 780 amino acids and weighs 110 kDa, was first 
isolated in the brain as a calmodulin-binding protein. It contains at least four protein-
protein interaction domains (see Figure 18), including caveolin-binding, coiled-coil, 
and Ca2+-calmodulin (CaM) binding at the N-terminus, and a series of eight WD 
repeat domains at the C-terminus (190). The N-terminus of striatin (amino acids 1-
203) has been found interact with the N-terminus of ERα (amino acids 185-253) while 
the C-terminal WD repeat domain binds the GPCR (Gαi) complex. In this context, 
striatin acts as a scaffold directing ERα to the plasma membrane and bridges ERα 
with the GPCR (Gαi) complex to facilitate assembly of a membrane signalling 
complexes required for rapid estrogen extra-nuclear activation of MAPK, Akt, and 
eNOS in endothelial cells (188).  
 
 Outside the brain, not much is known about striatin function apart from its 
connection to ER and, in the literature it is always viewed as a scaffolding protein 
that facilitates the interaction between different intervenients in a signalling cascade. 
It is proven that it binds to CAV1 (290) and that it assembles signalling complexes in 
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the vicinity of the cell membrane but it is the first time that a steroid hormone has 
been shown to influence its levels.  
 
 Having shown that aldosterone has nongenomic effects in the endothelial cells 
studied and, the presence of striatin in the same cells, it is was important to ascertain 
if the presence of striatin is necessary for the effects to occur and, if higher striatin 
levels changed the way MR signalling occurs in these cells. To explore these 
possibilities, striatin was knocked-down using siRNA technology and MR activation 
studies repeated in transfected cells. 
 
Through several rounds of optimization, ideal conditions for striatin knock-
down experiments using siRNA technology were established. Striatin gene 
expression and protein production was reduced to 25% when compared to 
untransfected cells and the oligonucleotide selected was shown not to affect the 
expression of the other two striatin family members.  
 
In order to ensure the consistency of the results, the same cell batch was used 
for all of the knock-down experiments. Untransfected EA.hy926 cells were once more 
stimulated with aldosterone in the presence/absence of MRA to determine if the cells 
are responsive to aldosterone stimulation and the baseline levels of ERK 
phosphorylation. Consistently with what was previously shown EA.hy926 cells 
showed an 1,5 fold increase in the pERK/ERK ratio, following incubation with 
aldosterone for 15 minutes, which was abrogated with MRA. 
 
When the cells were transfected with striatin siRNA, the rapid increase in 
pERK levels was abolished. The controls for these experiments were mock 
transfected cells. Results showed that the rapid rise in pERK levels is abolished but 
also, the overall phosphorylation levels were lower in the transfected cells. The first 
important point in these results is the fact that the controls used were, in fact, 
untransfected cells. Although this does not invalidate the conclusions, it would have 
been more adequate to use cells transfected with the scrambled control sequence 
instead. This way, the transfection effects on the cells would have been fully 
controlled for, including any potential changes in the levels of ERK phosphorylation. 
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Another point worth mentioning is the fact that pERK levels were lower in 
transfected cells when compared to mock transfected cells. The fact that 
untransfected cells are being compared to transfected ones might, very well, account 
for this difference and also, ERK protein levels seem to be more elevated in the 
transfected cells, which, due to the way the results are shown would in part justify the 
decrease in phosphorylation levels. Despite these possibilities, it is necessary to 
assume that this might also be a real biological find and look for possible 
explanations.  
  
One possible explanation is linked to the already described actions of striatin. 
The serine/threonine protein phosphatases are targeted to specific subcellular 
locations and substrates in part via interactions with a wide variety of regulatory 
proteins. Understanding these interactions is thus critical to understanding 
phosphatase function. Protein phosphatase 2A (PP2A) is a multifunctional 
serine/threonine phosphatase that is critical to many cellular processes including 
development, neuronal signalling, cell cycle regulation, and viral transformation. 
PP2A has been implicated in Ca2+-dependent signalling pathways, but how PP2A is 
targeted to these pathways was not understood until striatin was found to form a 
stable complex with the PP2A A/C heterodimer (291). Striatin, binds to CaM in a 
Ca2+-dependent manner. In addition to CaM and PP2A, several other proteins stably 
associate with the striatin-PP2A and SG2NA-PP2A complexes. Thus, one 
mechanism of targeting and organizing PP2A with components of Ca2+-dependent 
signalling pathways may be through the molecular scaffolding proteins striatin and 
SG2NA (291).  
Other proteins found in complexes with striatin family members include, but 
are not limited to, Mob3/phocein (227, 292), which is involved in vesicular trafficking 
(292-294); Mst3, Mst4, and STK25 (295), members of the Germinal Centre Kinase-III 
(GCK-III) subfamily of sterile 20-like kinases recently implicated in control of cell 
migration, cell cycle, Golgi assembly, and cell polarity (296-299); cerebral cavernous 
malformation 3 (CCM3) protein (295), which is required for stabilization of the GCK-III 
kinases and thus for their function (297); and striatin-interacting proteins (STRIP) 1 
and 2 (295). 
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Considering that, in most of the described interactions, striatin functions as a 
chaperone protein “taking” proteins where they need to go, it was hypothesized that 
lower levels of striatin might influence signalling molecules that come before ERK in 
the pathway and, in that way, inhibit its phosphorylation, this way it would make 
sense that the overall phosphorylation levels in transfected cells were lower than in 
cells that retain all its striatin.  
 
In order to establish that the scrambled (control) sequence did not affect the 
cell signalling, the short-time aldosterone treatment was repeated in cells transfected 
with the control duplex. Cells transfected with scrambled siRNA showed a significant 
increase in ERK phosphorylation levels confirming that the scrambled control 
sequence does not affect the way these cells signal. pERK levels were similar to 
what was shown previously and was abrogated by MRA. 
 
Finally, EA.hy926 cells, transfected with striatin siRNA or controls 
(untransfected) were treated with aldosterone and mRNA levels of WNK4 and SGK1 
measured to establish if a decrease in striatin gene expression influenced 
aldosterone’s known genomic responses. Results show that in both cases the 
genomic signalling was not affected. 
 
The above mentioned results indicate that striatin is a necessary player in 
aldosterone’s nongenomic effects and in its absence (or when in reduced levels) 
such effects (increase in ERK phosphorylation levels at 15 minutes) do not occur. 
They also indicate that striatin does not seem to be necessary for the classical, 
genomic effects to occur, suggesting that pathways independent of striatin, are more 
important or that the genomic aldosterone action in these cells is less sensitive to 
reduced striatin levels. 
 
Taking into account that striatin has a major role in aldosterone’s nongenomic 
effects via the MR and that it is know to associate with CAV1 (190), the importance of 
the caveolae in this process was also analysed.  
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Interactions between MR, Striatin and CAV1 
 
Co-immunoprecipitation (Co-IP) was used in order to explore possible protein-
protein interactions between the MR, striatin and CAV1. If proteins interact closely, it 
is possible to “pull” one of these proteins down (known) and use a different antibody 
to detect the other protein (unknown). This would support the notion that MR, striatin 
and CAV1 are involved in a reciprocal cellular mechanism. 
 
To determine if the technique was working, striatin was targeted to be pulled 
down and the resulting elution studied for the presence of CAV1 protein. Results 
showed an interaction between striatin and CAV1 in MAEC, EA.hy926 cells and 
mouse heart tissue. The result was expected and demonstrated that the technique 
chosen is an efficient study tool. To prevent any possible artefacts, the reverse Co-IP 
was always performed and in this case, CAV1 was shown to interact with striatin. 
 
The next round of Co-IPs connected MR to CAV1 and, as CAV1 is an integral 
caveolar protein, the presence of MR in the caveolae. Results point to a close 
interaction between MR and CAV1 and, potentially place MR in the caveolae structure 
located in the cell membrane. Results shown for heart tissue depict two different 
bands that correspond to the alpha and beta isoforms of CAV1, known to be 
expressed in cardiomyocytes (266). 
 
The next possible interaction studied was that between striatin and MR. It was 
already known that MR needs striatin to exert its nongenomic effects so this 
interaction was expected to be strong. As expected, when striatin was precipitated 
with A/G beads conjugated to striatin antibody, the resulting elution contained a high 
amount of MR, confirming the predicted interaction between the two proteins. The 
reverse Co-IP confirmed this interaction and showed the presence of two striatin 
isoforms in EA.hy926 cells.  
 
 Co-IP results show a strong interaction between MR, striatin and CAV1 and 
seem to indicate the formation of a possible triple complex. 
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Figure 63- Individual complexes shown on the left represent the results obtained in the     
Co-IP studies. On the right is represented the posited, potential triple complex  
between MR, striatin and CAV1. 
 
Considering the role of CAV1 in binding striatin protein it was proposed that 
caveolin could be acting as an intermediary in this complex, most likely serving as an 
anchor for MR in the cell membrane and keeping it in place for further interactions 
with other molecules, leading to rapid, nongenomic effects of MR activation. To test 
this hypothesis MAEC from wild-type and CAV1 knock-out animals were used for   
Co-IP studies. Results showed that in the absence of CAV1, the MR does not seem 
to interact with striatin or, the interaction is weakened and cannot be detected using 
co-immunoprecipitation techniques.  
 
 
 
 
 
 
 
Figure 64- Diagram representing CAV1 WT/KO MAEC Co-IP study results. In the absence of 
CAV1 protein there doesn’t seem to be an interaction between MR and striatin. 
 
 
Triple ComplexComplexes
WT KO
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Such results are very important and strengthen the existence of a triple 
complex, with CAV1 as the intermediary between the other the proteins. These 
results are consistent with caveolae playing a role in providing a platform for protein 
interactions and cell signalling to occur. To test this hypothesis, EA.hy926 cells were 
treated with lipid-raft disruptors, which inhibit caveolae formation, and subsequently 
stimulated with aldosterone. EA.hy926 cells were pre-incubated overnight with two 
lipid raft disrupting chemicals and then treated with 10nM aldosterone for 15 minutes. 
Results showed that aldosterone had no effect on pERK in the presence of either 
chemical. Results were not statistically significant but, the general trend seems to 
confirm that caveolae have a facilitating role in nongenomic aldosterone effects by 
providing a platform for MR to interact with other players to mediate subsequent cell 
signalling cascades.  
 
 
Originally caveolae were given the exclusive electron microscopic description 
of membrane invaginated “smooth” vesicles of 50 to 100 nm in size (as opposed to 
the more electron-dense and larger “coated” vesicles- i.e., clathrin-coated pits). 
However, with further investigation the definition of caveolae has expanded to also 
include vesicles detached from the plasma membrane, associated in groups as 
grape-like clusters or rosettes, and in fused form as elongated tubules or trans-
cellular channels (Figure 65).  
 
 
 The discovery of caveolin, the original member of the three-protein caveolin 
family, and its relationship to caveolae was converged upon by investigators from 
different fields with disparate research interests. In an antibody screen for tyrosine-
phosphorylated substrates in Rous sarcoma virus-transformed fibroblasts, four 
predominant proteins were isolated (300).  
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Figure 65- Different types of caveolae morphology (A). (B), two electron micrographs 
(16000x), an adipocyte (on the left) and an endothelial cell (on the right). Caveolar rosettes 
are frequently observed in adipoctyes, and endothelial cells are often found with caveolae in 
all states of membrane association- from membrane bound to fully invaginated (185). 
 
Antibodies raised against one of the proteins showed punctuated staining on 
the plasma membrane (174, 300). This distribution was curiously similar to that 
observed for flask-shaped caveolae and led to experiments linking this 22-kDa 
protein and caveolae (174). Caveolae were shown to be composed of a series of 
concentric striated rings that stained with antibodies directed against the 22-kDa 
protein. Moreover, treatment of cells with cholesterol binding agents, led to flattening 
of the vesicles and dissociation of the 22-kDa protein rich striations. Because this 
protein was so intimately associated with the structural components of caveolae, it 
was named caveolin (174). 
 
The subsequent cloning of the caveolin gene led to yet another surprise about 
the possible functions of the protein (176, 301). In an attempt to identify the cellular 
machinery involved in the differential sorting of vesicles to the apical or basolateral 
surface of polarized epithelial cells, VIP-21 (vesicular integral protein of 21 kDa) had 
been cloned (302). As it turned out, the caveolin sequence was identical to that of 
VIP-21, thereby showing that the same protein could possibly serve as a structural 
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component of plasma membrane caveolae, as well as have roles in oncogenesis and 
vesicular trafficking- all at the same time (301). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66- Detailed organization of lipid rafts and caveolae membranes.  
(A) lipid rafts. (B) caveolae. (185)  
 
Caveolin-1 was not only the first protein to be localized to caveolae but due to 
its apparent involvement in the structural integrity of caveolae was also the first 
caveolar “marker protein” (174). Caveolar resident proteins were identified using  
sucrose gradients. Of the numerous proteins identified in this manner, it was 
surprising to find that a large majority were signal transduction molecules, some at 
concentrations manifold higher than the bulk plasma membrane (179, 303). This 
observation led to the “caveolae/raft signalling hypothesis”: the compartmentalization 
of such molecules has distinct advantages as it provides a mechanism for the 
regulation of subsequent signalling events and explains cross-talk between different 
signalling pathways (232). Since this initial observation, an array of proteins (ranging 
from receptor tyrosine kinases, G-protein-coupled receptors, ion channels, adaptor 
proteins, and structural proteins) has now been reported to be preferentially localized 
to caveolae (185). This is a growing list but, nevertheless, it is clear that caveolae are 
involved in the compartmentalization of various signalling pathways and can be 
considered specialized signalling organelles. 
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Several lines of evidence now suggest that the caveolins might also act as 
scaffolding proteins by directly interacting with and modulating the activity of 
caveolae-localized signalling molecules. Residues 82-101 form a region termed the 
caveolin scaffolding domain (CSD) where G-proteins but also a host of other 
signalling proteins bind to. Caveolin-interacting molecules have caveolin binding 
domains (CBDs). Striatin is one of those molecules and it has been shown to 
modulate nongenomic actions of another steroid hormone, estrogen (188). Due to 
this last connection it was felt that it was necessary to investigate a possible 
connection between aldosterone and estrogen effects since aldosterone increases 
striatin levels in endothelial cells. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67- Diagram depicting the interaction between striatin and caveolin proteins.  
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Aldosterone’s influence on Estrogen’s nongenomic actions 
 
 Lu et al identified striatin as a scaffold protein that promotes localization of 
ER to the plasma membrane and assembly of the signalling complex of ER and Gi 
that is required for ER-dependent activation of MAPK, phosphatidylinositol 3–Akt 
kinase, and eNOS, a critical regulator of many physiologic and pathophysiological 
processes (188). Their results show a peak in eNOS phosphorylation at 15 minutes 
of estrogen stimulation that is abrogated if striatin is disrupted. They also show that 
overexpression of striatin increases the proportion of ER that is distributed along the 
plasma membrane. These results combined with the information that the binding of 
estrogen (E2) to the membrane has been confirmed, in addition to the presence of 
ER and caveolin in plasmalemmal caveolae and, their connection to nongenomic 
and short-term effect of E2 on endothelial NO release (186) led to the possibility of a 
an interaction/cross-talk relationship between aldosterone and estrogen signalling in 
endothelial cells. 
 
 The first step taken was to ascertain if, like aldosterone, estrogen treatment 
stimulated the production of striatin protein. EA.hy926 cells were treated with either 
10nM aldosterone or 50nM estrogen for 5 hours. Aldosterone but not estrogen 
treatment increases striatin protein levels. Results show that the increase in striatin 
protein seems to be specific to aldosterone’s MR activation. 
 
Because the experimental design used was different from aforementioned 
studies it was necessary to replicate the results already published. EA.hy926 cells 
were stimulated with estrogen (50nM) for 5, 15 and 30 minutes, with or without 
aldosterone (10nM) pre-treatment for 5 hours. peNOS/eNOS levels were then 
measured by western blot analysis. Results obtained successfully replicated the 
findings of Lu et al, exhibiting a peak in eNOS phosphorylation occurring at 15 
minutes of estrogen stimulation. This peak is smaller than previously observed and 
the estrogen dose employed higher which can be justified by the absence of 
overexpression of striatin protein in the present study. 
 
 When the aldosterone pre-treatment was added to the experimental paradigm, 
a very interesting event occurred; there was a shift in the pattern of the peNOS 
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activity; peNOS levels were not only increased compared to estrogen treatment 
alone but it also occurred sooner.  
 
 This is a novel result and might prove to change the way steroid signalling is 
viewed, adding a new level of complexity concerning cross-talk between different 
steroid receptors and subsequent downstream signalling cascades and cellular 
events. 
 
In order to confirm that this effect is dependent on striatin, EA.hy926 cells 
were transfected with striatin scrambled sequence or striatin siRNA. Cells were then 
treated with estrogen for 15 minutes with or without aldosterone pre-treatment. 
Results confirmed published observations and implicated striatin as a key player in 
estrogen signalling. Cells transfected with the scrambled sequence display a peak in 
peNOS levels at 15 minutes of estrogen treatment, which increases when the cells 
are subjected to aldosterone pre-treatment. When the cells are transfected with 
striatin siRNA, the response to estrogen stimulation is completely abrogated, even 
when pre-treatment with aldosterone is employed.  
 
With the mounting evidence of a potential cross-talk between estrogen and 
aldosterone signalling pathways, it was important to study the effect of estrogen on 
ERK phosphorylation. Results showed that, contrary to what was observed with 
aldosterone, estrogen pre-treatment does not increase pERK levels in EA.hy926 
cells.  
 
 Striatin siRNA did not damper the genomic effects of aldosterone stimulation 
but, the same had to be shown for estrogen. PTGIS, together with PTGS1 were 
selected as targets to study the effects of striatin knock-down on estrogen’s genomic 
actions. PTGIS and PTGS1 expression levels were measured by Real-Time PCR in 
EA.hy926 cells transfected/untransfected with striatin siRNA and subsequently 
treated with 50nM estrogen for 15 minutes and 5 hours. Results showed that, as 
described in the literature, treatment with estrogen stimulated PTGIS and PTGS1 
expression in the endothelial cells studied. Transfection with striatin siRNA, did not 
affect these genomic actions in anyway, with similar levels of mRNA observed for 
both untransfected and transfected cells. 
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 In an attempt to bring the results shown close to physiological relevance, 
MAEC were used in repeat experiments with estrogen stimulation with/without 
aldosterone pre-treatment. Just as seen with EA.hy926 cells, pre-treatment with 
aldosterone enhanced estrogen’s nongenomic response. There was a peak in eNOS 
phosphorylation at 15 minutes of estrogen stimulation with levels of phosphorylation 
very similar to previously observed for EA.hy926 cells. When an aldosterone pre-
treatment was added to the treatment conditions, there was, once more, a shift in the 
peNOS peak observed. In the case of MAEC there was no apparent increase in 
peNOS levels but, the nongenomic response at 5 minutes of estrogen stimulation 
was confirmed.  
 
Estrogen is a complex hormone with pleiotropic effects. Aging and estrogen 
loss are indelibly linked. Aging is associated with inflammation (304), with increased 
oxidative stress and a blunting of the protective heat shock response (305). In the 
cardiovascular system, aging is accompanied by increased stiffness, increased 
fibrosis, and loss of contractile reserve, increased ROS and endothelial dysfunction. 
All of these factors contribute to cardiovascular dysfunction. Estrogen, which is an 
antioxidant through indirect upregulation of antioxidant gene expression and 
increasing eNOS activity while decreasing superoxide production, is lost through 
menopause and may underlie such cardiovascular diseases that are often observed 
in postmenopausal women.  
 
Membrane associated ERα, when bound by estrogen, can activate a signalling 
cascade that includes PI3K and Akt, as well as ERK 1/2, JNK and p38 (306). This 
signalling cascade protects the cell from injury, except for JNK, which increases 
apoptosis. The signalling mediated by membrane associated ERα has been termed 
nongenomic signalling and has recently been shown to provide cardiovascular 
protection without increasing uterine or breast cancer growth in mice (307). Also, 
without rapid signalling, this apparent protective effect is lost (308). This supports the 
idea that the increased risk of cancer with estrogen therapy is related to estrogen's 
classical nuclear effects. 
 
 These facts combined with the findings here presented could potentially lead 
to two very different possible biological outcomes. Based on the data generated by 
experimental work herein, a general signalling model can be proposed.  
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 Figure 68- Diagram depicting the general conclusions drawn from the experimental  
studies here presented. 
 
 The left panel of the diagram shows the nongenomic and genomic actions of 
aldosterone that were described in this thesis. Aldosterone activates the MR that can 
be found at the cell membrane level in the form of a triple complex with striatin and 
CAV1. MR activation for a short period of time (15 minutes) leads to the nongenomic 
increase in phosphorylation of ERK1/2. When MR is activated for a longer period of 
time (5 hours), striatin protein expression levels are increased, which constitutes a 
genomic effect of aldosterone action. 
 
 In the right panel the nongenomic signalling pathway for estrogen action is 
depicted, as previously described (188). This panel also illustrates the potential 
cross-talk between the two steroid hormones with the increased striatin levels 
brought about by aldosterone’s genomic action.  
 
MR blockade has important effects on reno-cardiovascular remodelling and 
fibrosis, autonomic balance, fibrinolysis, oxidative stress, and activation of 
proinflammatory and profibrotic pathways (309). These are the adverse effects of 
aldosterone action. However, a very important aspect of the “ugly” actions of 
aldosterone is the fact that this hormone per se is incapable of eliciting damage but 
requires a certain pathological milieu, and only when correct conditions are met 
(Figure 69) does this leads to pathophysiological MR activation resulting in this 
adverse or ugly action. In 1992, Brilla and Weber reported that in the presence of 
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enhanced sodium intake, but not with sodium deprivation, chronic administration of 
aldosterone is associated with cardiac fibrosis and hypertrophy (107). Further in vivo 
studies confirmed that the damaging effect of aldosterone in reno-cardiovascular 
tissue depends on a high salt diet (310-315), which could be followed by a milieu 
characterized in part by enhanced reactive oxygen stress (ROS) and prevented by a 
low salt diet (314, 316-319). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 69- Hypothetical coincidence model of the signalling events, 
leading to damaging actions of MR-stimulation (320). 
 
 Adding this information to what has already been stated about nongenomic 
actions of estrogen there are two possible conclusions that can be drawn from the 
experimental studies herein. The first conclusion is that the cross-talk between 
aldosterone and estrogen, through striatin is of potential therapeutic significance, 
because it increases the anti-oxidative action of estrogen. This is only true when 
there is no evident, pre-existing, cardiovascular damage. In the case that there is 
already some inflammation due to age or a different initiating agent, the increase in 
striatin protein by aldosterone might be adverse to cardiovascular health and may 
preclude disease by, facilitating further MR activation, leading to more damage in the 
cardiovascular system. 
 174
Conclusion 
 
Cellular responses to steroids are mediated by two general mechanisms: 
genomic and rapid/nongenomic effects. Identification of the mechanisms underlying 
aldosterone’s nongenomic actions has been difficult to study and is still not clearly 
understood. In the presented thesis, the hypothesis that striatin is a critical 
intermediary of the rapid/nongenomic effects of aldosterone was explored.  
In human and mouse endothelial cells, aldosterone promoted an increase in 
pERK that peaked at 15 minutes. Striatin was shown to be a critical mediator in this 
process as reducing striatin levels with siRNA technology prevented the rise in pERK 
levels. In contrast, reducing striatin did not significantly affect two well-characterized 
genomic responses to aldosterone. Down regulation of striatin with siRNA produced 
similar effects on estrogen’s actions – reducing nongenomic, but not the genomic 
actions investigated and, aldosterone, but not estrogen, increased striatin levels. 
When endothelial cells were pre-treated with aldosterone, the rapid/nongenomic 
response to estrogen on peNOS/eNOS ratio was enhanced and accelerated 
significantly. Importantly, pre-treatment with estrogen did not enhance aldosterone’s 
nongenomic response on pERK.  
In conclusion, these results indicate that striatin is a novel mediator for both 
aldosterone’s and estrogen’s rapid and nongenomic mechanisms of action on pERK 
and peNOS, respectively, thereby providing evidence for a synergistic effect between 
the mineralocorticoid receptor and the estrogen receptor.  
Multiple studies in vivo and in vitro have indicated that estrogen has the ability 
to either confer cardiovascular protection or increase cardiovascular risk. For 
example, in the Women’s Health Initiative the overall findings support the concept 
that estrogen increases cardiovascular risk in post-menopausal females (321). 
However, a secondary analysis suggests that depending on the women’s age, 
estrogen can reduce or increase cardiovascular risk (322). Since aldosterone levels 
also vary with age (323), the results of the present study may provide one 
mechanistic explanation for these findings- varying striatin levels. Thus, these results 
suggest a unique level of interactions between steroids on the cardiovascular system 
that may have broad application for the treatment of cardiovascular diseases.  
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Future Directions 
 
The experimental work described in this thesis is by no means concluded and 
some of the conclusions described not fully investigated. Additional studies need to 
be performed to prove the posited triple complex and its relevance to 
Aldosterone/MR and estrogen/ERα signaling. The absence of an animal model 
lacking striatin hampers the ability to assess the physiological relevance of these 
findings. It has also been assumed that the mechanism observed is mediated by the 
classical MR since it is blocked by canrenoic acid. However, the possibility that 
ALDO is interacting with a recently proposed non-genomic regulator of ALDO 
function, GPR30 (324) cannot be excluded.  
 
In the future, one of the most significant experiments necessary is to assess 
the physiological relevance of striatin by employing a striatin KO animal model 
(heterozygous), especially relative to salt sensitivity and aldosterone-mediated 
cardiovascular damage. Some experiments are already underway connected to the 
salt sensitivity of the blood pressure (Hight Salt vs Low Salt in the Heterozydous vs 
Wild Type) and results seem promising. 
The physiological relevance in humans, is also to be assessed by looking at 
SNPs (Single Nucleotide Polymorphism) in the striatin gene, and by using the 
carefully phenotyped HyperPATH cohort already studied within the group. 
 Another interesting avenue would be the interaction between gender           (i.e. 
estrogen) and the effects of aldosterone, which could be assessed in the animal or 
even humans. 
Finally, other nongenomic events following aldosterone stimulation need to be 
clarified in order to build a clearer signalling pathway model. Akt phosphorylation is 
known to associate with ERK1/2 and would be a good first target. 
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